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Abstract
A clearer understanding of the physiological mechanisms controlling aldosterone
secretion is likely to be of major importance in appreciating the significance of the
abnormalities found in patients with conditions such as essential hypertension.
Although angiotensin II, adrenocorticotrophic hormone (ACTH) and potassium are
considered to be the major physiological regulators of aldosterone secretion, serotonin
(5-hydroxytryptamine, 5HT) is a potent stimulus for aldosterone secretion both in vivo and in
vitro in man and the rat. However, the physiological and pathophysiological role of serotonin
in the control of mineralocorticoid secretion remains unclear. Unlike the cardiovascular and
central nervous system (CNS), where specific serotonin receptors have been identified and
categorised into the 5HT-|a, 5HT-ib. 5HTic, 5HTich 5HT2 and 5HT3 sub-types, specific
receptors for serotonin in the adrenal zona glomerulosa and the second messenger system
to which they are coupled, have yet to be formally characterised. To resolve this, the effects
of the selective serotonin receptor antagonists ketanserin (5HT2), methysergide (5HT1/2).
mesulergine (5HT-|C/2), cyanopindolol (5HT1 a/ib) and ICS 205/930 (5HT3) have been
studied on the aldosterone response to serotonin in isolated rat adrenal zona glomerulosa
cells. The specificity of the antagonists was also investigated by observing the effects of the
drugs on the aldosterone response to angiotensin II, ACTH and potassium. The signal
transduction mechanism for serotonin in the zona glomerulosa was studied by measuring
cyclic AMP and phosphatidylinositol (PI) turnover and comparing the results with those of
angiotensin II and ACTH, which act through phospholipase C and adenylate cyclase
respectively. In addition, the role of calcium was investigated using the chelating agent
EGTA, the calcium channel inhibitors verapamil and nifedipine, the intracellular calcium
channel blocker TMB-8, and the calmodulin antagonist trifluoperazine (TFP). Transmembrane
calcium flux in response to serotonin was also studied directly by radiolabelled calcium influx
experiments.
XIV
Serotonin produced a dose-dependent increase in cyclic AMP and aldosterone
secretion, whilst PI turnover was unaffected. The cyclic AMP and aldosterone responses to
serotonin were inhibited by mesulergine, methysergide and ketanserin. The aldosterone
response to angiotensin II, but not ACTH or potassium, was also inhibited by these
antagonists. Cyanopindolol and ICS 205/930 produced a small inhibition of serotonin
stimulated aldosterone and cyclic AMP secretion, but had no effect on the aldosterone
response to the other agonists. The presence of EGTA, verapamil, nifedipine, TMB-8 and
TFP also significantly inhibited aldosterone secretion in response to serotonin. Radiolabelled
calcium influx was stimulated by serotonin and this could be blocked by verapamil.
In addition to the in vitro studies, two in vivo studies were also carried out. The effect of
acute serotonin enhancement was studied in rats with indwelling arterial cannulae. This
experimental model avoided the use of anaesthetics which can activate the renin-angiotensin
system (RAS). Plasma aldosterone was measured prior to and after administration of the
immediate precursor to serotonin, 5-hydroxytryptophan (5HTP). Aldosterone was elevated
45 minutes after administration of 5HTP, and this could be blocked, though not completely,
by pretreatment with both dexamethasone and captopril. The inhibitory effect of captopril
could be reversed by co-administration of angiotensin II. The effect of chronic serotonin
enhancement on adrenal zona glomerulosa growth was studied in rats given 5HTP for periods
of up to 2 weeks. 5HTP increased the width of the zona glomerulosa, although the effect was
less than that observed with sodium depletion. No changes were detected in plasma renin
activity (PRA), angiotensin II, corticosterone or aldosterone and the trophic effect could not
be reversed by chronic treatment with captopril or dexamethasone.
In conclusion, the aldosterone response to serotonin in the zona glomerulosa appears
to be mediated predominantly by 5HTic / 5HT2 like receptors which modulate the steroid
response to angiotensin II and, in contrast to other serotonin responsive tissues, couple to
the adenylate cyclase second messenger system, in addition, influx of extracellular calcium,
which may act cooperatively with cyclic AMP to activate the cascade mechanism resulting in
XV
steroidogenesis, is necessary for the action of serotonin. In vivo it appears that a number of
different mechanisms mediate the acute and chronic actions of serotonin. Acutely, serotonin
activates the hypothalamo-pituitary adrenal axis and the renin-angiotensin system, both of
which require to be intact for the full aldosterone response, although angiotensin II appears to
act purely in a permissive capacity. It is also likely that there is a direct action of serotonin on
the adrenal cortex. In contrast, chronic serotonin enhancement has no effect on the
renin-angiotensin system, the hypothalamo-pituitary adrenal axis or steroidogenesis,
although zona glomerulosa growth is stimulated, most probably by a direct action of serotonin,
although the possibility that serotonin could stimulate the production of another growth
factor(s), cannot be excluded at this stage. Therefore, chronically, there appears to be an
"escape" from continued mineralocorticoid augmentation by an as yet unidentified
mechanism.
The specific interaction between serotonin, the angiotensin II receptor, the
renin-angiotensin system and the hypothalamo-pituitary adrenal axis may be important
regulatory components of mineralocorticoid secretion, and any disturbance in this fine
balance may lead to alterations in steroid secretion. Further studies are required to




The Adrenal Gland and Aldosterone Secretion.
1*1. Introduction
This chapter serves as a brief review of the adrenal gland, describing its structure,
products and their function. However, in parallel with the theme of this thesis particular
emphasis is placed on the biosynthesis, metabolism, function and the secretory control of the
principal product of the zona glomerulosa, the mineralocorticoid aldosterone.
1.2. Topography and embryology of the adrenal gland
All higher vertebrates including man possess two pyramidal shaped adrenal glands
which are located in the fatty tissue on the upper pole of each kidney. A section across the
gland reveals two clearly distinct regions, an inner yellowish coloured core, the medulla,
surrounded by a dark red coloured cortex. The cells of the cortex originate from mesodermal
tissue and are associated with steroid secretion, whilst those of the medulla stem from
ectodermal cells which differentiate to form either mature ganglionic cells or the chromaffin
cells which secrete catecholamines. (Crowder 1957)
Each gland is supplied by a large volume of blood arising from several groups of arteries
which branch into an arteriole network as they approach the gland. After crossing the gland
they converge in the medulla which, in man, drains into the inferior vena cava from the right
adrenal and into the renal vein from the left adrenal. This expansive network of blood vessels
ensures a continuous supply of oxygen, co-factors and precursors, each necessary to
maintain the steroidogenic capacity of the gland, as well as providing a rapid clearance system
of the steroids from the adrenal, which is one of the few glands which does not store its own
products. (Gagnon 1957)
1*2. Histology
The adrenal cortex comprises three readily recognisable cell types which are arranged
in concentric zones or layers (Figure 1.1). Each of the zones has a specific function and is








Figure 1.1. The histology of the adrenal gland
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are exerted depending on the zone, stimulus and end product. The outermost zona
glomerulosa, whose component cells have a high nuclear: cytoplasmic ratio, aggregate to
form compact ball-like clusters. They also have an abundance of smooth endoplasmic
reticulum (E.R), and very little rough E.R. The intermediate zona fasciculata is the largest of
the zones and the cells are arranged in radially disposed columns extending from the
glomerulosa. They contain a large amount of smooth E.R and ascorbic acid and an
abundance of lipid. Lastly, the innermost zona reticularis cells are low in lipid content and are
arranged in a network system. The cortex surrounds the adrenal medulla which is composed
of columnar shaped chromaffin cells, individually innervated by cholinergic preganglionic
neurones and full of membrane-bounded electron dense granules which are thought to be the
main storage sites of the catecholamines adrenaline and noradrenaline. The three zones of
the cortex and the inner medulla are encased by a capsule composed of several layers of
elongated connective tissue cells surrounded by collagen fibres. (Dobb'e et al 1966)
(Elias and Pauly 1956)
1.4. Steroid Biosynthesis
The adrenal cortex synthesises at least 50 different steroids, each possessing a basic 4
ringed structure and a varying number of carbon atoms from which a number of substitutions,
e.g ketones, aldehydes and hydroxyls, may extend either above (P) or below (a) the plane of
the central ring structure. Many of the steroids have no hormonal activity and serve only as
intermediates or precursors to the main steroids, which can be divided into the 5 main groups
outlined below and illustrated in Figure 1.2.
1. Progestogens e.g progesterone contain 21 carbon atoms and are involved in the
preparation of the lining of the uterus for implantation of an ovum.
2. Androgens e.g testosterone contain 19 carbon atoms and have a ketone group on the
carbon position 17. These are responsible for the development of male secondary sex
characteristics.



































4. Glucocorticoids e.g Cortisol in man and corticosterone in the rat contain 21 carbon atoms
and an OH group at the 17 carbon position. These enhance gluconeogenesis and glycogen
formation in addition to degradation of fat and protein.
5. Mineralocorticoids e.g aldosterone contain 21 carbon atoms and cause reabsorption of
Na+, CI- and HCO3 by the distal tubule of the kidney.
All of the steroids synthesised in the adrenal are derived from cholesterol, which is
either synthesised by the adrenal cortex and other tissues or derived from animal fat in the
diot. Cholesterol is stored in close association with plasma lipoproteins e.g low density
lipoproteins (LDL), very low density lipoproteins (VLDL) and high density lipoproteins (HDL),
and of these, the cholesterol in co-existence with LDL appears to be the preferential
substrate for steroid biosynthesis. (Borkowski et al 1972) (Carr efa/1980)
LDL binds to specific receptors located on the adrenal cortical cell surface forming a
complex which is internalised and hydrolysed in lysosomes to release free cholesterol, part of
which is esterified and utilised as a substrate at a later stage whilst the remainder is used
directly for steroid biosynthesis.
The initial step in the biosynthetic pathway (Figurel .3) is the conversion of the liberated
(Whitehouse and Vinson 1968)
cholesterol to A-5-pregnenolone. This side chain cleavage step consists of several reactions,
catalysed by the cholesterol desmolase enzyme complex which is located in the mitochondria
and requires molecular oxygen and NADPH as co-factors. The complex comprises an
electron transport chain with the flavoprotein adrenodoxin reductase, an iron sulphur protein
adrenodoxin and a reaction specific cytochrome P450. which is just one of a large family of
cytochromes catalysing hydroxylations. There are at least 4 different types of cytochrome
(Simpson and Waterman 1988)
P450. these include P450-17a. ^450 -side chain cleavage (see). ^450 -C21 and P450-11p-
Hydroxylation occurs when electrons reduce the cytochrome P450 after passing along the
electron transport chain. This reaction reduces molecular oxygen to a molecule of water and
an atom of oxygen which is placed on the appropriate hydrogen moiety.





















Figure 1.3. The aldosterone biosynthetic pathway.
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reticulum where it is channelled into synthesis of the appropriate corticosteroid. This initial
side chain cleavage reaction is considered to be the rate limiting step in all the steroidogenic
pathways and is consequently under the control of a number of different factors e.g
angiotensin II, ACTH and serotonin.
Cortisol, the major glucocorticoid in man is formed by either 3-hydroxysteroid
dehydrogenation and isomerisation of pregnenolone to form progesterone, followed by the
sequential hydroxylation of the 17, 21 and 11 carbon atoms to form 17a-OH progesterone,
11-deoxycortisol and Cortisol respectively fit 17a-hydroxylation of pregnenolone to form
17a-OH-pregnenolone preceding the dehydrogenation/isomerisation reaction forming
17a-OH-progesterone and then 21 and 11 hydroxylation as before. Alternatively
progesterone can also be hydroxylated at the 21 and 11 carbon position to form
(Cameron etal 1968)
11-deoxycorticosterone and corticosterone respectively. The latter compound is the major
glucocorticoid in the rat, due to the absence of 17a-hydroxylase activity, which in man is
predominant in the zona glomerulosa (Figure 1.4). (Simpson and Mason 1976)
17 and 21 hydroxylations are catalysed by a microsomal enzyme complex consisting of
a NADPH-cytochrome P450 reductase and the appropriate cytochrome P450- The
11-13-hydroxylations which take place in the mitochondria are catalysed by another reaction
specific cytochrome enzyme similar to that involved in pregnenolone formation. The
dehydrogenation/isomerisation reactions are catalysed by 313 hydroxyctoroid dehydrogenase
which requires NAD+, and a5-3 ketosteroid isomerase. (Simpson and Mason 1976) (Grant 1978)
Aldosterone, the principal mineralocorticoid in man is formed predominantly from
corticosterone via 18-OH-corticosterone by 2 reactions, methyl oxidation 1 and methyl
oxidation 2 (Ulick 1976). This reaction involves a cytochrome P 450 with cytomethyloxidase
activity and takes place exclusively in the zona glomerulosa. Alternatively, aldosterone may
be formed from 18-OH-deoxycorticosterone, which is synthesised from
11-deoxycorticosterone. The 18-OH-deoxycorticosterone may either be converted to
11-deoxyaldosterone or to 18-OH-corticosterone before conversion to aldosterone (Muller
1980). The conversion of 18-OH-deoxycorticosterone to aldosterone has been shown in
7
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Figure 1.4. The zonation of adrenal steroidogenesis.




normal tissue but in particular in tumourous tissue (Grekin et al 1973). The normal and
alternative pathways for aldosterone biosynthesis are shown in figure 1.3.
Finally androgens including androstenedione and testosterone and oestrogens e.g
oestradiol are synthesised by a similar series of dehydrogenation/isomerisation and
hydroxylation reactions.
Two sites in the biosynthetic pathway of aldosterone appear to be rate limiting, the first
being the conversion of cholesterol to pregnenolone and the other occurring at a later stage
in the pathway, probably between the conversion of corticosterone to aldosterone. A
number of controlling factors, which will be discussed in detail in subsequent sections, act on
these early and late stages of the pathway to modulate and control aldosterone production.
UL Metabolism of steroids
The reactions which render steroids biologically inactive and readily water soluble for
excretion in urine or bile can be divided into 5 groups; reductions, hydroxylations, side-chain
cleavage, oxidations and esterifications. These reactions are carried out mainly in the liver,
but they can also take place in the kidney and the adrenal gland itself. (Bondy 1980)
1.5.1. Reductions
Steroids can be inactivated by removal of the A4,3-ketone group. This irreversible
reaction is carried out by reducing the double bond between the 4th and 5th carbon atoms to
yield a hydrogen atom on the 5th carbon in either the a or B position. The resulting reduced
19-carbon compounds are termed 5a or 5 p androstanes, whilst the 21 carbon compounds
are known as 5a or 56 pregnanes. Normally, the 19 carbon steroids are preferentially
reduced to the a form and the 21 carbon steroids to the B form. The initial reduction is usually




Cortisol in particular can be readily excreted by the addition of a hydroxyl group at the 68
position. This reaction, which takes place in the liver, is particularly important in children and
also patients with liver disease. A similar reaction at the 16a position converts oestradiol to
estriol.
1.5.3. Side Chain Cleavaoe
The removal of the carbon 20/21 side chain from 17-hydroxylated steroids such as
Cortisol occurs after reduction of the A ring and forms a 19 carbon compound with a ketone
group on the 17 carbon position.
1.5.4. Oxidations
Two types of oxidation reactions occur. Firstly, the 110 hydroxyl group of the steroid
can be converted to a ketone e.g Cortisol to cortisone, a reaction which is reversible providing
the A ring remains intact. Secondly, subsequent to 8 reduction of the A ring, the hydroxyl
group is oxidised to a carboxyl group to produce either the cortolic acids, which are formed
when the 11 B-hydroxyl group is intact, or the cortolonic acids if a ketone group is present at
the carbon 11 position.
1.5.5. Esterification
21 carbon steroids are esterified with glucoronic acid at the 3B-hydroxyl position by
glucuronyl transferase to form glucuronidates, whilst 19 carbon steroids are converted to
sulphates at the 3-hydroxyl position or doubly at the 3 and 21 carbon position.
1.5.6. Metabolism of aldosterone
Aldosterone is metabolised in a number of ways and the key metabolites are shown in







Figure 1.5. The metabolism of aldosterone.
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the A ring and the 3-ketone group forms tetrahydroaldosterone. This is then esterified at the
3-hydroxyl position with glucuronic acid and subsequently excreted. Alternatively,
conjugation of the 18 carbon position with glucoronic acid, without alterations of the A ring
and the 3-ketone group, can take place in the kidney. The latter derivative is labile in dilute
acid and therefore free aldosterone is released by hydrolysis at pH 1. It is this compound
which is referred to when urinary aldosterone measurements are made.
UL Actions of aldosterone
As early as the 1940s it was known that altered sodium status affected the width of the
zona glomerutosa, implying that this zone secreted a hormone involved in maintaining sodium
status. This was thought to be deoxycorticosterone until the 1950s when Simpson and Tait
isolated and characterised aldosterone which is now known to be the principal
mineralocorticoid in man.
Aldosterone has a short half life of approximately 20-30 minutes, and its circulating
concentration is low, i.e 200-800 pM. This may be explained in part by the fact that it is not
well protected by carrier proteins or binding globulins, and it is therefore rapidly metabolised
by the liver.
Aldosterone acts predominantly on the distal convoluting tubule and the collecting
ducts of the kidney, although extra-renal sites of action include the sweat and salivary glands.
In the kidney it diffuses into the epithelial cells and binds to highly specific cytoplasmic
receptor proteins. This complex moves into the nucleus where it induces transcription of a
specific RNA related to sodium / potassium transport. This RNA facilitates protein synthesis in
conjunction with the ribosomes located in the cytoplasm. The protein(s) formed are thought
to mediate reabsorption of sodium and excretion of potassium by (Figure 1.6);
a. Increasing the activity or production of various mitochondrial enzymes that increase cellular










Figure 1.6. The cellular action of aldosterone.
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b. Increasing the activity of the (Na +, K+)-ATP-ase directly.
c. Increasing the sodium permeability of the cortical collecting tubule apical membrane
exposed to the tubular lumen. (Sharp and Leaf 1966)
(Edelman and Fimognari 1968)
d. By other as yet unidentified factors. (Marver and Kokko 1983)
The resulting increase in intracellular sodium generates a negative potential which is
returned to its resting state by potassium excretion. Hydrogen ion secretion in the medullary
collecting tubules is also stimulated. The renal effects of aldosterone commence 1-2 hours
after administration, reflecting the time required for protein synthesis, and are sustained for
4-8 hours. As expected mineralocorticoid deficiency causes sodium loss, hyperkalemia and
(Kassirer et al 1970) (Seldin et al 1972)
acidosis, whilst excess production results in sodium retention, hypokalemia and alkalosis.
The overall action of aldosterone depends markedly on sodium status. Increased
sodium intake results in more tubular sodium available for reabsorption, thus enhancing
potassium excretion. Conversely, sodium restriction diminishes both sodium reabsorption
and kaliuresis. Potassium itself can stimulate aldosterone secretion and this will be fully
discussed in a subsequent section. This effect leads to eventual potassium excretion and
serves as an intrinsic part of the bodies defence mechanism against hyperkalemia. An
additional mechanism protects against persistent mineralocorticoid excess, whereby the body
'escapes' from further sodium retention and hypokalemia. This is thought to be mediated via
secondary increases in other factors, such as atrial natriuretic peptide and renal
haemodynamics.
LJL Control of aldosterone secretion
In order to fully understand the pathophysiology of aldosterone secretion in diseases
such as essential hypertension it is necessary to gain a detailed understanding of the
mechanisms which control its secretion under normal conditions.
Unlike many other steroids, whose biosynthesis is controlled by a singular mechanism,
the regulation of aldosterone production is a complicated multifactorial process involving a
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series of contrasting signal-transduction mechanisms, the main ones of which are discussed
below. However, although many of these stimulate or inhibit aldosterone secretion both in
vivo and / or in vitro, their physiological importance remain unclear.
1.7.1. The renin-angiotensin system
The renin-angiotensin system is thought to be the major physiological regulatory
component of aldosterone secretion, and parallel changes in plasma renin activity (PRA) and
aldosterone secretion under a variety of conditions confirm this (Davis et al 1975, Fraser et al
1979, Coghlan etal 1979).
The proteolytic enzyme renin is synthesised by the juxtaglomerular cells of the kidney
and stored in intracellular granules. It is released exocytotically in response to a number of
stimuli, including a decrease in blood volume, pressure or plasma sodium concentration.
Upon its release it diffuses into the circulation where it acts on angiotensinogen, perhaps
more commonly known as renin substrate, cleaving it at the leucine-leucine peptide bond to
form the biologically inactive angiotensin I. The 2 amino acids from the C-terminal of
angiotensin I are then cleaved by angiotensin converting enzyme (ACE), an endopeptidase
located in many tissues but predominantly the lung, to form the active octapeptide
angiotensin II. This step can be blocked specifically by a group of drugs known as ACE
inhibitors and these include captopril and enalapril.
Angiotensin II stimulates aldosterone production in the adrenal glomerulosa both in
vivo and in vitro at both the early and late stages of the biosynthetic pathway (Ganong et al
1962, Kaplan 1965, Haning etal 1970, Aguilera and Marusic 1971). In addition, it stimulates
catecholamine release from the medulla and is also a potent vasopressor, increasing
peripheral arteriole resistance and subsequently blood pressure. During sodium depletion
the aldosterone response to angiotensin II is enhanced and the glomerular filtration rate is
decreased therefore reducing sodium excretion directly. Conversely, during sodium







Figure l.gfr. The cyclic AMP system. Activation of the catalytic unit (C), of adenylate
cyclase, catalyses the conversion of ATP to cyclic AMP. Cyclic AMP activates protein kinase
A, which phosphorylates proteins, thus producing physiologic effects. Stimulatory ligands
f
such as ACTH, bind to the stimulatory receptor (Rs) and activate C via Gs, the stimulatory
nucleotide regulatory protein. Inhibitory ligands inhibit C via the inhibitory receptor (Rj) and
the inhibitory G protein (Gj).
Angiotensin II is subsequently cleaved to angiotensin III, which can also increase
aldosterone secretion. The stimulatory effect of angiotensin II and angiotensin III on
aldosterone secretion result in the inhibition of renin release from the kidney and aldosterone
secretion from the adrenal gland. This important negative feedback mechanism which is
involved in the regulation of aldosterone, sodium homeostasis and blood pressure is
illustrated in figure 1.7.
Angiotensin II stimulates aldosterone secretion by binding to specific high-affinity
receptors located on the plasma membrane of the zona glomerulosa cell, a reaction which can
be blocked by angiotensin antagonists such as saralasin (Goodfriend et al 1970). The
angiotensin II receptors are thought to be coupled to at least 2 guanine-nucleotide binding proteins
(G-proteins), which act as transducers of the primary interaction with the receptor and the
initiation of the intracellular events leading to cellular response (Hausdorff et al 1987). One of
these proteins is known to be the inhibitory G-protein (Gj),which plays no role in the
stimulatory action of angiotensin II, but does mediate the inhibitory effects of high
concentrations of angiotensin II on aldosterone secretion. The second G-protein does
mediate the stimulatory effect of angiotensin II on aldosterone production but has yet to be
fully characterised. However, it is insensitive to pertussis toxin, indicating that it is not the
common stimulatory G-protein (Gs) linked to a number of other receptors such as ACTH. (Figure 1.6b)
Aldosterone production in response to angiotensin II is increased by a mechanism
which does not appear to involve the coupling of the G-proteins to adenylate cyclase, the
enzyme which catalyses production of the common second messenger, cyclic AMP. This
remains true even in the presence of theophylline, an inhibitor of phosphodiesterase, the
enzyme responsible for cyclic AMP breakdown (Tait et al 1974, Shima et al 1978). Indeed
some studies have shown cyclic AMP levels to actually decrease. However, this was later
attributed to either an impure cell preparation or increased phosphodiesterase activity,
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Figure 1.7 The renin angiotensin system and
the negative feedback system
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1979). Therefore, with no apparent role for cyclic AMP, attention has focussed on the role of
calcium (Ca2+) as a second messenger, and it is now clear that changes in intracellular Ca2+
concentration coupled to changes in phosphatidylinositol metabolism are key events in the
mechanism of action of angiotensin II.
Ca2+ is particularly suited to act as a second messenger because of the very low
(10-7 M) concentration of intracellular ionised Ca2+ compared with the much higher
extracellular level (10-3 M). This equilibrium is maintained by the cell membrane which at rest
is highly impermeable to Ca2+, by a Ca2+ pump which expels Ca2+ at the expense of ATP
and also by intracellular proteins and organelles which have a high affinity for the Ca2+ ion.
Consequently, any increase in intracellular concentration caused by a particular stimulus is
detected by the cell as a signal or message.
The involvement of extracellular Ca2+ in the action of angiotensin II was shown by many
groups, who demonstrated in isolated cells that removal of extracellular Ca2+ from the
incubation medium using chelating agents, or prevention of Ca2+ transport across the plasma
membrane using Ca2+ antagonists such as lanthanum, verapamil and tetracaine, completely
abolished steroidogenesis (Shima efa/1978). However, unlike ACTH, the binding of
angiotensin II to its receptor was unaffected (Fakunding et al 1979). Radiolabeled 45ca2+
influx studies have demonstrated both Ca2+ influx and efflux. Direct experiments using
highly purified glomerulosa cells loaded with Quin-2 or Fura-2, specific dyes which fluoresce
intensely on binding Ca2+, have shown a clear biphasic increase in the concentration of
cytosolic Ca2+ following stimulation by angiotensin II. Firstly, a rapid transient increase,
leading to a secondary but sustained increase. The sustained rise is thought to be of
extracellular origin as it can be blocked by Ca2+ antagonists, whilst the primary transient
increase is derived from a dantrolene-sensitive non-mitochondrial intracellular pool, most
probably the ER (Foster and Lobo 1981, Williams et al 1981, Foster and Rasmussen 1983,
Capponi et al 1984, Braley et al 1986, Kojima et al 1985a). Following its translocation to the
cell cytosol, Ca2+ can mediate the cellular response by binding to specific proteins which
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require Ca2+ for activity. One of these proteins is calmodulin, a ubiquitous compound first
described by Cheung in 1982. Calmodulin itself is devoid of enzymatic activity. However, on
binding Ca2+ it undergoes conformational changes which alter its association with other
cellular enzymes such as phosphorylase kinase and calmodulin dependent protein kinases I,
II and III, rendering them active and capable of phosphorylating a number of other compounds
which eventually initiate the cellular response. Calmodulin has also been shown to activate
phosphodiesterase which may account for the fall in cyclic AMP levels following angiotensin II
stimulation observed by Bell et al 1981.
Closely coupled to the ionic events is the phosphatidylinositol (PI) system. Following
binding of angiotensin II to its receptor, and transduction of the initial signal by the G-proteins,
phosphatidylinositol 4, 5-bisphosphate (PIP2) is hydrolysed by the enzyme phospholipase C
leading to the rapid formation of inositol 1,4,5-triphosphate (IP3) and Sn-1,2,-diacyl glycerol
(DAG) (Farese 1984a, Farese et al 1984b, Enyedi et a/1985). The IP3 mobilises Ca2+from
the intracellular pool, whilst DAG is a known activator of protein kinase C. Protein kinase C
causes phosphorylation of the proteins ultimately responsible for stimulating the
steroidogenic response, and it can be activated by using phorbol esters such as
(Figure 1.7b)
12-O-tetradecanoyl phorbol-13-acetate (TPA). Although discussed separately, the Ca2+ and
PI system are very closely integrated and the activation of both systems is required for maximal
steroidogenesis. This was clearly shown using the Ca2+ ionophore A23187 and TPA. In an
isolated cell system both drugs were required in the incubation to induce maximal
steroidogenesis (Kojima etal 1983,1984).
The synergistic effects of the Ca2+ and PI second messenger system on the
steroidogenic response are a clear example of a cellular cascade mechanism, whereby a small
signal is transposed into a large response via a number of intracellular events.
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GDP GTP IP3 Phosphoproteins
Figure 1.7b. The phosphatidylinositol second messenger system. Binding of ligand
e.g. angiotensin II, to receptor (R) activates phospholipase C (PLC) via a G protein (Gp). The
resulting hydrolysis of PIP2 produces IP3, which releases calcium from the endoplasmic
reticulum (ER) and DAG, which activates protein kinase C (PKC). Binding of calcium to calcium
binding proteins (CaBP) and the phosphorylation of proteins by PKC leads to the initiation of
physiologic effects.
1.7.2. ACTH
A number of pituitary-derived factors increase aldosterone secretion, including
pro-opiomelanocortin (POMC), y-melanocyte stimulating hormone (y-MSH), a-MSH, B-MSH,
(^-lipotropic hormone (fJ-LPH) and B-endorphins (Vinson et al 1980, Matsuoka et al 1981,
Seidah et al 1981). However, ACTH, which is more usually concerned with the control of
glucocorticoid secretion, is the most potent secretagogue, stimulating aldosterone secretion
both in vitro and in vivo, by acting on the early stage of the steroidogenic pathway (Davis et al
1975, Fraser et al 1979). However, its role in the maintenance of aldosterone secretion under
normal physiological conditions appears to be an acute one, as either hypophysectomy or
dexamethasone suppression have no effect on circulating levels of aldosterone
(Himathongkam et a/1975, Fraser efa/1979). Sodium depletion and potassium loading
enhance the aldosterone response to ACTH, whereas chronic ACTH deficiency reduces the
response to sodium depletion (Kern et a/1975, Davis et al 1975, Fraser et a/1979, Coghlan
et a/1979).
ACTH binds to specific cell surface receptors. Two populations of binding site have
been reported, a low affinity-high capacity site and a high affinity-low capacity site, the latter of
which is well correlated to the concentration of ACTH required to produce half maximal
stimulation of aldosterone secretion (Gallo-Payet et al 1985). Binding of ACTH to its receptor
causes activation of the membrane bound adenylate cyclase, resulting in generation of the
second messenger cyclic AMP (Kojima et al 1985b). The ACTH receptor is coupled to
adenylate cyclase by a stimulatory G protein (Gs) which binds GTP and stimulates the enzyme
and cyclic AMP production respectively (Kojima et al 1985b). The cyclic AMP generated
binds to inactive cyclic AMP-dependent protein kinases which consist of two distinct
sub-units; one of a catalytic nature, the other regulatory. Cyclic AMP binds to the regulatory
sub-unit, causing dissociation and subsequent release of the active catalytic moiety. This
active unit catalyses the phosphorylation of specific proteins which mediate the steroidogenic
response. There appear to be a number of cyclic AMP-dependent protein kinases, which
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integrate to phosphorylate common protein substrates. Meanwhile the Gs-protein slowly
hydrolyses guanosine tri-phosphate (GTP) to guanosine di-phosphate (GDP) and phosphate
(P), inactivating the adenylate cyclase moiety, and thus terminating cyclic AMP production and
the end response.
Some studies have suggested that different signal transduction mechanisms operate,
depending on the concentration of acth, for example at concentrations >10*9 m, cyclic
amp and steroid output are increased, whereas at < 10-10 m there is no increase in cyclic
amp although steroidogenesis is enhanced (Kojima et al 1985b).
In the action of ACTH, Ca2+ again plays a key role in the coupling of the initial signal to
the end response and K is closely associated with activation of the adenylate cyclase system.
The requirement of extracellular Ca2+ was shown by a number of groups who demonstrated
that in the absence of extracellular Ca2+, cyclic AMP and aldosterone secretion were
inhibited, and ACTH had a greater effect on cyclic AMP production when extracellular Ca2+
was elevated (Fakunding et al 1979, Shima et al 1979). The former effect was later partly
attributed to the requirement of Ca2+ for ACTH binding to its receptor (Cheitlin et a/1985).
However, Ca2+ is also required at several stages in the transduction process subsequent to
receptor binding. Stimulation of the transmembrane influx of Ca2+ by ACTH was
demonstrated by 45ca2+ studies, however, Ca2+ efflux was unaffected (Leier and Jungman
1973, Williams et al 1981, Kojima et al 1985b). Further studies showed similarly that Ca2+ was
not mobilised from an intracellular pool as was found with angiotensin II, but was derived solely
from an extracellular source (Kojima et al 1985b). Ca2+ itself can partially mimic the
steroidogenic effect of ACTH, although A23187, a Ca2+ ionophore, only weakly stimulates
secretion, indicating a permissive rather than mediatory effect of Ca2+ on steroidogenesis.
The events which couple Ca2+ influx to the cellular response are similar to those
induced by the action of angiotensin II, i.e. binding of the Ca2+ to calmodulin resulting in the
activation of protein kinases and phosphodiesterase which result in increased
steroidogenesis and the termination of the cyclic AMP response respectively.
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1.7.3. Sodium
In 1954 Leutscher and Axelrad first observed a link between sodium status and
aldosterone secretion, and it is now apparent that sodium depletion increases both
aldosterone secretion and the width of the zona glomerulosa. Conversely, sodium loading
decreases aldosterone secretion and zona glomerulosa width. However, the exact
mechanism of this has remained somewhat unclear, mainly due to the large number of
physiological effects initiated by altered sodium status whose individual relevance and relative
contribution to the change in aldosterone output are poorly understood.
During a low sodium diet, for example, these effects include;
1. Modulation of the renin-angiotensin system, in that lowering sodium increases renin
secretion from the juxtaglomerular cells of the kidney, which acts as described in the previous
section. An increase in the number of angiotensin II receptors, and subsequent zona
glomerulosa resposiveness to angiotensin II has also been observed.
2. Decreased extracellular fluid volume, circulating plasma volume and arterial blood pressure,
which may also activate the renin-angiotensin system.
3. Retention of potassium ions, which can stimulate aldosterone production directly.
The effects of sodium on aldosterone secretion therefore appear to be largely indirect,
and it has been suggested that its principal action is on the renin-angiotensin system.
However, studies in nephrectomised animals whose renin-angiotensin system is therefore
absent, have shown that aldosterone output is still enhanced during sodium restriction.
Some groups have suggested the involvement of a pituitary-derived substance, not ACTH,
which is secreted during sodium depletion and stimulates aldosterone production (McCaa et
al 1974, Pratt et al 1981). Other studies have suggested a direct adrenal action of low
sodium, acting at both the early and late stage of the biosynthetic pathway (Davis et al 1968,
Tait etal 1970). More recently a local renin-angiotensin system has been identified in the
adrenal cortex which is activated during sodium depletion. This could perhaps account to
some extent for the increase in aldosterone secretion during sodium depletion in
22
nephrectomised animals (Doi et a/1983,1984).
1.7.4. Potassium
In contrast to sodium, potassium loading increases aldosterone secretion whilst
potassium depletion decreases it. Acutely, it appears to act exclusively and directly on the
zona glomerulosa to stimulate the early step in the aldosterone biosynthetic pathway.
However, chronic potassium loading stimulates the conversion of corticosterone to
aldosterone, and increases the width of the zona glomerulosa. Chronic potassium depletion
can also act directly at the kidney to increase renin release (Abbrecht and Vander 1970,
Brunner et al 1970).
The mechanism by which potassium stimulates aldosterone secretion has been
investigated in the same way as the other stimuli. The aldosterone response, which appears
to be maximal at approximately 8.4 mM potassium, can be completely inhibited by the Ca2+
channel blocker nifedipine, thus indicating a role for extracellular Ca2+ and a
voltage-dependent Ca2+ channel. 45Ca2+ influx and efflux studies confirmed that the Ca2+
is of extracellular origin and is not mobilised from an intracellular source (Fakunding et al 1979
and Williams et al 1981). However, some studies using 8-(diethylamino) octyl
3,4,5-trimethoxybenzoate (TMB-8), which blocks release of Ca2+ from an internal source,
have suggested the involvement of the intracellular pool, though the non-specific and side
effects of these agents have yet to be fully characterised (Mackie et al 1978, Braley et al
1986). Direct experiments using the fluorescent dyes Quin-2 and Fura-2 have shown that the
increase in cytosolic calcium could be completely blocked with nifedipine, indicating that the
elevated intracellular Ca2+ concentration is derived from a purely extracellular source and the
response is therefore sustained and not biphasic like that of angiotensin II (Capponi et al
1984) .
It is therefore now generally believed that the stimulatory effect of potassium on
aldosterone secretion is not a receptor mediated event but results from depolarisation of the
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plasma membrane by potassium which causes Ca2+ influx via the voltage dependent Ca2+
channel. In addition to its effects on Ca2+, several groups have shown that potassium
causes a small but significant increase in cyclic AMP production, although this has been
disputed by others and shown to be prevalent only at higher concentrations of potassium
(Boyd et a/1973, Albano et al 1974, Tait ef a/1974, Fakunding et al 1979, Kojima et al 1985c,
Hyatt et al 1986). However, it is still unclear if the increase in cyclic AMP is a direct effect of the
potassium or indeed secondary to the changes in intracellular Ca2+ concentration. No
increase in radiolabeled IP3 or 3H-inositol incorporation was observed in the presence of
increasing potassium concentration, although a small transient decrease in PIP2 and increase
in IP3 has been reported in isolated cells in the presence of 8.7 mM potassium (Whitely etal
1984, Kojima et al 1985c, Underwood e/a/1987).
1.7.5. Serotonin
The stimulatory capacity of serotonin (5-hydroxytryptamine; 5HT) on adrenal steroid
secretion was first observed by several groups, who demonstrated that serotonin increased
secretion of a compound from isolated adrenal tissue of many species (Rosencrantz 1959,
Rosencrantz and Laferte 1960, Connors and Rosencrantz 1962). This compound was not a
metabolite of serotonin but a steroid which possessed similar chromatographic properties to
aldosterone and caused marked sodium retention when administered to adrenalectomised
rats. The compound was therefore tentatively identified as aldosterone. At around the same
time it was also shown that rat serum, but not plasma, stimulated corticosteroid production in
rat glomerulosa cells, suggesting that a component of the blood clotting system may
contribute to the steroidogenic effect (Bakker and Wied 1960). However, they dismissed the
role of serotonin as the effect could not be blocked by dihydroergotamine. Some years later it
was shown that both human and rat serum caused the same stimulatory effect on steroid
secretion and further studies revealed that this could be blocked by the serotonin antagonist
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methysergide (Muller and Ziegler 1968, Mendelsohn and Kachel 1981).
Since these initial studies many groups have clearly demonstrated the aldosterone
stimulatory properties of serotonin in isolated glomerulosa cells, where it is thought to act like
many other of the stimuli at the early stage of the biosynthetic pathway, although the effect
does appear to be species dependent (Blair-West et al 1962, Haning et al 1970, Tait et al
1972, McDougall et al 1976, Bing and Schulster 1977, Fujita et al 1979). Serotonin has no
effect on zona fasciculata cells (Mu'ller et al 1970, Haning et al 1970). In vivo studies have
proved considerably more difficult to carry out, mainly due to the immediate uptake of
serotonin by the platelets or its rapid metabolism to 5-hydroxyindoleacetic-acid (5HIAA).
Despite this, stimulatory effects on aldosterone have been reported by a number of groups
and others have shown an effect with administration of the precursors to serotonin;
5-hydroxytryptophan (5HTP) and tryptophan (Modlinger et al 1979, Al-Dujaili et al 1980,
Mantero et a/1982, Shenker et al 1985a,1985b, Maestri et a/1988).
The mechanism by which serotonin stimulates steroidogenesis is not entirely clear.
Some studies have shown that serotonin can stimulate release of corticotrophin releasing
factor (CRF) from rat hypothalamic tissue (Fuller and Clemens 1981, Holmes et al 1982).
Similarly, it was observed that ACTH and Cortisol output, in addition to aldosterone, were also
increased when tryptophan or 5HTP was administered to humans (Modlinger et al 1979,
Maestri et al 1988). These results indicate that in vivo, serotonin may act centrally to release
CRF and subsequently ACTH which stimulates aldosterone secretion. A similar hypothesis
was also suggested by Shenker et al 1985b, who showed that peripheral blockade of
serotonin synthesis using carbidopa, augmented the aldosterone response to 5HTP
administration, whilst the serotonin antagonists ketanserin or methysergide had no effect. A
centrally mediated action may account for the mechanism of action of serotonin in vivo, but
they fail to explain the stimulatory effect on isolated cells, which are obviously devoid of any
central involvement. They also fail to explain the stimulatory effect of serotonin on perfusion
flow and steroid secretion in the isolated perfused rat adrenal gland in situ (Hinson et al
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1989).
A direct action of serotonin on the zona glomerulosa remains a possible theory,
however specific receptors for serotonin in the adrenal have yet to be identified and fully
characterised as they have been in the CNS, vasculature and platelets (see chapter 2). If
these receptors exist then a signal-transduction mechanism would be in operation, and many
groups have reported an increase in cyclic AMP output in isolated giomerulosa cells
stimulated with serotonin (Albano et al 1974, Fujita et al 1979). Indirect studies using various
Ca2+ antagonists, which block the aldosterone stimulating properties of serotonin have also
indicated a possible role for Ca2+ influx (Ganguly and Hampton 1985). No change in Ca2+
efflux from an intracellular source has been observed in isolated zona glomerulosa cells
loaded with 45ca2+ and stimulated with serotonin suggesting overall that it may act in a similar
fashion to ACTH (Williams et al 1981). Similarty, studies in isolated zona glomerulosa cells
using Ca2+ sensitive fluorescent dyes have shown no increase in intracellular Ca2+ levels.
However, these experiments were carried out in bovine derived cells, which do not respond
steroidogenically to serotoninergic stimulation (Capponi etal 1987).
The biochemistry of serotonin is discussed more fully in the following chapter and it is
the aim of the subsequent chapters of this thesis to answer the unsolved questions
pertaining to serotonin and the adrenal gland, and establish its physiological role in the control
of aldosterone secretion, which has so far remained elusive.
1.7.6. Aldosterone Stimulating Factor
A protein fraction isolated from human urine was found to increase aldosterone
production in isolated zona glomerulosa cells from many species, and also cause
hypertension and elevated plasma aldosterone levels when chronically administered to rats
(Sen etal 1977, Bravo etal 1980, Saito efa/1981 and Sen etal 1981a, 1981b). The
compound, termed aldosterone stimulating factor (ASF), was found to be a glycoprotein
localised exclusively in the cells of the pituitary anterior lobe and found to be elevated in
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patients with idiopathic hyperaldosteronism (Sen et al 1981b, Carey efa/1984). The
stimulatory properties of ASF, unlike angiotensin II, remain unaffected by sodium depletion or
by the introducton of antagonists of angiotensin II or ACTH, indicating that the stimulatory
properties of ASF could not be attributed to an interaction with the angiotensin II or ACTH
receptor. High concentrations of ASF do however potentiate the aldosterone response to
angiotensin II in isolated zona glomerulosa cells, but only during sodium depletion.
Conversely, similar concentrations of ASF inhibit the response to ACTH in both sodium
deplete and replete conditions (Hata et al 1984, Bravo et al 1980, Saito et al 1981 ).
1.7.7. Catecholamines
Catecholamines, e.g adrenaline and noradrenaline, are stored in the chromaffin cells of
the adrenal medulla and are normally concerned with control of glucocorticoid biosynthesis in
the zona fasciculata, a reaction facilitated by the close proximity of the two areas. However, De
Lean et al 1984a, showed that both noradrenaline and analogues of noradrenaline could
stimulate aldosterone production in vitro with a concommitant increase in cyclic AMP. This
process is mediated by B-1 receptors.
1.7.8. Vasopressin
Arginine vasopressin (AVP) has been shown to increase aldosterone secretion in vitro
in a cell superfusion system though the effect is small and transient (Balla et al 1985). No
stimulatory effects have been reported in either a static cell system or in vivo (Vinson et al
1981). However, at low concentrations it potentiates the aldosterone response to low doses
of ACTH. Conversely, at higher concentrations AVP blocks the response to high doses of
ACTH (Payet and Lehoux 1982).
Specific V-2 receptors have been identified on zona glomerulosa cells, and these are
thought to be coupled to the PI second messenger system as PIP2 breakdown and IP3
formation has been demonstrated (Woodcock et al 1986). In addition, AVP has been
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localised in the adrenal medulla using RIA, HPLC and histochemical techniques (Ang and
Jenkins 1984). This is thought to influence the secretion of catecholamines which, as
discussed previously, can stimulate corticosteroid secretion.
1.7.9. Prostaglandins
Prostaglandins were first implicated in the control of aldosterone secretion by Flack ot al
1969, who showed a stimulatory effect on aldosterone output in vitro by prostaglandins Fiu,
Ei and E2- However, conflicting results were reported by Splat and Jozan 1975, who showed
a stimulatory effect by prostaglandins only of the type E.
It has been suggested that prostaglandins may play a role in the enhanced aldosterone
response to ACTH, observed during sodium depletion, as indomethacin, an inhibitor of
prostaglandin synthesis, blocks the enhanced response (Morise et a/1982).
1.7.10. Atrial natriuretic peptide
In 1981 de Bold et al demonstrated that intravenous administration of atrial extracts to
rats provoked a slight fall in arterial blood pressure and a large natriuresis, which was absent
when similar experiments were conducted using ventricular tissue. The compound(s)
responsible for these effects were found in atrial granules similar to those of the kidney JG
cells and were termed the atrial natriuretic peptides (ANP). It was found that the granularity
could be altered by water and salt depletion and adrenalectomy (Kisch 1956, Jamieson and
Palade 1964, de Bold et al 1978)
Since these early studies a number of groups have since purified and fully
characterised the various peptides in humans and other species (Thibault et al 1983, Atlas et
al 1984). Consequently, synthetic ANP has been manufactured and used in a number of
experiments, where it has been shown to inhibit basal aldosterone secretion both in vivo and
in vitro, in addition to the aldosterone response to angiotensin II, potassium and ACTH
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(Chartier et a/1984, Maack ef a/1984, Atarashi efa/1984, Volpe et al 1985). More recently,
work by Espiner and Richardson 1989, has shown that infusion of physiological doses of ANP
decreases aldosterone secretion, PRA and systolic blood pressure.
The mechanism by which ANP decreases aldosterone production is not entirely clear.
Specific membrane receptors of both a high and low affinity have been identified, which are
distinct from those of angiotensin II and ACTH (De Lean et al 1984b, 1984c). ANP has been
shown to inhibit adenylate cyclase, and although this may account for the inhibitory effect on
the action of ACTH, it fails to explain the effect on angiotensin II stimulated aldosterone
output, which does not involve adenylate cyclase (Anand-Srivastava et al 1984). In addition to
its effects on adenylate cyclase, ANP has been shown to increase cyclic GMP production.
However, it is unclear which is the primary mechanism (Waldman et al 1984). It has also been
postulated that ANP may act as a Ca2+ channel blocker, and this may explain its inhibitory
effect on angiotensin II, potassium and ACTH stimulated aldosterone secretion, which all
utilise calcium as a second messenger. However, the effect of ANP on Ca2+ entry is
controversial, with some groups reporting inhibition and others reporting no change.
(Capponi et al 1986, Chartier and Schiffrin 1987). However, recently patch clamp techniques
have shown that in bovine cells, ANP inhibits T(transient) -type Ca2+ channels and stimulates
L(k>ng lasting, large capacitance)-type channels (McCarthy et al 1990).
In addition to regulating steroid biosynthesis, ANP may also act as an adrenal growth
factor as it stimulates incorporation of thymidine into the DNA of adrenal zona glomerulosa
cells in primary culture (Horiba et al 1985).
1.7.11. Dopamine
A possible role for dopamine in regulating aldosterone secretion came largely from
pharmacological in vivo experiments using the dopamine antagonist metoclopramide which
enhanced aldosterone secretion but not plasma renin activity (PRA), ACTH or plasma
potassium , indicating that under normal circumstances aldosterone secretion is under tonic
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inhibition by dopamine (Carey et al 1979). Although this theory is not supported by other
workers who have suggested that the inhibition of aldosterone synthesis by dopamine is an
extra-adrenal effect caused by increased renal clearance of angiotensin II (Inglis et al 1987,
Connell et a/1987). Further studies, using a rat adrenal cell superfusion system, showed that
the steroid enhancing effects of metoclopramide could be blocked by dopamine, but not
angiotensin II (Brown efa/1977, Carey efa/1979, Edwards et al 1980a). However, Aguilera
and Catt 1984, demonstrated that during sodium repletion the sensitivity of the aldosterone
response to angiotensin II was enhanced in the presence of metoclopramide, suggesting that
the antagonist reversed the inhibitory effect of dopamine. However, in sharp contrast, other
groups have failed to demonstrate a stimulatory effect of metoclopramide on aldosterone
secretion either in vivo or in vitro or a inhibitory effect of dopamine itself on aldosterone
secretion, (Campbell et al 1981, Hampton and Ganguly 1986) and also the serotoninergic
agonist properties of metoclopramide must be remembered, which makes interpretation of
these results difficult. In vitro studies using isolated bovine and rat zona glomerulosa cells
with dopamine itself are less conclusive. These have shown that dopamine has either no
effect or only a moderate inhibitory effect on basal aldosterone secretion or secretion
stimulated with angiotensin II or ACTH and only at very high concentrations of > 10~5 M
(Boscaro et al 1979, Edwards et al 1980a, McKenna et al 1979, Aguilera and Catt 1984,
Sequeira and McKenna 1985). In contrast, infusions of angiotensin II plus dopamine in
sodium deplete human impeded the increased sensitivity to angiotensin II normally observed.
This regulatory role of dopamine during altered sodium status has been supported by other
studies which have shown a decrease in urinary dopamine during sodium depletion and
conversely an increase during sodium loading (Alexander et a/1974, Carey et a/1981).
These effects on the adrenal are thought to be mediated by specific dopamine
receptors located on the zona glomerulosa. Recently these receptors have been classified
into DA-1 and DA-2 sub-types. The mechanism of dopaminergic action is not entirely clear,
though some groups have suggested that the DA-1 receptor stimulates adenylate cyclase
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activity and aldosterone production, whilst the DA-2 receptor inhibits adenylate cyclase and
aldosterone (Missale etal 1986).
The dopamine involved in the control of aldosterone secretion may be derived from the
circulation or the adrenal itself as several groups have shown the presence of dopamine
containing chromaffin granules in many species. Further support for the local effect are
studies which showed that the stimulatory effects of metoclopramide infusion on aldosterone
secretion was not altered by ganglionic blockade of the autonomic nervous system (Van
Loom efa/1980, Wilson etal 1983). The dopaminergic mechanism appears to be
independent of the nervous system as adrenal catecholamine content is not depleted by
splanchnic nerve section or central inhibitors of catecholamine biosynthesis (McCarty et al
1984).
1.7.12. Histamine
The role of histamine in the control of aldosterone secretion was first shown by
Edwards et al 1980b, using isolated superfused rat adrenal zona glomerulosa cells. The H2
antagonists cimetidine and ranitidine elevated basal aldosterone secretion and blocked the
response to angiotensin II, but not serotonin, ACTH or potassium. In contrast, the Hi
antagonist chlorphenhydramine, enhanced the aldosterone response to both angiotensin II
and ACTH, indicating a possible link between the histamine and the angiotensin II receptor.
1.7.13. Somatostatin
Somatostatin inhibits the aldosterone response to angiotensin II, but not ACTH,
potassium or 8-bromo-cyclic AMP (Aguilera et al 1981a). However, at high concentrations it
moderately increases basal aldosterone secretion in isolated zona glomerulosa cells. This
agonistic effect has been attributed to a weak interaction of the peptide with the angiotensin II
receptor. Firstly, as it can be blocked by the addition of saralasin and secondly, in high
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concentrations somatostatin can displace radiolabeled angiotensin II from its binding site. In
contrast, the inhibitory effect of somatostatin on angiotensin II stimulated aldosterone output
is probably due to an interaction with its own specific receptor within the adrenal. Indeed
studies have demonstrated specific binding sites within the adrenal zona glomerulosa and
immunohistochemical studies have shown the presence of somatostatin itself, although this
has been disputed by other groups (Aguilera et al 1981,1982, Srikant and Patel 1985).
UL Disorders of mlneralocortlcold secretion
1.8.1. Mineralocorticoid excess
Overproduction of aldosterone associated with suppressed renin is termed primary or
idiopathic hyperaldosteronism, or more commonly Conn's Syndrome. It is caused by either an
adrenal adenoma, micro or macro nodular hyperplasia or more rarely a carcinoma. The
symptoms of this disease are hypertension, headaches and hypokalemia leading to muscle
weakness and polyuria. Oedema rarely occurs. Diagnosis is based on elevated plasma
aldosterone and low renin levels. If only one gland is affected, treatment is by unilateral
adrenalectomy. If both adrenals are involved, large doses of an aldosterone antagonist, such
as spironolactone which is now known to have potentially dangerous side effects, or
amiloride, are administered.
Secondary hyperaldosteronism results from over production of renin, causing a
subsequent increase in angiotensin II and therefore aldosterone, resulting in the same
symptoms as the primary condition. The cause of the persistent renin secretion may be due
to a tumour of the juxtaglomerular cells of the kidney or hyperplasia (Barber's Syndrome). A
positive diagnosis is made from the plasma levels of aldosterone and renin which are both
elevated. Treatment is similar to that of the primary condition.
1.8.2. Mineralocorticoid deficiency
Addison's disease is the result of autoimmune or idiopathic atrophy, causing both
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mineralocorticoid and glucocorticoid deficiency. Hypo-secretion of aldosterone results in
increased natriuresis, diuresis, plasma potassium concentration, and decreased plasma
sodium and blood volume, resulting in postural hypotension and faintness. Glucocorticoid
deficiency leads to high levels of plasma ACTH, an attempt by the body to increase steroid
secretion from the damaged gland, a condition which also causes skin pigmentation. Patients
normally present during an Addisonian crisis i.e abdominal pain, fever and hypotensive
collapse. Confirmation of Addison's disease is by an ACTH stimulation test, wherby
administration of synthetic ACTH (Synacthen) fails to stimulate Cortisol production. The
immediate treatment is by intravenous infusion of saline and hydrocortisone and maintenance
with glucocorticoid and mineralocorticoid replacement therapy.
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Chapter Two
The Biochemistry of Serotonin.
ZAl Introduction
Serotonin is a potent vasoconstricting agent, present in serum after blood has clotted,
and with the knowledge that serotonin may therefore affect blood vessels throughout the
body, many researchers have focussed their interests on the potential role of serotonin as a
humoral agent responsible for the development and maintenance of hypertension and
cardiovascular disease. However to date, despite many years of intensive clinical and
laboratory studies, the physiological and pathophysiological relevance of serotonin in man
remains elusive.
2*2* Discovery of serotonin
In 1933 Erspamer and Asero isolated a phenolic compound called enteramine from the
gastric mucosa, which stimulated contraction of intestinal and uterine muscle strips. Some 15
years later Rapport and his colleagues isolated a potent vasoconstrictive compound from
serum which they called serotonin. The former group later confirmed in 1952 that enteramine
and serotonin were in fact the same compound, systematically named
5-hydroxy-3-(2-aminoethyl)-indole or more simply 5-hydroxytryptamine (5HT) and commonly
now known as serotonin (Figure 2.1).
2.3. Biosynthesis of serotonin
With the exception of platelets, serotonin is synthesised in most of the tissues in which
it is stored, including the central nervous system (CNS) and the pineal gland. However the
enterochromaffin cells of the gut, also known as amine precursor uptake and decarboxylation
(APUD) cells remain the major site of biosynthesis in man (Pearse 1968).
Serotonin is synthesised from the essential amino acid L-tryptophan by two enzymatic
reactions (Figure 2.2). These represent a minor metabolic pathway for tryptophan and utilise
approximately 2% of the total dietary intake. The first step which converts tryptophan to
5-hydroxytryptophan (5HTP) is catalysed by the enzyme tryptophan hydroxylase. This has
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Figure 2.2. The biosynthesis of serotonin.
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been localised by immunohistochemical staining extensively in the brain and periphery but
not in platelets (Joh et al 1975, Gershon et al 1977a, Morrissey et al 1977). The enzyme
requires tetrahydrobiopterin as a co-factor and is easily inactivated by molecular oxygen (Kuhn
etal 1980a). The Km is approximately 3x10-5 M, which is high in comparison with the normal
circulating levels of tryptophan (Tong and Kaufman 1975). Therefore, as it is not saturated
with substrate its action appears to be the rate limiting step, and thus a point of control in the
serotonin biosynthetic pathway. Tryptophan hydroxylase activity can be inhibited both in vivo
and in vitro by the amino acid p-chlorophenylalanine (PCPA), causing a subsequent fall in
serotonin concentration, and thus providing a useful tool to investigate the effects of
serotonin depletion (Jecquier et a/1967).
The second step, which converts 5-hydroxytryptophan to serotonin, is catalysed by
L-aromatic amino acid decarboxylase, an enzyme which also catalyses the decarboxylation of
many other amino acids e.g tyrosine and phenylalanine to form catecholamines, such as
dopamine. It is located in a number of tissues, particularly the liver and kidney and also the
adrenal gland. It requires pyridoxal phosphate as a co-factor, which paradoxically, inhibits the
enzyme when present in excess i.e > 6x10-7 M (Bouchard and Roberge 1979). The Km for
this enzyme is low i.e 8 x 10 -6 M and consequently is not a rate limiting step. Inhibition of this
step by carbidopa and other amino acid analogs provide yet another useful method of
depleting circulating levels of serotonin, however, it must be remembered that a concomitant
decrease in the levels of circulating catecholamines will also occur (Gershon et al 1977b).
2*4* Metabolism of serotonin
The primary route of serotonin metabolism (Figure 2.3) is by oxidative deamination to
the unstable intermediate 5-hydroxyindoleacetaldehyde by monoamine oxidase, a
ubiquitous enzyme localised on the outer mitochondrial surface, and requiring FAD+ as a

































Figure 2.3. The metabolism of serotonin.
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A , found both intra and extra-neuronally, is responsible for the deamination of serotonin and
noradrenaline, and secondly the type B, solely extra-neural, which deaminates other amines
including dopamine and phenylalanine (Youdim and Ashkenazi 1982). Under normal
conditions the 5-hydroxyindoleacetaldehyde is rapidly converted to 5-hydroxyindoleacetic
acid (5HIAA) by aldehyde dehydrogenase. This is the major urinary excretory product in
mammals. Alternatively, and in particular following ingestion of ethyl alcohol, the oxidative
pathway is switched off and the reductive pathway, catalysed by aldehyde reductase, is
switched on forming 5-hydroxytryptophol (Davis et a/1967). This enzyme requires NADP as a
co-factor and has a high affinity for its substrate (Km = 4 x 10*6 M) (Turner and Tipton 1972).
Other minor pathways of serotonin metabolism include sulfation by serotonin-
sulfotransferase to form the biologically inactive serotonin-o-sulfate. However, only a very
small amount of serotonin-o-sulfate can be detected even when the monoamine oxidase
pathway is blocked (Hammond etal 1981,1984). This step can be reversed by aryl sulfatase
enzymes, indicating that sulfation may therefore serve as a temporary serotonin inactivating
system (Kishimoto et al 1961).
Glucoronidation, a common detoxifying mechanism which takes place mainly in the liver,
is catalysed by uridine diphosphate glucoronyltransferase. This reaction forms
serotonin-o-glucoronide which is excreted in large quantities when the monoamine oxidase
pathway is blocked (Tyce et al 1968).
N-acetylation is the initial step in the conversion of serotonin to the hormone melatonin,
formed primarily in the pineal gland. Serotonin is converted to N-acetylserotonin by
serotonin-N-acetyltransferase, which is localised within the cell cytosol, and requires acetyl
co-enzyme A (Paul et al 1974). This is then methylated to form melatonin by
hydroxyindole-O-methyltransferase which utilises S-adenosylmethionine as the methyl donor.
The activity of serotonin N-acetyltransferase exhibits a marked rhythm throughout the day,
being highest at night and lowest during the day. Consequently, the levels of melatonin
exhibit a similar diurnal rhythm (Klein and Weller 1970).
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2JL Storage and release of serotonin
Serotonin is widely distributed throughout the plant and animal kingdom, and storage
sites have been located in the pituitary gland, the pineal gland, the pancreas and of particular
interest to this project, the adrenal gland (Saavedra et al 1974, Verhofstadt and Jonsson
1983, Holzwarth et al 1984, Koevary et al 1983). However, the most common sites of storage
are discussed in the sections below.
2.5.1. Serotonin in the central nervous system
Neurones containing serotonin were first identified in the central nervous system
using fluorescent histochemical techniques (Dahlstrom and Fuxe 1964). Serotonin is formed
locally within the neurones as it does not easily cross the blood-brain barrier. These neurones
are easily identified by the presence of tryptophan hydroxylase, the first enzyme in the
serotonin biosynthetic pathway (Kuhar et a/1972) (see section 2.2). Although serotonin itself
does not readily cross the blood-brain barrier, 5HTP the immediate precursor does and
systemic administration of this compound increases both cerebral and peripheral levels of
serotonin. Similarly depletion of serotonin levels in the CNS can be carried out again using
PCPA as previously described or using the cytotoxic agents 5,6 dihydroxytryptamine or 5,7
dihydroxytryptamine which are taken up by the neurons.
Serotoninergic neurones are derived from clusters of serotonin containing cell bodies
situated in the raphe nucleii of the brain stem, which project both upwards and downwards to
various areas of the CNS. The downward projecting neurones which terminate in the spinal
cord are associated with spinal motor reflexes and the conduction of painful stimuli, whilst the
ascending neurones project towards the forebrain structure, particularly the cortex, striatum
and hippocampus where they are thought to be involved in depression, anxiety and
behavioral patterns. A great deal of interest has focussed on the ascending neurones
projecting towards the hypothalamus, which itself is known to play a key role in cardiovascular
function.
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2.5.2. Serotonin in the gastro intestinal tract
Serotonin is synthesised, as previously described, and stored in the enterochromaffin
(APUD) cells of the gut, where it has a short half life of 10-17 hours (Udenfreind and
Weissbach 1958, Erspamer and Testini 1959). It is then stored in secretory granules in close
association with substance P (Alumets et al 1977). Its release into the lumen of the bowel or
the portal blood supply from the basolateral membrane of the enterochromaffin cells by
emeiocytosis can be triggered by a number of stimuli, including acetylcholine, an increase in
transluminal pressure or a decrease in intestinal pH (Forsberg and Miller 1983, Bulbring and
Crema 1959, Kellum and Jaffe 1976). Upon its release it is thought to stimulate secretion of
pepsin and mucus and inhibit gastric acid production (Menguy 1969, Haverback et al 1958). It
also increases the motility of the small intestine i.e the peristaltic reflex, in addition to water
and electrolyte secretion (Brownlee and Johnson 1963, Kiskoff and Moore 1977).
The alternative source of serotonin in the gut are the serotoninergic neurones which
synthesise and take up serotonin by an energy dependent process which requires Na+ and
Ca2+ (Gershon and Altman 1971). Release of serotonin from these neurones produces an
inhibitory effect on the processes initiated by its release from the enterochromaffin cells.
2.5.3. Serotonin in the blood
The potentially lethal capacity of serotonin to increase vascular permeability and
mediate anaphylactic shock means very little, if any, free serotonin is found in the circulatory
system of a healthy individual (Majno and Palade 1961, Gershon and Ross 1962). This status
is maintained by a number of mechanisms including serotonin binding proteins in the blood
e.g serotonectin (Pignatti and Cavalli-Sforza 1975). However, the majority of serotonin in the
blood is taken up by platelets. These are small anucleate cells which cannot synthesise
serotonin and whose main function is hemostasis. The serotonin is stored within dense
granules in close association with cations, nucleotides and proteins, where it has a half life of
between 33-48 hours. The serotonin uptake process consists of at least 3 complicated
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steps. Firstly, serotonin is transported through the platelet membrane either passively when
extracellular serotonin concentration is high i.e > 10 pM or actively when the concentration is
less than 5 pM. These processes are aided by serotonectin which is localised on the platelet
cell surface. The former passive process is highly temperature dependent, whilst the latter
active system depends markedly on the presence of extracellular sodium. Once inside the
platelet serotonin is taken up into the membrane enclosed dense granules, a process which
again is temperature dependent, but not active, as shown by the apparent ineffectiveness of
oubain or iodoacetate as inhibitory agents. Finally, once inside the granules, serotonin forms
a complex with ATP and divalent cations, by a mechanism which is poorly understood (Bom
and Bricknell 1959, Pletscher 1968).
Serotonin is released from the platelets by four main mechanisms; exocytosis,
exchange, inhibition of transport at the granular membrane and by aminophores and
protonophores. These reactions are triggered by a number of stimuli including thrombin,
which is involved in the blood-clotting reaction. The serotonin released acts synergistically
with the primary trigger causing further activation and enhancement of the shape change and
aggregatory reaction.
Thus platelets play an important role in serotonin storage and it has recently been
suggested that they may act as a circulating store of serotonin, which can be released by a
process other than irreversible aggregation, at a specific tissue or site which has no nearby
source of serotonin but does possess serotonin receptors (Osim and Wylie 1983).
2.6. Serotonin receptors
Initially 2 types of serotonin receptor, both found in the guinea-pig ileum, were
described by Gaddum and Picarelli in 1957. One, termed D, which mediated the contraction
of enteric smooth muscle could be antagonised by dibenzylamine. The other, termed M,
could be antagonised by morphine. This classification was based purely on pharmacological
studies. However, with the advent of radioligands, which have proved extremely valuable
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research tools, more detailed studies have been made in the classification of the serotonin
receptor.
One of the first studies of serotonin receptors using radioligands was carried out in rat
brain cortex membranes by Peroutka and Snyder in 1979, who demonstrated that
3H-serotonin and 3H-spiperone, a potent serotonin antagonist, each bound to distinct sites.
They named the binding site with high affinity for 3H-serotonin the Si -serotonergic (5HTi)
receptor and that with high affinity for 3H-spiperone the S2-serotonergic (5HT2) receptor.
Recent studies have shown that there is a close correlation between the cortical 5HT2 binding
site and the previously described D receptor, and that they are in fact probably identical.
However, studies with methiothepin and ketanserin, specific antagonists for the 5HTi and
5HT2 receptors have shown that the original M receptor cannot be categorised into either the
5HTi or 5HT2 receptor types. Therefore a third receptor type clearly exists, which has been
termed 5HT3. it is now apparent that each of the three receptor types has a specific
distribution and function within higher vertebrates and each will be reviewed here briefly. A
summary of the characteristics of each of the serotonin receptors is illustrated in table 2.1.
2,6,1, 5HTi Receptors
These receptors bind serotonin in the nanomolar range and have a particularly high
affinity for indole derivatives such as ergotamine and metergoline (Peroutka and Snyder
1979). Compared to the 5HT2 receptor they exhibit very little affinity for the classical
serotonin antagonists such as cyproheptadine. They are located in all areas of the brain,
particularly the hippocampus and striatum, and also in the gut where they mediate the
inhibitory action of serotonin on acetylcholine release from enteric cholinergic neurones.
Heterogeneity of the 5HTi receptor has been demonstrated by autoradiography and
radioligand binding studies, resulting in its sub-classification into the 4 pharmacologically
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distinct 5HT-|a, 5HTit». 5HT-|C and 5HT-|d sites. The 5HT-|a site has a high affinity for
8-OH-DPAT and spiroperidol, the 5HT-|b for cyanopindolol, Ru 24969 and 13-blockers, the
5HT-|C site binds mesulergine and is analogous to the 5HT2 receptor, which also binds
mesulergine and the 5HTid site has a high affinity for metergoline (Gozlan et al 1983, Hoyer
et al 1985a, 1985b, Pazos et a/1984, Pazos and Palacios 1985).
The second messenger system coupling the 5HTia, 5HT-|b and 5HT-|<j receptors to
the end response seems to be primarily by modulation of adenylate cyclase activity. In
contrast however, the 5HT-|C receptor, like the 5HT2 receptor, is coupled to the PI second
messenger system (Enjalbert ef a/1978, Peroutka e/a/1981, Conn and Sanders-Bush 1984,
De Chaffoy de Courcelles 1985).
2.6.2. 5HTo Receptors
These receptors bind serotonin and serotonin agonists such as quipazine and
bufotenine in the micromolar range, and the specific 5HT2 antagonist ketanserin and other
antagonists e.g cyproheptadine and methysergide in the nanomolar range (Leysen et al
1978). They are found in a number of locations throughout the body, including the cerebral
cortex where they mediate neuronal depolarisation, a variety of smooth muscle cells e.g
those of the ileum and uterus, where they mediate contraction, and lastly in platelets where
two types are thought to exist. Firstly, a low capacity high affinity receptor, involved in
aggregation and secondly a high capacity low affinity receptor, antagonised by
chlorimipramine and involved in the uptake of serotonin.
In the vascular system serotonin mediates both contraction and dilatation, and it is
generally agreed that the contractile response is mediated predominantly by the 5HT2
receptor as the effects can be specifically blocked by ketanserin (Cheng et al 1980, Peroutka
et al 1982, Van Neuten e/a/1981, 1982a, 1982b, 1983). However, other groups have
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shown that the contractile properties ot 5HT in the rabbit ear artery could be blocked with
phentolamine, an a-antagonist, suggesting that in some vascular beds serotonin may
interact with a-receptors, and that the anti-hypertensive effect of ketanserin may be due at
least in part to its interaction with ai-receptors (Black et al 1981, Fozard 1982).
In addition to its own direct effects serotonin can potentiate the vascular response to
other stimuli such as angiotensin II, prostaglandins, histamine and noradrenaline (Van Neuten
efa/1981, 1982a). These effects can be blocked by ketanserin indicating that the
amplification effect of serotonin is mediated by the 5HT2 receptor.
The 5HT2 receptor is also thought to play an important role in clinical depression, as
administration of anti-depressants to rats showed a reduction in 5HT2 receptor binding and
density (Peroutka and Snyder 1980a, 1980b). Studies in patients using the drug
amitryptyline showed similar changes in the 5HT2 receptors which correlate well with the
therapeutic effect, indicating that depression may in part be due to increased sensitivity of this
receptor.
The 5HT2 receptors are coupled to phospholipase C and activation results in
phosphatidyl inositol breakdown, mobilisation of intracellular calcium and accumulation of
diacylglycerol which activates the protein kinase and subsequently the cellular response (De
Chaffoy de Courcelles et al 1985). A regulatory mechanism has been observed for the 5HT2
receptor by Nelson et al 1978, who showed that depletion of serotonin using the toxin 5,7,
dihydroxytryptamine caused an increase in serotonin binding associated with an increase in
receptor density.
2.6.3, 5HT3 Receptors
This is the serotonin receptor most recently identified and very little is known about its
properties or function. However, these are found on peripheral efferent and afferent
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autonomic neurones, and mediate the release of neurotransmitters including noradrenalin
from cardiac sympathetic neurones and acetylcholine from cholinergic enteric neurones
(Richardson and Engel 1986). Like the 5HTi receptor there appears to be some level of
heterogeneity within the 5HT3 receptor (Richardson et al 1985). The second messenger
system to which this receptor is coupled is still unknown, although some data suggests that
these receptors are coupled to an ion channel, most probably Ca2+ (Neijt et al 1988). A
number of antagonists bind to this receptor e.g cocaine and ICS 205/930, and it has recently
been found that 5HT3 antagonists are of considerable therapeutic value, particularly in
nausea and vomiting induced by chemotherapy in the treatment of cancer (Fozard 1987).
2>Zi The pathophysiological role of serotonin
2.7.1. Carcinoid Syndrome
Serotonin has been loosely associated with a number of clinical disorders, but perhaps
the best documented and most positive role is in the Carcinoid Syndrome. In this disease
tumourous growth of the enterochromaffin cells of the gut results in the over production of
serotonin and consequently its main urinary metabolite 5HIAA, which is used as a marker for
the syndrome, and which correlates roughly with the mass of the tumour (Strodel et al 1983).
The symptoms of the disease are watery diarrhoea, due to inordinate peristalsis and intestinal
hypermotility, flushing, abdominal pain and fibrotic disease of the cardiac valves. Treatment is
either by surgical removal of the tumour or administration of serotonin antagonists e.g
ketanserin, or inhibitors of serotonin synthesis e.g methyldopa, which alleviate the diarrhoea.
Anti-histamines are used to treat the flushing (Grahame-Smith 1972).
2.7.2. Hypertension
The etiology of the increase in peripheral vascular resistance in chronic hypertension
remains uncertain, although numerous factors including natriuretic peptides, the
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renin-angiotensin-aldosterone system and the sympathetic nervous system have all been
implicated. Recently however, serotonin has emerged as a possible causative factor.
Serotonin can itself act as a potent vasoconstrictor and vasodilator as well as amplify the
pressor effects of other compounds in the periphery. Therefore it would seem logical that
elevated serotonin levels may be related to the increased peripheral vascular resistance
observed in hypertension. However, abnormal serotonin levels have not been shown in
hypertensive patients. Similarly, serotonin antagonists, with the exception of ketanserin,
which exhibits affinity for a-adrenergic receptors, do not provoke a large anti-hypertensive
effect.
These observations do not totally eliminate a role for serotonin. It may be that the actual
vascular response to serotonin is either enhanced or sustained or that the vasodilatory
response is suppressed. Evidence for these explanations stem predominantly from studies
in spontaneously hypertensive rats (SHRs). Young SHRs have abnormally high levels of
noradrenaline and angiotensin II, and although the level of serotonin itself is not increased it
acts to augment the pressor effects of these stimuli. Further studies in adult SHRs have
shown that the vascular wall is extremely sensitive to the vasoconstrictive properties of
serotonin, and tachyphylaxis, the rate of decay of the response to repeated exposure to
stimulus, is considerably delayed (Collis and Vanhoutte 1977, 1981). In addition, the
vasodilator effect of serotonin is reduced in SHRs, thus causing the vasoconstrictive effect,
normally offset by the vasodilatory effect, to be more marked (Kubo and Su 1983). However,
in light of this evidence it remains to be shown whether the vascular changes act as a catalyst
and provoke hypertension or whether they are in fact secondary to changes resulting from
the hypertension itself.
The arrangement of the serotonin containing cell bodies in the CNS closely resemble
those involved in cardiovascular regulation, indicating a putative role of serotoninergic
neurones in this system. The ascending and descending serotoninergic neurones have
been described in a previous section, and their purported role in cardiovascular homeostasis
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comes from several studies. Activation of the ascending system by electrical stimulation
increases blood pressure and produces variable changes in heart rate (Kuhn et al 1980b,
1980c). This response can be attenuated by administration of PCPA, which depletes central
serotonin levels, and then partially restored by administration of 5HTP. The pressor
response can also be both enhanced and sustained by giving fluoxetine, an inhibitor of
serotonin uptake or indeed diminished using 2-Bromolysergic acid (BOL), a serotonin
antagonist, applied to the hypothalamus. These results indicate that when activated, the
ascending serotoninergic neurones increase blood pressure and this effect is mediated at
least in part by the hypothalamus.
2.7.3. Others
Serotonin abnormalities have been tentatively linked to a number of other illnesses,
particularly in the CNS. As previously mentioned in section 2.5.1. serotonin has been
associated with depression. Treatment with amitriptyline, a drug which inhibits the re-uptake
mechanism of 5HT from the synaptic cleft and therefore sustains the levels and actions of
serotonin, causes a decrease in 5HT2 receptors, i.e down regulation, which correlates well
with the therapeutic effect of the drug on the depression. These patients are thought to have
supersensitive 5HT2 receptors (Peroutka et al 1980a).
Serotonin is also thought to play a role in Alzheimers disease, as these patients have
degenerative serotoninergic neurones, and in anorexia nervosa and other appetite disorders,
as fenfluramine which enhances release of serotonin from neurones induces anorexia and is
used in the treatment of obesity (Rosser and Iverson 1986). Schizophrenia may also be due
to a central serotonin disorder, as the hallucinogenic properties of LSD, a potent 5HT2
agonist, are similar to those experienced by schizophrenics.
Outwith the CNS in addition to its role in the Carcinoid Syndrome and hypertension,
serotonin may play a role in migraine. Studies in these patients show abnormalities in the
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storage and release of serotonin from the platelets (Hanington 1978). Treatment with
methysergide and pizotifen, non selective serotonin antagonists, have proved somewhat
successful.
Serotonin may be involved in many other conditions which are too numerous to
describe here, however the reader is referred to the following references : Raynaud's
phenomenon (Seibold 1985), pre-eclampsia (Weiner 1985) and acute respiratory failure
(Hechtman 1985).
2JL Objectives of project
It is clear that serotonin is an important compound found within the circulatory system
and therefore has the potential to act on almost any part of the body. Although its action as a
neurotransmitter and its role in the blood clotting process are well documented, the role of
serotonin in the control of adrenal function and mineralocorticoid secretion has so far received
relatively little attention.
The main objectives of this study were to establish a role for serotonin in the control of
aldosterone secretion. Firstly, by identifying which serotonin receptor(s) are present in the
zona glomerulosa and establish whether they may interact with the classical secretagogues of
aldosterone. Secondly, to study the mechanism by which serotonin stimulates aldosterone
secretion, with particular reference to cyclic AMP and calcium as intracellular messengers.
Thirdly, to study the physiological importance of serotonin in stimulating aldosterone
secretion and establish its mechanism of action in vivo and finally, to study the importance of
serotonin as a trophic factor for the zona glomerulosa and establish if any changes observed
are a direct action on the adrenal gland or are secondary to activation of the renin -angiotensin





This section describes the general methodology, specialised techniques and
laboratory procedures used routinely throughout these studies. A brief review of the
methods used in each chapter is given at the beginning of that chapter.
3.2. In vitro studies
3.2.1. Isolation of zona olomemlosa cells
The adrenal glands from female Wistar rats (180-220 g), killed by cervical dislocation,
were removed and trimmed of surrounding fat. The capsules and adhering zona glomerulosa
were removed following the method of Haning et al 1970, and incubated for 1 hour at 37°C in
medium 199, pH 7.35-7.45, equilibriated in an atmosphere of 95% O2 / 5% CO2 and
containing 2 mg/ml/rat collagenase and 2% (weight for volume, w/v) bovine serum albumin
(BSA). The cells were disaggregated gently at 20 minute intervals using a wide mouthed 5 ml
pipette. After 1 hour the dispersed cells were filtered through 100 p gauze and washed 3
times by centrifugation for 15 minutes at 200g with resuspension of the cell pellet in 10 ml of
medium 199. After the final spin the cells were resuspended in medium 199 containing 0.5%
BSA (w/v), and an aliquot was removed for cell counting using a haemocytometer. On
average this method produced a zona glomerulosa population with less than 5%
contamination by zona fasciculata.
3.2.2. Cell counting
100 pi of a 0.2% (w/v) solution of trypan blue was added to 100 pi of the cell
suspension. This was mixed thoroughly and a small aliquot placed on the counting chamber
of a haemocytometer and allowed to diffuse. The cells were then viewed microscopically at a
400 fold magnification and those in the outside 4 and centre squares which excluded trypan
blue, and therefore considered viable, were counted. This number was then corrected as
follows to give the total number of cells.
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Total cells = number counted within the squares x2 (trypan blue dilution tactor) x 20 000
(converts volume ot chamber to total volume ot cells i.e 10 ml).
3.2.3. Static cell incubations
0.4 ml aliquots of the cell suspension, adjusted to contain on average 7.5 x 104 cells,
were added to polyethylene vials containing 0.6 ml of medium 199 (0.5% w/v BSA) in which all
the agonists / antagonists and other test substances had been dissolved to the required final
concentration. Control incubates contained cells and medium 199 only. Each incubation was
carried out in triplicate. The vials were mixed thoroughly and incubated for 1 hour at 37°C in a
shaking water bath. After 1 hour they were placed on ice to prevent further steroid production
and centrifuged at 20 OOOg for 2 minutes at 40c. The supernatant was decanted and 500 pi
removed for immediate processing for the cyclic AMP radioimmunoassay (RIA) as described
later. The remainder was used for aldosterone estimation, also by RIA.
3.2.4. Potassium studies
The potassium concentration of the medium 199 (normally 3.9 mM) was increased by
the addition of KCI. A compensatory adjustment was made to the sodium concentration by
decreasing the volume of NaCI added. For the static incubations, the cells were resuspended
after the final spin in medium 199 with the required potassium concentration and as before,
0.4 ml of cells were added to 0.6 ml of the same medium 199 containing all the test
substances.
3.3. Radioimmunoassays for In vitro studies
3.3.1. Aldosterone radioimmunoassay
Aldosterone was measured by a highly specific direct RIA (Campbell et al 1981). 25 pi
aliquots from the eel! incubation extracts or 25 pi containing a known concentration of
aldosterone, for the standard curve, were incubated in duplicate with 200 pi of phosphate
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The counter plotted the best fit line through the logarithmic plot of counts per minute
against the concentration of standard. The % free in each charcoal pellet for each standard
could be calculated from the total number of counts added to each tube. The % bound (B)
could then be calculated by subtracting the % free from 100%. Each assay had negligible
non-specific binding. All standard curves depicted have been drawn logarithmically as
B/Bo(zero standard)0/0 versus the concentration of standard.
buffer containing 125-|0dohistamine-3-mono-oxime-aldosterone (125 l-aldosterone)
(3000-4000 counts per minute, cpm) and antisera (402 L) to aldosterone diluted to give a
final titre of 1:100 000. The antibody was kindly provided by Dr F A O Mendelsohn, Australia.
The tubes were allowed to equilibrate overnight at 4°C. Separation of the bound and
free radiolabel was carried out at 4°c by the addition of 0.6 ml of dextran coated charcoal
followed by centrifugation at 2500g for 20 minutes, also at 40C. The supernatant was
aspirated and the charcoal pellet, containing the free fraction, counted in an LKB multiwell
gamma counter.
The lower limit of detection for the assay was 0.07 nM and the working range for
aldosterone measurement was 0.07 to 20 nM. A typical standard curve is shown in figure 3.1.
The intra and interassay co-efficient of variation was 7 and 15% respectively.
3.3.2. Cyclic AMP radioimmunoassay
Cyclic AMP was measured by a highly specific direct RIA developed in this department
by Dr I F Gow (Harper and Brooker 1975). Prior to RIA, 500 pi of the cell incubation extract
was acidified by adding 5 pi of 20% (v/v) concentrated acetic acid and acetylated with 15 pi of a
solution containing 2 parts triethylamine: 1 part acetic anhydride. 50 pi aliquots of the
resulting cell incubation extract or 50 pi containing a known concentration of cyclic AMP for
the standard curve were incubated in duplicate with 200 pi of acetate buffer containing 125.|
tyrosine-methyl-ester succinyl cyclic AMP ("125 |-cyclic AMP) (3000-4000 cpm) and antisera
(FB6) to cyclic AMP to give a final titre of 1:40 000. The tubes were allowed to equilibrate
overnight at 4°c. Separation of bound and free radiolabel was carried out using dextran
coated charcoal as described in the previous section. The lower limit of detection for the
assay was 0.06 nM, and the working range of the assay was 0.06 to 32nM. A typical standard




Figure 3.1. A typical standard curve for the measurement of
aldosterone (In vitro) by RIA.
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Figure 3.2. A typical standard curve for the measurement of
cyclic AMP (In vitro) by RIA.
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3.4. In vivo studies
3.4.1. Cannulation
Male Wistar rats (250-300 g) were anaesthetised by intra-peritoneal (i.p) injection of
Hypnorm (0.05 ml /100 g) and Hypnovel (0.05 ml /100 g). The carotid artery was cannulated
and the free end of the cannula threaded through to the back of the animal's neck using a
trochar, where it was tied in position and kept closed by means of a small metal pin in the free
end. The trochar was removed and the neck wound closed using metal clips. Immediately
following surgery the cannulae were flushed with 20 pi of neat heparin (5000 units/ml) and
then daily with 20 pi of neat heparin. The animals were allowed a 2 day post-operative
recovery period before any experimental work commenced. The cannulae were used as a
route of blood sampling throughout the experimental procedure.
3.4.2. Captoprii pretreatment
Captopril was dissolved in the animals drinking water (0.5 mg/ml) and allowed ad libitum
for 5 days prior to the cannulation and throughout the experimental procedure. Control
animals received normal drinking water. Each animal consumed approximately 50 ml of
water/day.
3.4.3. Dexamethasone pretreatment
1 ml of dexamethasone (15 pg/ml) dissolved in saline was administered i.p at 5 pm on
the day prior to and at 9 am on the morning of the experimental procedure. Control animals
received 1 ml of saline i.p.
3.4.4. Implantation of osmotic pumps
In the fifth study, 2 of the groups of animals were implanted with osmotic pumps, the
same day as commencing captopril pretreatment, that is 5 days prior to the cannulation and 7
days prior to the experimental procedure.
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The animals were anaesthetised as previously described. The skin of the back was
shaved and a small incision was made. A subcutaneous pocket was made using a hemostat
and the osmotic pump was inserted. The wound was closed by means of 2 metal clips. The
pumps delivered either angiotensin II (3.5 pg /60 pJ / hour) or 0.9% saline (60 pi / hour). The
pumps were capable of delivering the required substance for up to 14 days.
3.4.5. Experimental procedure
All the experiments commenced at 9.30 am. A basal blood sample (time=0) was taken
via the cannulae from all the animals immediately before i.p administration of 1ml of 5HTP
(4 mg/ml) or saline (0.9% w/v), depending on the group . Further blood samples were taken at
45 minute intervals thereafter. A total of four blood samples including the basal were taken on
the day of the experiment in addition to a 24 hour sample taken the following day. The
cannulae were flushed immediately after drawing blood with 30 pJ of heparin diluted 1:20 in
saline. Only 250 pi of blood was drawn off at each time point to avoid volume depletion.
3.4.6. Measurement of blood pressure
Blood pressure was monitored using a Lectromed pressure transducer coupled to a
carotid arteriole cannula. Mean arterial blood pressure (MABP) (mm Hg) was calculated using
the formula ; systolic - diastolic + diastolic.
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3.4.7. Treatment of blood samples
225 pi of the blood was transferred to a tube containing 25 pi of ice cold
ethylenediaminetetraacetic acid (EDTA) inhibitor. This was mixed thoroughly and centrifuged
at 10 OOOg for 15 minutes. The plasma was removed and stored at -20°C until measurement
of PRA, corticosterone and aldosterone by RIA. Sodium and potassium were measured by
Flame photometry at the Royal Hospital for Sick Children, Edinburgh.
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20 pi of the remaining whole blood was added to 180 til of a cocktail containing
thrombin, chlorimipramine and pargyline. This was then left at 4°C for at least 2 hours to allow
complete release of serotonin by the platelets and then centrifuged at 10 OOOg for 15
minutes. The supernatant was removed and stored at -20°C before estimation of 5HTP, 5HT
and 5HIAA by HPLC.
Radioimmunoassays for In vivo studies
3.5.1. Plasma aldosterone radioimunnoassav
Plasma aldosterone was measured by a highly specific direct RIA (Campbell et al 1981).
25 pi of neat plasma or 25 pi of standard containing a known concentration of aldosterone for
the standard curve were incubated in duplicate with 200 pi of phosphate citrate buffer
containing 125|-aidosterone (3000-4000 cpm) and antisera (402L) to aldosterone diluted to
give a final titre of 1:100 000. The standards were made up in charcoal stripped rat plasma.
The tubes were allowed to equilibrate overnight at 40C. Free and bound radiolabel
were separated using dextran coated charcoal as previously described. The lower limit of
detection of the assay was 0.195 nM and the working range was from 0.195 to 25 nM. A
typical standard curve is shown in figure 3.3. The intra and inter assay co-efficient of variation
was 7 and 15% respectively.
3.5.2. Plasma corticosterone radioimunnoassav
Plasma corticosterone was measured by a highly specific direct RIA (Al-Dujaili et al
1981). 10 pi of neat plasma was diluted with 90 pi of phosphate/citrate buffer. 25 pi of this
dilution or 25 pi of standard containing a known concentration of corticosterone for the
standard curve were incubated in duplicate with 400 pi phosphate/citrate buffer containing
125|-j0dohistamine-corticosterone-3-mono-oxime (^Spcorticosterone) (3000-4000 cpm)
and antisera (R1B4) to corticosterone diluted to give a final litre of 1:40 000. Standards were
made up in charcoal stripped plasma.
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Figure 3.3. A typical standard curve for the measurement
of plasma aldosterone by RIA.
Corticosterone (nM)
Figure 3.4. A typical standard curve for the measurement
of plasma corticosterone by RIA.
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The tubes were allowed to equilibrate overnight at 4°C. Free and bound radiolabel
were separated using dextran coated charcoal as previously described. The lower limit of
detection of the assay was 1.25 nM and the working range was from 1.25 to 160 nM. A typical
standard curve is shown in figure 3.4. The results were corrected for the initial 10 fold dilution.
The intra and inter assay co-efficient of variation was 8 and 14% respectively.
3.5.3. Plasma renin activity radioimunnoassav
Plasma renin activity (PRA) was evaluated by measuring angiotensin I generated from
sheep substrate at 4 and 37°C. 10 pi of plasma was mixed with 190 pi of a premix containing
400 parts sheep substrate, 415 parts phosphate buffer, and 20 parts each of EDTA, British
Anti-Lewisite (BAL) and 8-OH-quinoline. The mixture was then divided and one haif incubated
at 370C for 4 hours, whilst the remaining half was maintained at 4°C. Angiotensin I was
measured using a highly specific direct RIA. 25 p.l of each of the plasma samples or 25 pJ
containing a known concentration of angiotensin I for the standard curve were incubated in
duplicate with 200 p.l of phosphate buffer containing 125|.angiotensin I (3000-4000 cpm) and
antisera to angiotensin I (R5B4) diluted to give a final titre of 1:10 000. Standards were made
up in the premix solution.
The tubes were allowed to equilibrate overnight at 40c. Free and bound radiolabel
were separated using dextran coated charcoal as previously described. For this assay the
results are expressed in grams rather than molar terms, this is in accordance with expression
of PRA in many journals. The lower limit of detection of the assay was 0.5 ng/ml and the
working range was from 0.5 to 64 ng/ml. A typical standard curve is shown in figure 3.5. The
PRA was calculated by subtracting the concentration of angiotensin I in the sample
maintained at 4°C from that of the sample incubated at 37°C. The results were corrected for
the initial 20 fold dilution and the 4 hour incubation period. The intra and inter assay
co-effcicient of variation was 8 and 16% respectively.
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Figure 3.5. A typical standard curve for the measurement
of plasma angiotensin I by RIA for PRA.
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3.6. HPLC system for measurement of serotonin. 5HTP. AND 5HIAA
5HTP, 5HT and 5HIAA were measured in each serum sample using a high pressure
liquid chromatography (HPLC) technique with a stationary phase C 18 column and
electrochemical detection (Gow et al 1987).
120 pi ot serum was mixed thoroughly with 15 pi ot the internal standard
N-methylserotonin (18.5 pM) and deproteinised with 15 pi of 15% (v/v) perchloric acid. After
15 minutes at 4°C the sample was centrifuged at 10 OOOg for 15 minutes at 4°C. The
supernatant was removed and 20-100 pi injected into the HPLC system.
The mobile phase used in the system is given in section 3.11.12. The flow rate was
0.5 ml /minute and the electrochemical detection set at +0.7 volts with 5 nA full scale
deflection.
25 pi of each standard, containing known concentrations of 5HT (700 nM), 5HTP (300
nM), 5HIAA (500 nM) and the internal standard N-methylserotonin (1.85 pM) were injected at
regular intervals during the process in order to monitor the retention time and peak height,
which is directly proportional to concentration, of each of the compounds throughout the day.
The internal standard acted as a marker of % recovery. A typical HPLC elution profile for
serotonin, its precursor and metabolite is shown in figure 3.6.
3.7. Calcium Influx studies
3.7.1. Percoll density gradients
An 80% (v/v) stock solution of percoll was made by adding 80 ml of percoll to 20 ml of
Krebs Ringer which was 5 times the normal concentration. 60, 40, 30 and 10% percoll
solutions were then made from the stock solution by diluting it appropriately with Krebs Ringer
of normal concentration. Discontinuous step gradients were made by layering 2 ml of 80 and
60, 24 ml of 40 and 2 ml of 30 and 10% percoll, sequentially into a large centrifuge tube using
a peristaltic pump. Adrenal cells, isolated as described, and resuspended in a volume of 2 ml,














5. N -methylserotonin (internal standard)
5 min
Figure 3.6. A typical HPLC elution profile of 5HTP, 5HT
and 5HIAA.
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Ringer containing red and blue marker beads of densities 1.062 and 1.076 g/ml respectively .
The gradients were centrifuged at 800g for 20 minutes to allow separation of contaminating
red blood cells, zona fasciculata cells and cellular debris from the glomerulosa cells. The
glomerulosa cells were located between the blue and red marker beads, whereas the red
blood cells were found at the bottom of the gradient. The cells were removed and washed
twice by centrifugation for 10 minutes at 200g and resuspension in 10 ml Krebs Ringer to
remove any percoll contamination.
3.7.2. Calcium influx experimental procedure
Following purification by percoll density gradient centrifugation, the cells were counted
and adjusted to give 106 cells / 385 pi and incubated for 30 minutes at 370C in Krebs buffer
with 2% (w/v) BSA.
Following a modified version of the method of Mauger et al 1984. 385 pi of the cell
suspension was added to 15 pi of 45caCl2 (5 pCi) and 100 pi of Krebs buffer (control) or
100 pi of stimulus dissolved in Krebs Ringer to the appropriate concentration. Where an
antagonist was used, 50 pi of this was pre-incubated with the cells for 30 minutes at 37°C and
the volume of buffer/stimulus was adjusted accordingly so that the final volume of each
incubation was 500 pi. The specific activity of the 45CaCl2 was 10-40 mCi / mg Ca2+.
Following the addition of the cell suspension to the 45CaCl2 ± agonist, a 100 pi aliqout
of the incubation was removed at 15, 45, 75 and 105 second intervals. This was immediately
diluted in 4 ml of ice cold Tris washing solution, filtered through a Whatman GF/C glass-fibre
filter and washed a further 3 times with the washing solution. The radioactivity within the cells,





Female Wistar rats of the same age and weight (200-220g) were maintained on one of
the following diets for a period of 1-2 weeks. Each group of animals was allowed water ad
libitum and consumed approximately 50 ml of water /day. The drinking water containing
5HTP, captopril, dexamethasone. 5HTP plus captopril or 5HTP plus dexamethasone was




Normal chow diet. Normal drinking water.
Normal chow diet. 5HTP dissolved in the drinking water
(80 pg/ml).
Normal chow diet. Captopril dissolved in the
drinking water (0.5 mg/ml).





9. Dexamethasone + 5HTP
Normal chow diet. 5HTP (80 pg/ml) and captopril
(0.5 mg/ml), dissolved in the drinking water.
Wholemeal diet containing 0.06% NaCI.
Wholemeal diet containing 0.4% NaCI.
Wholemeal diet containing 3% NaCI.
Normal chow diet. Dexamethasone dissolved in the
drinking water (0.6 pg/ml).
Normal chow diet. Dexamethasone (0.6 pg/ml) and
captopril (0.5 mg/ml) dissolved in the drinking water.
3.8.2. Adrenal sections
After the appropriate time period the animals were killed by cervical dislocation, the
adrenal glands removed, trimmed of fat and snap frozen in isopentane cooled to -150°C in
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liquid nitrogen. The glands were cut into 10 p sections using a cryostat and placed on
standard microscope slides. Approximately 2/3 sections were taken fron the centre of each
gland.
3.8.3. Adrenal staining
To examine the zonation of the glands, the sections were stained by immersing the
slides into the following solutions in order.
1. 60% (v/v) isopropyl alcohol
2. Oil red-o for 10 minutes
3. 60% (v/v) isopropyl alcohol
4. Distilled water
5. Haematoxylin for 2 minutes
6. Hot water (60°C)
7. Distilled water
The sections were then mounted in gelatin, and the width of the zona glomerulosa and
zona fasciculata / reticularis was measured using a graticule attached to a light microscope.
With 100 fold magnification 1 division of the graticule was equivalent to 10 p. Five
measurements were taken from around each section and averaged. Oil red-o is a lipid stain,
whilst haematoxylin is specific for the nucleus.
3.8.4. Blood sampling
Blood samples from the animals maintained on the various diets were taken by cardiac
puncture preceded by gentle cervical dislocation. This method ensured a relatively large
volume of blood without using an anaesthetic which can significantly affect hormone
secretion rates, and also avoided decapitation, the standard method of collecting large
volumes of blood.
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3.9. Radioimmunoassays for morphology study
3.9.1. Plasma angiotensin II radio immunoassay
Plasma angiotensin II was measured by a highly specific RIA (Morton and Webb 1985).
Blood was collected into ice cold EDTA / phenanthrolene inhibitor (20 parts blood: 1 part
inhibitor) and mixed thoroughly. The sample was centrifuged at 2500g for 30 minutes at 4°C.
The plasma was removed and a measured volume loaded on to a Sep-pak C-|8 cartridge
already primed with 5 ml of methanol followed by 5 ml of water. After the plasma sample the
cartridge was washed with a further 5 ml of water. The angiotensin II attached to the column
was eluted with 2.2 ml of methanol (80% v/v). The eluate was collected and dried down at
370C under a stream of air. The resulting extract was resuspended in 0.5 ml of tris buffer.
The angiotensin II in each extract was measured by a highly specific RIA. 50 pi of the
extract or 50 pi containing a known concentration of angiotensin II for the standard curve were
incubated in duplicate with 200 pi of tris buffer containing 125|.angiotensin II (3000-4000
cpm) and antisera to angiotensin II (R2B5) diluted to give a final titre of 1:300 000. Standards
were made up in tris buffer.
The tubes were allowed to equilibrate overnight at 4°C. Free and bound radiolabel
were separated using dextran coated charcoal as previously described. The lower limit of
detection for the assay was 0.02 nM and the working range was 0.02 to 10.24 nM. A typical
standard curve is shown in figure 3.7. The intra and inter assay co-efficient of variation was 7
and 17% respectively.
In parallel, the angiotensin I concentration in each tube was also measured using a
similar protocol to the angiotensin I measurement for the PRA assay, with the exception that
the standards were made up in tris buffer. As the angiotensin II antisera cross reacts with
angiotensin I by 0.5%, this was corrected for, as was a 95% recovery rate from the Sep-pak
cartridge and the volume of plasma initially utilsed.
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Figure 3,7. A typical standard curve for the measurement










Figure 3.8. A typical standard curve for the measurement
of serum serotonin by RIA.
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3.9.2. Serum serotonin radioimmunoassay
Serum serotonin was measured using a highly specific RIA (Gow et al 1987). Blood
was taken from the animal and allowed to clot at 4°C for 4 hours. It was then centrifuged at
2500g for 15 minutes at 4°C. 10 pJ of the serum was added to 900 pJ of citrate buffer and
900 pi of the resulting solution was deproteinised by adding 100 pi of perchloric acid (15%
v/v) containing 2 mM cysteine, followed by centrifugation for 30 minutes at 1720g and 4°C.
600 pJ of the supernatant was removed and acetylated with N-acetylsuccinimide (1 mg). The
solution was then neutralised with 150 pi of sodium hydroxide (0.5 M) and the excess
acetylating agent mopped up by adding 150 pi of glycine (16.6 pM). 200 pi of this or 200 pi of
standard containing a known concentration of serotonin for the standard curve was then
incubated in duplicate with 300pl of a pre-mix solution containing 125|-g|yCy|-tyrosine
N-succinamyl serotonin (125|-5HT) (3000-4000 cpm), antisera to serotonin (R16B4), non
immune rabbit serum (NIRS) and donkey anti-rabbit serum (DARS), diluted in citrate buffer,
the final concentration of which were 1:25, 1:20 000,1:4000 and 1:400 respectively.
The tubes were allowed to equilibrate overnight at 4°C. Separation of the bound and
free fractions was by centrifugtion for 25 minutes at 1720g and 4°C. The supernatant was
removed and the pellet containing the bound fraction counted in a gamma counter. The
lower limit of detection of the assay was 3.9 nM and the working range was 3.9 to 500 nM. A
typical standard curve is shown in figure 3.8. The intra and inter assay co-efficient of variation
was 8 and 17 % respectively. The results were corrected for the number of dilutions carried
out.
3.9.3. Plasma aldosterone radioimmunoassay
The radioimmunoassay for measurement of plasma aldosterone concentration has
already been described in section 3.5.1.
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3.9.4. Plasma renin activity radioimmunoassay
The radioimmunoassay for PRA has already been described in section 3.5.3.








Percoll density marker beads
Salts for buffer solutions
Glucose
Flow Laboratories, Irvine, Scotland.
Miles Laboratories, Slough, England.
Worthington Biochemical Corp, USA.
Sigma Chemical Company Ltd, Poole, England.
Henry Simon Ltd, Stockport, England.
Sigma Chemical Company Ltd, Poole, England.
Pharmacia Ltd, Milton Keynes, England.
BDH Ltd, Poole, England.








Sigma Chemical Company Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.
Universal Biologicals, Cambridge, England.
Sigma Chemical Company Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.
Ciba Laboratories, Horsham, England.




Sigma Chemical Company Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.



























Sigma Chemical Company Ltd, Poole, England.
Abbott Laboratories Ltd, Kent, England.
Janssen Pharmaceuticals, Wantage, England.
Sandoz Pharmaceuticals, Middlesex, England.
Sandoz Pharmaceuticals, Middlesex, England.
Sandoz Pharmaceuticals, Middlesex, England.
Sandoz Pharmaceuticals, Middlesex, England.
E.R Squibb, Moreton, England.
Organon Laboratories Ltd, Cambridge, England.
Sigma Chemical Company Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.
Taab Laboratories, Berkshire, England.
BDH Ltd, Poole, England.
BDH Ltd, Poole, England.
BDH Ltd, Poole, England.
BDH Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.
British Oxygen Company, Surrey, England.
Sigma Chemical Company Ltd, Poole, England.
Aldridge Chemical Co. Ltd, Gillingham, England.
May and Baker, Manchester, England.
Rathburn Chemicals Ltd, Walkerburn, Scotland.
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HPLC grade methanol
Salts for mobile phase
Rathburn Chemicals Ltd, Walkerbum, Scotland.
BDH Ltd, poole, England.
3.10.6. Radiolabeled calcium studies
GF/C Filters Whatman International Ltd, Maidstone, England.
45CaCl2 Amersham International pic, England.

















Sigma Chemical Company Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.
BDH Ltd, Poole, England.
Millipore/Waters Ltd, Edinburgh, Scotland.
Ciba Laboratories, Horsham, England.
Janssen Pharmaceuticals Ltd, Oxford, England.
Roche Pharmaceuticals Ltd, Herts, England.
Leo Laboratories, Bucks, England.
Sigma Chemical Company Ltd, Poole, England.
BDH Ltd, Poole, England.
BDH Ltd, Poole, England.
Sigma Chemical Company Ltd, Poole, England.
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Dextran T-70 Pharmacia Ltd, Milton Keynes, England.
BAL Sigma Chemical Company Ltd, Poole, England.
8-OH-quinoline Sigma Chemical Company Ltd, Poole, England.
Aracis oil Hospital Phamacy.
Benzyl benzoate Sigma Chemical Company Ltd, Poole, England.
Perchloric acid BDH Ltd, Poole, England.
DARS Scottish antibody production unit, Carluke, Scotland.
NIRS Scottish antibody production unit, Carluke, Scotland.
Cysteine Sigma Chemical Company Ltd, Poole, England.
Glycine Sigma Chemical Company Ltd, Poole, England.
Osmotic pumps Alzet, Alza corp, Bucks, England.
N-acetylsuccinimide Synthesised by Dr IF Gow in this laboratory. See Gow
et al 1987.
3.11. Buffers / Inhibitors / Solutions etc
The constituents of all the solutions used throughout these studies are given below.
Standard abbreviations or chemical names are used.
3.11.1. Medium 199
1 sachet of medium 199 was dissolved in 100 ml of distilled water and a 15 ml aliquot
was added to 210 ml of salt solution containing NaHC03, MgS04, KH2P04, CaCl2 and NaCI.
The final concentration of ions in the medium in mM were; sodium 145, potassium 3.9,
calcium 2.5, magnesium 1.2, bicarbonate 25, chloride 128, phosphate 1.2, and sulphate 1.2.
The other constituents of medium 199 are too numerous to describe, but are given in page
55 of the Flow Laboratories catalogue.
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3.11.2. Medium 199 with altered potassium concentration
When potassium concentration was increased, by the addition of KCI, a compensatory
adjustment was made to the NaCI added, which was decreased by the same concentration.
3.11.3. Phosphate buffer
This solution contained 80 mM Na2HP04, 20 mM KH2PO4, and 15 mM NaN3, made up
in distilled water. The pH was adjusted to 7.4
3.11.4. Dextran coated charcoal
6.25 g of charcoal, 0.4 g of gelatin predissolved in 20 ml of warm phosphate buffer and
0.62 g of dextran were added to 1 litre of phosphate buffer. The pH was adjusted to 7.4.
3.11.5. Sodium acetate buffer
This solution was made from 120 ml of acetic acid (0.1 M) and 80 ml of sodium acetate
(0.1 M). The pH was adjusted to 4.75.
3.11.6. EDTA inhibitor for blood collection
This solution contained 27 mM EDTA, made up in 0.9% (w/v) saline.
3.11.7. Cocktail for blood collection
This solution contained 1.1 pM chlorimipramine, 11.1 pM pargyline and 1.1 units of
thrombin /ml, made up in distilled water.
3.11.8. Phosphate / citrate Buffer
This solution contained 20 mM citric acid and 12 mM NaH2P04. The pH was adjusted
to 4.
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3.11.9. EDTA for angiotensin I RIA
This solution contained 270 mM EDTA, made up in distilled water.
3.11.10. BAL
This solution contained15 ml Aracis oil, 242 pi 2-3 dimercapto-propan-1-ol and 535 pi
benzyl benzoate.
3.11.11. 8-OH-Quinoline
This solution contained 454 mM 8-hydroxyquinoline, made up in distilled water.
3.11.12. HPLC mobile Phase
This solution was made up in 80% water and 20% methanol and contained 130 mM
NaH2P04,1 mM EDTA, and 2.4 mM octane sulphonic acid which was previously dissolved in
8ml of acetic acid (0.5 M).
3.11.13. Krebs Rinoer (5 times normal concentration!
This solution contained 600 mM NaCI, 13 mM KCI, 6.2 mM CaCl2, 5.9 mM KH2PO4,
5.9 mM MgS04 and 124 mM NaHC03, made up in distilled water. The pH was adjusted to
7.4.
3.11.14. Krebs Rinoer (normal concentration!
This solution contained 120 mM NaCI, 2.6 mM KCI, 1.2 mM CaCl2, 1.18 mM KH2PO4,
1.18 mM MgS04 and 25.8 mM NaHCC>3, made up in distilled water. The pH was adjusted to
7.4.
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3.11.15. Tris washing solution
This solution contained 144 mM NaCI, 5mM CaCl2.2H20, 5 mM Tris and 5 mM HCI. The pH
was adjusted to 7.4.
3.11.16. EDTA / ohenanthroline inhibitor
This solution contained 125 mM EDTA and 23 mM phenanthroline, previously
dissolved in 1 ml ethanol, made up in distilled water.
3.11.17. Tris buffer
This solution contained 30 mM Tris and 15 mM NaN3 made up in 30mM HCI. The pH
was adjusted to 7.4.
3.11.18. Citrate buffer
This solution contained 100 mM citric acid, 300 mM NaOH, 1 mM EDTA and 1 g/ litre of
gelatin, made up in distilled water. The pH was adjusted to 6.2.
3.11.19. Haematoxvlin
1 g of hamatoxylin was dissolved in 10 ml of ethanol. 20 g of AI.K (S04)2-12 H2O was
dissolved in 200 ml of hot distilled water. The two solutions were mixed and 0.5 g of mercuric
oxide and 0.25 g of sodium iodate added.
3.11.20. Oilred-o
1 g of oil red o was added to 200 ml of isopropyl alcohol. The solution was diluted by
40% with distilled water immediately before use.
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3.11.21. Charcoal stripped plasma
1 g of charcoal plus 10 ml of plasma was mixed overnight and then spun at 2500g for 1
hour. The plasma was then filtered through Whatman number 1 paper.
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Chapter Four
Identification and Characterisation of Adrenal
Serotonin Receptors.
4x1* Introduction
Three main groups of serotonin receptors have been identified and characterised
within the CNS and cardiovascular system, and these have been named the 5HT-|, 5HT2 and
5HT3 binding sites. More recently, the availability of a number of new antagonists has clearly
demonstrated the heterogeneity of the 5HT-| site, resulting in its sub-classification into the
5HT-|a. 5HT-|b, 5HT-|C and 5HTid receptor sites. However, very little attention has focussed
on the serotonin receptors within the adrenal zona glomerulosa which responds to
serotoninergic stimulation by increasing aldosterone secretion.
In order to define more clearly the serotonin receptor type(s) which mediate the
steroidogenic response we have employed a wide range of serotonin antagonists and
studied their effect on aldosterone secretion by isolated rat adrenal zona glomerulosa cells. In
addition, their specificity was screened by observing their effects on the major aldosterone
secretagogues i.e angiotensin II, ACTH and potassium.
4.2. Alms of study
1. To define which serotonin receptor(s) mediate the aldosterone response to serotonin, by
studying the effects of a wide range of serotonin antagonists, which have a high affinity for
specific serotonin receptors, on the aldosterone dose response to serotonin in isolated zona
glomerulosa cells.
2. To assess the specificity of the antagonists by examining their effects on the aldosterone
response to angiotensin II, ACTH and potassium .
3. To examine a possible interaction between the adrenal serotonin receptor and the
angiotensin II receptor.
4.3. Materials and methods
The methods used in this chapter have been previously described in chapter 3
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sections 3.2 to 3.3.2.
Briefly, rat adrenal zona glomerulosa cells were isolated and incubated with either
1. No stimulus (basal control).
2. 5HT (10"®, 10-6 M).
3. Angiotensin II (10*8, 10"10 M).
4. ACTH (10"9, 10-11 M) or
5. Potassium (5.9, 8.4, 13.2 mM) in the presence or absence of one of the 5 serotonin
antagonists at a concentration of 10"6 M. Following a 1 hour incubation period and removal of
the cells, aldosterone and cyclic AMP were measured by RIA.
4A Serotonin antagonists
5 serotonin antagonists, covering the entire range of serotonin receptors were utilised
in this study. The chemical structures, molecular weights, solubility and receptor specificity of
ketanserin, methysergide, mesulergine, cyanopindolol and ICS 205/930 are illustrated in
figure 4.1 and table 4.1.
4x5, Graphical Illustration
The graphs illustrated are single experiments incubated in triplicate and are
representative of the general trends observed in each type of experiment. Each experiment
shown was repeated at least once and on most occassions twice.
Although the cell number remained constant, small variations in basal cyclic AMP and
aldosterone secretion were observed between experiments. For this reason aldosterone
and cyclic AMP secretion are expressed as stimulation ratio ± standard error mean (SEM) in
relation to the basal secretion of the control samples which have been given a value of 1.
Variations in the responsiveness of the cells to a particular stimulus were also observed
between experiments. These variations in basal secretion and responsiveness have been
reported by other workers and are the result of differing degrees of cellular damage caused by
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The properties of the serotonin antagonists
Antagonist Mol. Wt. Solubility Receptor
Specificity
Mesulergine 362.5 Saline 5HT1c
Methysergide 460 Saline 5HT1/2
Ketanserin 545.5 Saline 5HT2
ICS 205/930 320.8 Saline 5HT3
Cyanopindolol 287.3 Et OH 5HTia/1b
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the harsh collagenase digestion (Vinson etal 1985).
The mean basal aldosterone secretion in 10 individual experiments was 1.212 ± 0.251
nM. The mean basal cyclic AMP secretion in 8 individual experiments was 0.431± 0.125 nM.
4JL Statistical analysis
Statistical significance was calculated in the individual experiments by Students' t-test
for unpaired samples. A p value of <0.05 was considered significant. NS indicates non
significance. The p values in this section are illustrated in the figures and are not quoted in
the text. *, " and "* on the figures indicates that p<0.05, p<0.01 and p<0.001 respectively.
4LZ. Results
4.7.1. The cyclic AMP and aldosterone response to serotonin In vitro
This preliminary study illustrates the changes in cyclic AMP and aldosterone secretion in
isolated rat adrenal zona glomerulosa cells following stimulation by serotonin.
Figure 4.2 shows a typical aldosterone dose response to serotonin (0, 10"9, 10"8,
10-7,10-6 M) in the rat zona glomerulosa cell preparation used routinely throughout these
studies. 10'8 M serotonin was sufficient to cause a significant increase in aldosterone
secretion. Maximal stimulation was acheived by 10-8 M serotonin which caused a 3 fold
increase in steroid output. In subsequent experiments only 2 concentrations of serotonin
were studied; 108 and 10'6 M.
Figure 4.3 shows the corresponding cyclic AMP response to serotonin. Cyclic AMP
output was not significantly increased at 10-8 M serotonin, although aldosterone secretion
was elevated. 10"7 M serotonin caused a significant increase in cyclic AMP secretion and




4.7.2. The effects of the serotonin antagonists on the aldosterone and
cyclic AMP dose response to serotonin In vitro
Having clarified that rat zona glomerulosa cells do respond to serotonin, an attempt was
made to identify and characterise the adrenal zona glomerulosa receptor(s) for serotonin, by
examining the effect of a wide range of antagonists specific for different serotonin receptors,
on the aldosterone and cyclic AMP response to serotonin.
Figure 4.4 shows a typical aldosterone response to serotonin (0, 10 8,10'6 M) in the
presence and absence of either 10-6 M ketanserin, methysergide, mesulergine,
cyanopindolol or ICS 205-930. The receptor specificity and properties of these drugs have
already been described in figure 4.1 and table 4.1.
Basal aldosterone secretion was significantly inhibited in the presence of
methysergide, ketanserin and mesulergine. Cyanopindolol and ICS 205-930 showed no
significant effect. At 10 8 M serotonin, all the antagonists caused significant inhibition of
aldosterone secretion. With the exception of cyanopindolol and ketanserin, which failed to
show any effect, all the antagonists sustained their inhibitory properties at 10~6 M serotonin.
The combined % inhibition of each of the antagonists on the aldosterone response to
serotonin from the means of three separate experiments is shown in table 4.2. This clearly
indicates that purely on the basis of % inhibition, mesulergine, methysergide and ketanserin
are by far the most effective antagonists.
Figure 4.5 shows the corresponding cyclic AMP dose response to serotonin in the
presence and absence of each of the serotonin antagonists (106 M). None of the
antagonists significantly inhibited basal cyclic AMP secretion. At 10~8 M serotonin, all the
antagonists significantly inhibited cyclic AMP secretion, an effect which was sustained at 10~6
M serotonin.







































The effect of serotonin antagonists (10"6M) on the






The combined % inhibition ± SEM of each antagonist on the
aldosterone response to serotonin from 3 experiments
5HT Concentration (M)
Antagonist 0 10"8 10"6
Mesulergine 39 ±6 78 ±11 50 ±14
Methysergide 36 ±4 70 ±7 39 ±8
Ketanserin 42 ±6 57 ±11 22 ±4
ICS 205/930 8 ±0.5 27 ±6 14 ± 4




























The effect of serotonin antagonists (10"^M) on the cyc'ic








The combined % inhibition ± SD of each antagonist on the
cyclic AMP response to serotonin from 2 experiments
5HT Concentration (M)
Antagonist 0 10"8 o■o
Mesulergine 25 ± 12 41 ±5 41 ±8
Methysergide 9 ±0.7 36 + 6 36 ±8
Ketanserin 13 ± 2 40 ± 10 26 ±6
ICS 205/930 13 ± 1 37 ± 11 22 ±4
Cyanopindolol 16 + 5 26 ±6 23 ±4
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experiments is shown in table 4.3. This again indicates that mesulergine, methysergide and
ketanserin are the most effective antagonists.
4.7.3. The specificity of the serotonin antagonists
The results of the previous section demonstrate quite clearly that the antagonists
inhibit the cyclic AMP and aldosterone response to serotonin. However, it is unclear if the
effects observed are due to the presence of specific serotonin receptors in the zona
glomerulosa or are caused by non-specific or toxic effects of the antagonists on the cells. In
order to investigate this hypothesis the effects of each the antagonists were studied on the
aldosterone response to angiotensin II, ACTH and potassium.
Figure 4.6 shows a typical aldosterone dose response to angiotensin II (0, 10-10,10-8
M) in the presence and absence of each of the serotonin antagonists (10-6 M). In this
experiment mesulergine significantly inhibited basal secretion. However, the inhibitory effect
of ketanserin and methysergide on basal secretion was less pronounced and non-significant.
At 10"10 M angiotensin II, all of the antagonists significantly inhibited aldosterone secretion.
The combined % inhibition of each of the antagonists on the aldosterone response to
angiotensin II from the means of three individual experiments is shown in table 4.4.
Cyclic AMP was not measured in this experiment as angiotensin II stimulation of
aldosterone secretion is mediated by the phosphatidylinositol second messenger system
and not the adenylate cyclase system.
Figure 4.7 shows a typical aldosterone dose response to ACTH (0, 10"H, 10"9 M) in
the presence and absence of each of the serotonin antagonists (10"6 M). Although basal
secretion was significantly inhibited by ketanserin, mesulergine and methysergide, the dose












The effect of serotonin antagonists (10"6M) on the






The combined % inhibition + SEM of each antagonist on the
aldosterone response to angiotensin II from 3 experiments
Angiotensin II Concentration (M)
Antagonist 0 io-1o 10-8
Mesulergine 20 ±1 29 ±7 21 ±8
Methysergide 15 ± 0.2 23 ±6 21 ±4
Ketanserin 11 ±0.5 25 ±9 15 ± 3
ICS 205/930 10 ± 0.4 22 + 6 10 ± 2





The effect of serotonin antagonists (10*6M) on the



































The effect of serotonin antagonists (10_6M) on the
aldosterone dose response to potassium.
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Figure 4.8 shows a typical aldosterone response to potassium (3.9, 5.9, 8.4,13.2 mM)
in the presence and absence of each of the serotonin antagonists (10~6 M). Although basal
aldosterone secretion was significantly inhibited by ketanserin and methysergide the dose
response curve was not significantly affected by the presence of any of the antagonists.
4.7.4. The adrenal interaction of serotonin and angiotensin II
The results of the previous section demonstrate that the serotonin antagonists inhibit
angiotensin II stimulated aldosterone secretion, particularly at low agonist concentration, but
have no effect on the response to other stimuli. This suggests a possible interaction
between angiotensin II and serotonin in the control of adrenal function. In order to investigate
whether serotonin mediates its effects by acting at least partially on the angiotensin II
receptor, the effects of the angiotensin II antagonist saralasin were studied on the
aldosterone response to serotonin and angiotensin II as a control. In addition, the additive
effects of serotonin and angiotensin II on steroid secretion were also studied.
Figure 4.9 shows a typical aldosterone dose response to angiotensin II (0,10-10,
10"8 M) or 5HT (0, 10"8, 10"6 M) in the presence and absence of saralasin (10"6 M). The
aldosterone dose response to angiotensin II was completely abolished in the presence of
saralasin, although basal aldosterone secretion was not affected. The aldosterone response
to serotonin was not affected by the presence of saralasin.
Figure 4.10 shows a typical aldosterone dose response to serotonin (0,10'8,10~6 M)
in the presence and absence of angiotensin II (10-1°, 10"8 M). 10-10 M angiotensin II caused
a significant increase in basal secretion as expected. However, it had no significant effect on
10"8 or 10"6 M serotoninergic stimulated secretion. 10-8 M angiotensin II significantly

















































Figure 4.9. The effect of saralasin on the aldosterone
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■ +Angiotensin II (10~8M)
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Figure 4.10. The effect of serotonin, angiotensin II and





The effects of a number of serotonin antagonists, which have a high affinity for a wide
range of serotonin receptors, were studied on the aldosterone dose response to serotonin,
angiotensin II, ACTH and potassium , in an attempt to characterise the serotonin receptor
within the zona glomerulosa, in addition to assessing the specificity of the antagonists
utilised. The lack of availability of a suitable radioactive derivative of serotonin make
radioligand binding studies in adrenal cells extremely difficult; 3H-5HT has a very low specific
activity, whilst 125|. 5HT is unstable and causes structural distortion of the serotonin
molecule. These technical limitations necessitate the use of largely indirect pharmacological
studies on the end steroid response to serotoninergic stimulation.
The results obtained from these studies confirm those of other groups that serotonin
acts directly on the zona glomerulosa cells to increase aldosterone secretion in vitro (MUller
and Zeigler 1968, Haning et al 1970, Tait et al 1972, Bing and Schulster 1977). Serotonin
caused a 2.5 to 4 fold increase in aldosterone output, reaching maximal stimulation at
approximately 1(H> M. The stimulatory capacity observed compares favourably with a number
of groups but is slightly lower than the 8 fold increase shown by Tait et al 1972.
The introduction of ketanserin, methysergide and mesulergine, which have a high
affinity for the 5HT2, 5HT-|/2 and 5HT-|C receptors respectively, caused a significant
inhibition of basal aldosterone secretion, although this effect was somewhat variable between
experiments. No inhibition of basal secretion was observed with ICS 205/930 or
cyanopindolol, which have a high affinity for the 5HT3 and 5HT-|a/lb receptors respectively.
Basal inhibition has also been observed by a number of other groups for ketanserin,
methysergide and metergoline (Muller and Zeigler 1968, Mendelsohn et a/1981, Matsuoka et
al 1985). Due to the large inhibition of basal secretion the possibility of adrenal toxicity by
ketanserin, methysergide and mesulergine was therefore considered. However, it was
thought to be improbable, mainly because of their lack of inhibition on the aldosterone dose
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response to either ACTH or potassium. The lack of inhibition of the antagonists on the
aldosterone dose response to ACTH has been confirmed for ketanserin, methysergide and
cyproheptadine by other groups (Muller and Zeigler 1968, Matsuoka et al 1985), although in
contrast, other workers have reported inhibition of the aldosterone response to potassium
and ACTH with ketanserin (Rocco et al 1986). A more plausible explanation for the basal
inhibition is the presence of endogenous serotonin within the adrenal itself as has been
previously reported at least in the medulla (Verhofstadt and Jonsson 1983, Holzwarth et al
1984). However, although radiolabelling studies have shown the rapid uptake of serotonin
and its metabolism to 5HIAA, there is very little conclusive evidence of serotonin storage
within the capsular tissue (Trost and Muller 1976). If endogenous serotonin is present it may
occupy serotonin receptors and exert a tonic stimulatory influence on aldosterone
production, an effect which is negated by the introduction of the antagonists which displace
the endogenous serotonin. Endogenous serotonin concentration may vary in each cell
preparation, and the differing degrees of basal inhibition for the same antagonist between
experiments may be indicative of this concentration. It is also feasible this concentration of
serotonin may in some way be related to stress levels in the animals preceding cervical
dislocation. Stress facilitates the release of ACTH from the pituitary gland resulting in
increased adrenal perfusion by the blood. Serotonin which is transported by the platelets
may be released locally at the adrenal and bind to the serotonin recognition sites within the
zona glomerulosa. Therefore, the more stressed an animal becomes the more serotonin
could be released, by a mechanism other than the blood clotting cascade.
Alternatively, the serotonin antagonists may exhibit partial dopaminergic agonist
properties which would enhance the tonic inhibitory influence of dopamine on aldosterone
secretion, resulting in decreased basal output (Carey et a/1979). High affinities of serotonin
antagonists for dopamine receptors have been reported by Leysen et al 1981, who showed
spiperone and haloperidol were 7 and 40 times more potent at dopamine than at 5HT2
receptors. A high affinity for the dopamine receptor was also reported for methysergide.
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However, only very high concentrations (>10-5 M) of dopamine have been shown to inhibit
basal aldosterone secretion and the effect is only moderate, therefore it is unlikely that a lower
dose of a serotonin antagonist would act on dopamine receptors (Aguilera and Catt 1984).
The stimulatory capacity of serotonin on aldosterone output was blocked to different
degrees by all the antagonists we tested. Based purely on the % inhibition from 3 combined
experiments, the order of effectiveness of the antagonists was mesulergine > methysergide
> ketanserin > ICS 205/930 > cyanopindolol, the latter two showing only minor inhibition.
Serotonin also caused a significant increase in cyclic AMP secretion, but only at or above 10"®
M. 10'9 M serotonin failed to stimulate cyclic AMP, although steroid secretion was enhanced.
This apparent dissociation between second messenger and end steroid response has also
been observed by other groups and is similar to the results obtained with ACTH (Beall et al
1972, Albano et al 1974, Fujita et al 1979). The cyclic AMP response was also inhibited to
varying degrees by all the antagonists tested, and these showed a similar order of potency for
inhibition of cyclic AMP as they did for aldosterone.
The results suggest that in vitro, the aldosterone response to serotonin is mediated
by specific serotonin receptors located in the zona glomerulosa and these are closely
coupled to the adenylate cyclase second messenger system. However, identifying the
specific receptor(s) involved is a more difficult task, even although a wide range of antagonists
was employed.
Before the heterogeneity of the 5HTi receptor was discovered, methysergide was
originally classified as a 5HTi receptor antagonist which also displayed a relatively high affinity
for the type-2 binding site. Ketanserin and the more recently developed mesulergine on the
other hand were considered to be selective for the 5HT2 and 5HT-|C sites respectively.
Therefore, the particularly potent inhibitory properties of mesulergine and methysergide
suggest that the aldosterone response to serotonin is predominantly a 5HTi mediated effect,
and this is consistent with the cyclic AMP data and the fact that 5HTi receptors are coupled to
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the adenylate cyclase second messenger system (Enjalbert etal 1978, Peroutka etal 1981).
However, a recent review by Hoyer which examined the binding affinities of a wide
range of serotonin antagonists for each of the serotonin receptors, clearly shows that some of
the antagonists may not be as specific for one receptor as originally believed (Hoyer 1988a).
The pKp values reported by Hoyer of ketanserin, methysergide, mesulergine, ICS 205/930
and cyanopindolol for each of the serotonin receptors are shown in table 4.5. The data shows
clearly that those antagonists which display a high affinity for the 5HTic binding site, e.g
mesulergine also have an equally high affinity for the type-2 binding site. Similarly,
methysergide displays equally high affinity for the 5HT-|C, 5HT2 site and 5HT-|d binding sites.
In contrast, cyanopindolol displays very low affinity for the 5HT-|C and 5HT2 sites, but does
have a high affinitiy for both the 5HT-|b and 5HT-|a binding sites. The data also reveals that
although ketanserin is one of the most selective antagonists available, it does display
moderate affinity for the 5HT-|C site, which is approximately 100 fold less than the magnitude
of its affinity for the 5HT2 site. ICS 205/930 remains selective for the 5HT3 site.
Considering these facts together with the results obtained in the zona glomerulosa, it
seems clear from the weak inhibitory effects of cyanopindolol and ICS 205/930, that the
5HT-|a, 5HT-|b and 5HT3 receptors play very little, if any role, in mediating the aldosterone
response to serotonin. Similarly, the 5HT-|d receptor can be eliminated as methysergide is
the only antagonist which displays appreciable affinity for this receptor. Therefore, it seems
likely that the potent inhibitory properties of mesulergine, methysergide and ketanserin are
due to the presence of 5HT2 and / or 5HT-|C receptors within the zona glomerulosa.
However, which receptor predominates is less clear. If it is the type-2 receptor then
ketanserin, which has the highest affinity for this receptor, would be expected to produce the
greatest inhibititory effect and this was not the case. If it is the 5HT-|C receptor the order of
effectiveness of the drugs is consistent with their individual affinities for the 5HT-|C site
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Table 4.5.
The affinity values of the antagonists for the 5HT-| and 5HT2 receptors
(pKp values -log mol/l).
DRUG 5HT1a 5HT1b 5HT1c 5HT1d 5HT2
Mesulergine 6.23 4.88 8.79 5.20 8.42
Methysergide 7.63 5.82 8.61 8.42 8.57
Ketanserin 5.86 5.72 7.01 6.00 8.86
Cyanopindolol 8.27 8.28 4.44 6.85 4.53
ICS 205/930 4.70 4.35 4.59 5.28
(Taken from Hoyer 1988)
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reported by Hoyer and it seems this is the most likely. This theory was supported by a more
detailed pharmacological profile of the adrenal serotonin receptor, carried out by a student in
the department (LA Bishop 1989, BSc Honours project, Department of Pharmacology,
University of Edinburgh). By using varying concentrations of serotonin and each antagonist,
the dose-ratio was calculated for each concentration and Schild plots were set up. Utilisation
of the Schild equation provided an estimation of the dissociation constant for each of the
antagonists for the serotonin binding site (Arunlakshana and Schild 1959). The results
obtained are illustrated in table 4.6, and they show that the 5HT-|C antagonist mesulergine
has the highest binding affinity. Although this is indicative of the presence of the 5HT-|C
receptor, a more definitive demonstration of its specific involvement, rather than a 5HT2 site,
must await the development of a more selective 5HT-|C receptor antagonist.
It is interesting that current evidence from studies in other tissues, indicates that the
5HT-|c binding site bears striking similarities to the 5HT2 site both pharmacologically in that it
exhibits high affinity for so-called 5HT2 selective antagonists and functionally in that its signal
transduction mechanism is not via the adenylate cyclase system as is usual for 5HT-J
receptors, but via the phosphatidylinositol (PI) system normally associated with the type-2
receptors (Hoyer 1988b). However, the increased cyclic AMP levels observed during
serotoninergic stimulation of aldosterone secretion both by this laboratory and a number of
other groups (Tait et al 1974, Albano et at 1974, Fujita et al 1979), suggest that in the adrenal
gland the 5HT2 and/or 5HTic receptors are coupled to the adenylate cyclase system and not
the PI system. This supports the view of other workers (Matsuoka et al 1985) and ultimately
indicates that the same serotonin receptors may be coupled to different G-proteins in
different tissues. A more detailed study of the signal transduction system coupled to
serotoninergic stimulation is carried out in the next chapter.
It is also conceivable that in addition to the serotonin receptor another receptor type
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Table 4.6.
The estimated pKp values of the serotonin antagonists







(Taken from Lisa Bishop's honours project)
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could be involved in the adrenal response to serotonin. The a-adrenergic receptors have
been previously reported to partly mediate the anti-hypertensive action of ketanserin at high
concentrations (Fozard 1982). However, their involvement has been eliminated by previous
studies in our laboratories which demonstated that neither prazosin, a selective a~i
antagonist, nor phentolamine, a non selective a-antagonist, inhibited the aldosterone
response to serotonin in rat adrenal zona glomerulosa cells (Williams et al 1984).
Although the antagonists utilised do not inhibit the aldosterone response to ACTH
and potassium, thus excluding adrenal toxicity, they do however inhibit the aldosterone
response to angiotensin II, particularly at low agonist concentration. Once again mesulergine,
methysergide and ketanserin appear to be the most effective. This inhibitory effect of the
serotonin antagonists on angiotensin II stimulated aldosterone secretion has been reported
by other workers at least for ketanserin and cyproheptadine (Matsuoka et al 1985, Rocco et al
1986). In addition, radioligand binding studies carried out in this department using
125|-angiotensin II have shown conclusively that ketanserin and methysergide inhibit the
binding of angiotensin II to rat zona glomerulosa cells (CJ Waugh et al, unpublished data).
The inhibitory effect of the serotonin antagonists on angiotensin II stimulated
aldosterone secretion may be explained in a number of ways. Firstly, the drugs may be toxic
and affect a number of important cellular processes non-specifically. Secondly, that serotonin
increases aldosterone output by acting at least partially on the angiotensin II receptor, thirdly
that the effects are due to the dopaminergic agonist properties of the drugs used, or finally
that local serotonin and its receptor exert a modulatory role on the angiotensin II receptor and
hence the aldosterone response.
The first possibility has been excluded at least partly, in that the intact cellular response
to ACTH and potassium in the presence of the antagonists makes adrenal toxicity very
unlikely.
The second possibility that serotonin stimulates aldosterone by acting directly on the
angiotensin II receptor seems unlikely, not only as the compounds are so structurally dissimilar
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but also because the presence of saralasin (10-6 M), a specific angiotensin II receptor
antagonist, does not inhibit the aldosterone response to serotonin in vitro, although the
response to angiotensin II is completely abolished. A similar result was found by Mendelsohn
and Kachel 1981, who demonstrated that the stimulatory effect of serum containing serotonin
on aldosterone secretion could not be blocked by saralasin, although the effect of
angiotensin II was completely abolished. The additivity experiments were also designed to
show that serotonin and angiotensin II act on different receptors. However, there is no
additive effect in the true sense that if each stimulus caused a 2 fold increase in steroid
secretion, then together they should cause a 4 fold increase, if they act on separate
receptors. There is however some degree of potentiation, particularly with high doses of one
stimulus and low doses of the other. The lack of additivity suggests that each stimulus may
not act completely independently and may interact with each other.
The third hypothesis that the inhibitory properties of the serotonin antagonists on the
aldosterone response to angiotensin II may be due to their dopaminergic agonist properties is
a feasible explanation. Dopamine has been shown to inhibit angiotensin II stimulated
aldosterone secretion both in vivo and in vitro (McKenna et al 1979, Edwards et al 1980a,
Aguilera et al 1984). Similarly, metoclopramide, a dopamine antagonist, potentiates the
aldosterone response to angiotensin II (Edwards et al 1980a). However, these effects are
only observed at very high doses (>10"5 M) of dopamine, whereas the effects here are
observed with 10"6 M antagonist.
However, the final possibility that serotonin and its receptor can interact with the
angiotensin II receptor and exert a modulatory role seems the most likely. Therefore, blocking
the serotonin receptor with the various antagonists decreases the adrenal responsiveness to
angiotensin II. This supposed synergistic relationship between angiotensin II and serotonin is
not a new theory and many groups have reported similar effects in a wide range of tissues.
Serotonin potentiates the vasocontrictive action of angiotensin II and a number of other
substances such as catecholamines and prostaglandins (Van Neuten etal 1982a, Weiner etal
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1987). Conversely, it is possible that angiotensin II may exhibit a modulatory effect on the
stimulatory properties of serotonin, as behavioural studies in rats have shown angiotensin II
increases serotonin and tryptophan induced hyposensitivity to painful stimuli and also
yawning which is a serotonin dependent process, and this potentiation could be blocked by
the serotonin antagonists mianserin and ketanserin. The enhancing action of angiotensin II
may be mediated by an increase in number and/or sensitivity of post-synaptic serotonin
receptors as it does not result from altered synthesis, release or uptake of serotonin (Braszko
et al 1985). Similarly, other studies using isolated cells either statically or in a perfusion
system, have shown that a sodium deplete diet augments the in vitro aldosterone response
to serotonin, whilst a sodium replete diet diminishes the response (Al-Dujaili et al 1982,
Shaikh et al 1986). However, this interaction may not specifically relate to serotonin alone, as
the sensitivity of the response to other stimuli are similarly affected. Diverging somewhat from
steroidogenesis but strengthening the argument for an interaction between angiotensin II
and serotonin, it has recently been found that the mas-oncoaene encodes an angiotensin II
receptor, whilst the 5HT-|C receptor acts under certain circumstances as a proto-oncogene
(Jackson et al 1988, Julius et al 1989).
The pharmacological profile and putative identification of a second messenger system
suggests the existence of specific serotonin receptors within the zona glomerulosa.
However, conclusive evidence requires a more detailed pharmacological profile and molecular
experiments, probing the adrenal cortex for the presence of unique amino acid sequences
encoding the serotonin receptor(s). The 5HT-|a. 5HT-|C and 5HT2 receptors from other
tissues have already been cloned and sequenced (Julius et al 1988, Fargin et al 1988,
Pritchett et al 1988). The serotonin receptor type(s) which mediates the effect of serotonin
on aldosterone secretion cannot be fully classified with the available antagonists, although it
seems likely that the 5HT-|C and /or 5HT2 receptor types predominate and in contrast to other
tissues, in the zona glomerulosa these appear to be coupled to the adenylate cyclase signal
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transduction system.
In addition, serotonin may also modulate the action of angiotensin II, as it does in other
tissues. This modulatory effect may be responsible for increasing adrenal responsiveness to
angiotensin II in vivo. This interaction may be an important physiological regulatory
component of mineralocorticoid secretion and blood pressure control and the nature of this
interaction and precise characterisation of the receptors involved requires further
investigation. However, the ability of specific serotonin antagonists to inhibit the aldosterone
response to serotonin and angiotensin II could find useful therapeutic application in the future
treatment of disorders associated with altered adrenal function.
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Chapter Five
The Mechanism of Action of Serotonin In Vitro.
5xL Introduction
Although the stimulatory effect of serotonin on aldosterone secretion in vitro is well
documented, the mechanism by which the effect is mediated remains unclear.
The results from the previous chapter indicate that specific serotonin receptors exist
within the zona glomerulosa and these appear primarily to be of the 5HT-|C and/or 5HT2
classes. However, in direct contrast to the central nervous system and periphery, where they
are coupled to the PI system, in the adrenal gland they appear to be coupled to the
adenylate cyclase second messenger system. In other well characterised models acting via
adenylate cyclase e.g ACTH, the enzymatic changes are closely coupled to ionic changes,
particularly alterations in Ca2+ transport.
Although a number of groups have confirmed the involvement of adenylate cyclase in
the action of serotonin on the adrenal gland, controversy surrounds the role of the PI system,
and only a limited number of studies have focussed on the synarchic role of Ca2+.
This chapter aims to study the intracellular mechanisms, in particular the role of
adenylate cyclase and Ca2+, which mediate the aldosterone response to serotonin following
the binding to its zona glomerulosa receptor and compare these with the already well
characterised mechanisms of action of angiotensin II, ACTH and potassium.
5.2. Alms of study
1. To study the involvement of the adenylate cyclase and the PI second messenger system
in the action of serotonin on the adrenal and compare this with the well characterised action of
angiotensin II.
2. To study the role of calcium as a mediator of the steroid response to serotonin by utilising
calcium antagonists which block either extra or intracellular movement of calcium
3. To study the calcium requirement directly, by carrying out 45CaCl2 influx studies and
comparing any changes with those observed with angiotensin il.
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5JL Materials and Methods
The isolation of zona glomerulosa cells, static incubations, radioimmunoassays, percoll
density gradient cell purification and calcium influx methodology has been previously
described in chapter 3, sections 3.2 to 3.3 and 3.7. Measurement of the components of the
PI system has been previously described by Bird et al 1987.
5A. Graphical Illustration
As in chapter 4, with the exception of the radiolabelled calcium influx experiments, the
graphs illustrated are single experiments incubated in triplicate, and are representative of the
general trends observed in each study. Each study was repeated at least once and on most
occasions twice. Aldosterone secretion is expressed as a stimulation ratio ± SEM in relation
to the basal output of the control sample which has been given a value of 1. The mean basal
aldosterone secretion from 10 individual experiments was 1.000 ±0.100 nM. The mean basal
cyclic AMP secretion from 6 individual experiments was 0.449 ± 0.111 nM.
For the radiolabelled Ca2+ uptake studies, the increase in intracellular radiolabelled
calcium is expressed as a % of the total number of counts added to each incubation at the
beginning of the experiment i.e 5 p Ci. The graphs are derived from pooling the values from a
number of individual experiments.
5.5. Statistic?! Analysis
Statistical significance was calculated using Student's t-test for unpaired samples. A p
value of <0.05 was considered significant. NS indicates non-significance. The p values in the
steroid output studies are illustrated predominantly in the figures, though on some occasions
in the text. The p values for the 45ca2+ influx studies are quoted in the text. *, " and ***
indicates that p<0.05, p<0.01 and p<0.001 respectively.
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5JL Results
5.6.1. The effect of serotonin, angiotensin II. ACTH and potassium on
aldosterone and cyclic AMP secretion.
This initial preliminary study illustrates the already well characterised changes in cyclic
AMP and aldosterone secretion following stimulation with serotonin, angiotensin II, ACTH and
potassium.
Figure 5.1 shows a typical aldosterone dose response to serotonin (0, 10-9, 10-8,
10-7, 10*6 M) in the rat zona glomerulosa cell preparation used routinely throughout these
studies. 10~8 M serotonin was sufficient to cause a significant increase in aldosterone
secretion. Maximal stimulation was acheived by 10-6 M serotonin which caused a 3 fold
increase in steroid output. In subsequent experiments only 2 concentrations of serotonin
were studied; 10"8 and 10"8 M.
Figure 5.2 shows the corresponding cyclic AMP response to serotonin. Cyclic AMP
output was not significantly increased at 10"8 M serotonin, although aldosterone secretion
was elevated. 10*7 M serotonin caused a significant increase in cyclic AMP secretion and
10-6 M serotonin, which caused maximal steroidogenesis, caused a 3 fold increase in
cyclic AMP.
Figure 5.3 shows a typical aldosterone dose response to angiotensin II (0, 10"1°, 10"8
M). Angiotensin II caused a significant dose-dependent stimulation of aldosterone secretion.
Figure 5.4 shows the corresponding cyclic AMP dose response to angiotensin II (0,
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Figure 5.4. A typical cyclic AMP response to angiotensin II. (n=3)
in
Figure 5.5 shows a typical aldosterone dose response to ACTH (0, 10-11, 10~9 M).
ACTH caused a significant dose-dependent stimulation of aldosterone secretion.
Figure 5.6 shows the corresponding cyclic AMP dose response to ACTH (0, 10"H,
10"9 M). ACTH stimulated cyclic AMP secretion, although the effect was only significant at
10"9 M. 10-11 M did not significantly increase cyclic AMP secretion, even although
steroidogenesis was enhanced.
Figure 5.7 shows a typical aldosterone response to potassium (3.9, 5.9, 8.4,13.2 mM).
5.9 and 8.4 mM potassium caused a significant dose-dependent increase in aldosterone
secretion. Compared with 8.4 mM, 13.2 mM potassium caused a decrease in aldosterone
secretion, however the secretion was still significantly increased compared to the control
group.
Figure 5.8 shows the corresponding cyclic AMP response to potassium (3.9, 5.9, 8.4,
13.2 mM). All 3 concentrations of potassium caused a significant increase in cyclic AMP
secretion. This followed a similar secretory pattern to that of aldosterone, although the effect
was much smaller.
5.6.2. The effect of serotonin and angiotensin II on various components of
the phosphatldyllnosltol system.
The results of the previous study show clearly that, with the exception of angiotensin II,
all the secretagogues increase secretion of the second messenger cyclic AMP. Angiotensin
II is already known to act through th PI system. Therefore, the effect of angiotensin II, which
acted as a positive control, on lipid, inositol and inositol phosphate content of zona
glomerulosa cells was studied and compared with that of serotonin, which is known to be









































































































A typical cyclic AMP response to potassium. (n=3)
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data was kindly provided by Dr I Bird of the Royal Infirmary, Edinburgh. The content of lipid,
inositol phosphate and inositol within the cells following stimulation is given as a % value
compared to the unstimulated control groups which have been given a value of 100%.
Figure 5.9 shows the lipid content of isolated zona glomerulosa cells following
stimulation with angiotensin II (0, 10*11,10*1°, 109,10"8 M) or serotonin (0,10*11,10*1°,
10"9, 10"8 M). Angiotensin II caused a significant dose-dependent decrease in the lipid
content of the cells, which decreased from 100 ± 2.6 % in the unstimulated control group to
91.1 ±2.6, 65.4 ±2.1, 39.6 ± 1.8 and 34.1 ± 1.3 % at 10-11. 10"10, 10*9 and 10-8 M
respectively. Serotonin showed no significant effect at any concentration.
Figure 5.10 shows the inositol phosphate (IPn) content of isolated zona glomerulosa
cells following stimulation with angiotensin II (0,10"11, 10*10, 10"9, 10-8 M) or serotonin (0,
10-11,10*1°, 10"9,10"8 M). Angiotensin II caused a significant dose-dependent increase in
IPn content of the cells, which increased from 100 ± 12.2 % to 173 ± 5.2, 392 ± 9.5, 623 ±
31.1 and 710 ±66.5 % at 10 -11,10*1°, 10"9 and 10"8 M respectively. Serotonin showed no
significant effect at any concentration.
Figure 5.11 shows the inositol (Ins) content of isolated zona glomerulosa cells following
stimulation with angiotensin II (0,10*11,10-10, 10*9,10'8 M) or serotonin (0,10*11,10-10,
10"9, 10"8 M). With the exception of 10"9 M angiotensin II, which caused a significant
increase from 100 ± 1.9 to 113 ± 2.6 %, no other concentration of angiotensin II nor
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Figure 5.10. The effect of angiotensin II and serotonin on















5.6.3. The effect of pertussis toxin on the aldosterone dose response to
serotonin, angiotensin II. ACTH and potassium.
The participation of a receptor coupled G-protein in mediating the end steroid
response was investigated using pertussis toxin, which blocks the inhibitory action of the
Gj-protein on adenylate cyclase.
Figure 5.12 shows a typical aldosterone response to serotonin (0, 10-8,10-6 M) in the
presence and absence of pertussis toxin (10, 50 ng/ml). The toxin caused a small but
significant dose dependent increase in aldosterone secretion stimulated with 10-8 M
serotonin. However, it failed to show any effect on either basal output or secretion stimulated
with 10-6 M serotonin.
Figure 5.13 shows a typical aldosterone response to angiotensin II (0,10"-10,10-8 M) in
the presence and absence of pertussis toxin (10, 50 ng/ml). The toxin (50 ng/ml) showed a
small but significant inhibition of basal aldosterone secretion. Angiotensin II stimulated
aldosterone secretion remained unaffected.
Figure 5.14 shows a typical aldosterone response to ACTH (0, 10"11,10-9 M) in the
presence and absence of pertussis toxin (10, 50 ng/ml). The toxin showed no significant
effect on either basal or ACTH stimulated aldosterone secretion.
Figure 5.15 shows a typical aldosterone response to potassium (3.9, 5.9, 8.4,13.2 mM)
in the presence and absence of pertussis toxin (10, 50 ng/ml). The toxin showed no
significant effect on either basal or aldosterone secretion stimulated with 5.9 or 8.4 mM
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Figure 5.13. The effect of pertussis toxin on the aldosterone dose
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Figure 5.15. The effect of pertussis toxin on the aldosterone dose
response to potassium.
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5.6.4. The effect of removal of extracellular calcium on the aldosterone
response to serotonin
Having established the putative role of cyclic AMP as a second messenger, the role of
extracellular Ca2+ in the mechanism of action of serotonin was studied by removal of Ca2+
from the bathing medium of the cells using the chelating agent EGTA.
Figure 5.16 shows basal (1) and aldosterone secretion stimulated with serotonin (10"6
M) (2). Serotonin caused a significant increase in aldosterone secretion (p<0.001). The
addition of 2.5 mM CaCl2 to the medium had no significant effect on serotoninergic stimulated
aldosterone secretion (3). The addition of 5 mM EGTA significantly inhibited aldosterone
secretion (p<0.001) and this remained inhibited when EGTA was lowered to 2.5 mM
(p<0.001) (5). Gradual re-introduction of calcium to the medium partially restored the
inhibitory effects of EGTA.
5.6.5. The effect of verapamil on the aldosterone dose response to
serotonin, angiotensin II. ACTH and potassium.
Having determined that extracellular Ca2+ is necessary for the steroidogenic action of
serotonin, the role of transmembrane Ca2+ flux was invesigated using the Ca2+ antagonist
verapamil, which blocks influx of Ca2+ across the plasma membrane via L(long lasting, large
capacitance)-type channels.
Figure 5.17 shows a typical aldosterone response to serotonin (0, 10"8,10~6 M) in the
presence and absence of verapamil (1.56,12.5 pM). 12.5 pM verapamil significantly inhibited
both basal and serotoninergic stimulated aldosterone secretion. 1.56 pM verapamil also
caused significant inhibition of basal and aldosterone stimulated with 10"8 M serotonin, but
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Figure 5.16. The effect of removal and gradual
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Figure 5.18. The effect of verapamil on the aldosterone dose
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Figure 5.19. The effect of verapamil on the aldosterone dose
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Figure 5.20. The effect of verapamil on the aldosterone dose
response to potassium. , ^
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Figure 5.18 shows a typical aldosterone response to angiotensin II (0,10"10,10-6 M) in
the presence and absence of verapamil (1.56, 12.5 pM). 12.5 pM verapamil significantly
inhibited both basal and angiotensin II stimulated aldosterone secretion. 1.56 pM verapamil
showed no significant effect.
Figure 5.19 shows a typical aldosterone response to ACTH (0, 10'11, 10-9 M) in the
presence and absence of verapamil (1.56,12.5 pM). 12.5 pM verapamil significantly inhibited
ACTFI stimulated aldosterone secretion, but had no effect on basal output. 1.56 pM
verapamil showed no significant effect.
Figure 5.20 shows a typical aldosterone response to potassium (3.9, 5.9, 8.4,13.2 mM)
in the presence and absence of verapamil (1.56, 12.5 pM). 12.5 pM verapamil significantly
inhibited both basal and aldosterone secretion stimulated with potassium. 1.56 pM verapamil
significantly inhibited basal and 5.9 mM potassium stimulated secretion, but had no effect on
8.4 or 13.2 mM potassium stimulated output.
5.6.6. The effect of nifedipine on the aldosterone dose response to
serotonin, angiotensin II. ACTH and potassium.
A similar series of experiments was conducted using another Ca2+ antagonist
nifedipine, which also acts on the L-type channel, but is considered to be more selective.
Figure 5.21 shows a typical aldosterone response to serotonin (0, 10~8,10~6 M) in the
presence and absence of nifedipine (12.5, 50 pM). Nifedipine caused a marked dose
dependent significant inhibition of both basal and serotoninergic stimulated aldosterone
secretion.
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Figure 5.22. The effect of nifedipine on the aldosterone dose















□ +12.5 pM nifedipine
□ +50 pM nifedipine


























□ +12.5 pM nifedipine











the presence and absence of nifedipine (12.5, 50 pM). Nifedipine caused a marked dose
dependent significant inhibition of both basal and angiotensin II stimulated aldosterone
secretion.
Figure 5.23 shows a typical aldosterone response to ACTH (0, 10-11, 10" 9 M) in the
presence and absence of nifedipine (12.5, 50 pM). Nifedipine caused a marked dose
dependent significant inhibition of basal and aldosterone secretion stimulated with 10"11 M
ACTH. 50pM nifedipine sustained the inhibition at 10 _9 M ACTH. However, 12.5 pM
nifedipine was ineffective at this concentration of agonist.
Figure 5.24 shows a typical aldosterone response to potassium (3.9, 5.9, 8.4,13.2 mM)
in the presence and absence of nifedipine (12.5, 50 pM). Nifedipine showed no significant
effect on basal aldosterone secretion. A dose dependent inhibition of aldosterone secretion
by nifedipine was observed at 5.9 mM potassium however, this was not sustained at 8.4 mM
potassium. At 13.2 mM potassium, nifedipine at 12.5 and 50 pM showed a marked dose
dependent stimulatory effect on aldosterone secretion.
5.6.7. The effect of TMB-8 on the aldosterone dose response to serotonin.
angiotensin II. ACTH and potassium.
It is clear that extracellular Ca2+ plays a key role in the action of serotonin. The release
of Ca2+ from intracellular storage sites, such as the ER, has been shown to be an important
component in the mechanism of action of angiotensin II. The role of intracellular Ca2+ in the
action of serotonin was studied using TMB-8, which blocks release of calcium from intracellular
organelles.
Figure 5.25 shows a typical aldosterone response to serotonin (0, 10"8,10"6 M) in the
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Figure 5.26. The effect of TMB-8 on the aldosterone dose














Figure 5.27. The effect of TMB-8 on the aldosterone dose
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inhibition of both basal and serotoninergic stimulated aldosterone secretion.
Figure 5.26 shows a typical aldosterone response to angiotensin II (0,10"10,10-8 M) in
the presence and absence of TMB-8 (1.56, 12.5 pM). TMB-8 showed a marked
dose-dependent inhibition of both basal and angiotensin II stimulated aldosterone secretion.
Figure 5.27 shows a typical aldosterone response to ACTH (0, 10"11, 10"9 M) in the
presence and absence of TMB-8 (1.56,12.5 pM). TMB-8 showed a marked dose-dependent
inhibition of ACTH stimulated aldosterone secretion. No significant effect was observed on
basal secretion.
Figure 5.28 shows a typical aldosterone response to potassium (3.9, 5.9, 8.4,13.2 mM)
in the presence and absence of TMB-8 (1.56, 12.5 pMI). 12.5 pM TMB-8 caused significant
inhibition of basal and potassium stimulated aldosterone secretion. 1.56 pM TMB-8 showed
no significant inhibition except at 13.2 mM potassium.
5-6.8. The effect of trifluoperazine on the aldosterone dose response to
serotonin, angiotensin II. ACTH and potassium.
The liberation of calcium as a second messenger must be accompanied by its binding to
a protein, which is rendered active and free to activate the cascade mechanism resulting in
steroidogenesis. One such binding protein is calmodulin, whose activity can be blocked by
phenothiazines such as trifluoperazine (TFP). The role of calmodulin in the action of
serotonin was monitored by studying the effects of TFP on serotoninergic stimulated
aldosterone secretion.
Figure 5.29 shows a typical aldosterone response to serotonin (0, 10-8,10-6 M) in the
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Figure 5.29. The effect of trifluoperazine on the aldosterone dose
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Figure 5.30. The effect of trifluoperazine on the aldosterone dose
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significant inhibition of both basal and serotoninergic stimulated aldosterone production.
1.56 pM TFP significantly inhibited aldosterone production stimulated with 10"8 M serotonin,
but had no effect on 10-6 M serotonin or basal secretion.
Figure 5.30 shows a typical aldosterone response to angiotensin II (0,10_1°, 10-8 M) in
the presence and absence of TFP (1.56, 12.5 pM). 12.5 pM TFP showed significant
inhibition of both basal and aldosterone secretion stimulated with angiotensin II. 1.56 pM
showed no significant inhibition.
Figure 5.31 shows a typical aldosterone response to ACTH (0, 10"11, 10" 9 M) in the
presence and absence of TFP (1.56, 12.5 pM). 12.5 pM TFP showed a significant inhibitory
effect on the aldosterone response to ACTH, though no effect on basal secretion. 1.56 pM
TFP showed no significant inhibition.
Figure 5.32 shows a typical aldosterone response to potassium (3.9, 5.9, 8.4,13.2 mM)
in the presence and absence of TFP (1.56, 12.5 pM). 12.5 pM TFP significantly inhibited
basal (3.9 mM) and aldosterone secretion stimulated by 5.9 and 8.4 mM potassium. 1.56 pM
TFP showed no significant inhibition.
5.6.9. Radiolabeled calcium uptake studies
Although the previous experiments indicate that calcium plays an important role as a
second messenger in the action of serotonin, they are largely indirect pharmacological
studies and therefore open to the non-specific and possible toxic actions of the drugs
utilised, in order to investigate the role of calcium more directly, radiolabelled calcium influx
studies were carried out in isolated cells using 45caCl2-
Figure 5.33 shows the uptake of 45Ca2+ over a 105 second time course by
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unstimulated cells, those stimulated with serotonin (10-6 M) and angiotensin II (10 *8 M) from
5 combined experiments. The uptake was calculated as a % of the total number of radioactive
counts added to each incubation. Compared to the control, serotonin caused a significant
uptake of 45ca2+ within 15 seconds of addition (p<0.05). This uptake continued at 45, 75
and 105 seconds (p<0.001), (p<0.01) and (p<0.001) respectively. Compared to the control,
angiotensin II also caused a significant increase in 45ca2+ uptake. However, the effect was
much slower and was not statistically significant until 105 seconds. Comparison of the uptake
between serotonin and angiotensin II revealed that at 15, 75 and 105 seconds, serotonin
caused a significantly greater uptake of 45ca2+ (p<0.05),(p<0.01) and (p<0.01) respectively.
Figure 5.34 shows the uptake of 45ca2+ over a 105 second time course by
unstimulated cells, those stimulated with serotonin (10~6 M) and those stimulated with
serotonin in the presence of the Ca2+ antagonist verapamil (12.5 pM) from 3 combined
experiments. As before, compared to the control, serotonin caused a significant uptake of
45ca2+ within 15 seconds (p<0.05) and this continued at 45, 75 and 105 seconds (p<0.05),
(p<0.001) and (pxO.01) respectively. The addition of verapamil caused significant inhibition
of serotoninergic stimulated 45ca2+ uptake at 75 and 105 seconds (p<0.001) and (p<0.01)
respectively. The effect of verapamil at 15 and 45 seconds was marginally outside the
significance cut off of 0.05. There was no significant difference between the control curve
and the serotonin plus verapamil curve.
Figure 5.35 shows the uptake of 45ca2+ over a 105 second time course by
unstimulated cells, those stimulated with serotonin (10 6 M) and those stimulated with
serotonin in the presence of the serotonin antagonist mesulergine (10-6 M) from 2 combined
experiments. As before serotonin caused a significant increase in 45ca2+ uptake within 15
seconds (p<0.05) and this continued at 45, 75 and 105 seconds (p<0.05), (p<0.01) and
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serotoninergic stimulated 45Ca2+ uptake. However, the eftect was not significant, probably
due to the large error bars and small experimental number.
Figure 5.36 shows the uptake of 45ca2+ over a 105 second time course by
unstimulated cells, those stimulated with serotonin (10-6 M) and those stimulated with
serotonin in the presence of the serotonin antagonist methysergide (10-6 M) from 2
combined experiments. As before serotonin caused a significant increase in 45ca2+ uptake
within 15 seconds (p<0.05) and this continued at 45, 75 and 105 seconds (p<0.05), (p<0.01)
and (p<0.05) respectively. The addition of methysergide showed a tendency to inhibit
serotoninergic stimulated 45Ca2+ uptake. However, the effect was not significant until 105
seconds (p<0.05).
Figure 5.37 shows the uptake of 45ca2+ over a 105 second time course by
unstimulated cells, those stimulated with serotonin (10-6 M) and those stimulated with
serotonin in the presence of the serotonin antagonist ketanserin (10"6 M) from 2 combined
experiments. As before serotonin caused a significant increase in 45ca2+ uptake within 15
seconds (p<0.05) and this continued at 45, 75 and 105 seconds (p<0.05), (p<0.01) and
(p<0.05) respectively. In contrast, the addition of ketanserin showed a tendency to increase
^Ca2"1" uptake. However, the effect was not significant, probably due to the large error bars
and small experimental number.
5.7. Discussion
Having established the possible existence of specific receptors for serotonin within the
adrenal zona glomerulosa, by basic pharmacological studies, more definitive proof of the
presence of receptors requires the existence of a second messenger system which acts as a
coupling mechanism between initial hormone / receptor interaction and end steroid
response, thus enabling the transformation of an initially small signal to a large end response
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by a complex cascade mechanism.
The second messenger systems coupled to ACTH and angiotensin II and potassium,
the major physiological regulators of aldosterone secretion, have already been studied in
great detail by a number of groups and have been thoroughly reviewed in chapter one. It is
now generally accepted that ACTH and angiotensin II act through the adenyl cyclase and PI
second messenger systems respectively, and each stimulus causes complex ionic changes
within the cell. Potassium, in contrast acts predominantly by cellular depolarisation resulting in
calcium influx. An increase in cyclic AMP is also observed, but it is unclear if this is the primary
event or secondary to calcium influx. Similarly, the second messenger systems coupled to
serotonin receptors within the CNS and the cardiovascular system have also been well
characterised. The 5HT2 and 5HT-|C receptors are coupled to the PI system, whilst the other
receptors are known to modulate adenyl cyclase activity (Enjalbert etal 1978, Peroutka etal
1981, Conn and Sanders Bush 1984, De Chaffoy de Courcelles 1985). This chapter has
attempted to elucidate the second messenger system coupled to serotonin receptors in the
zona glomerulosa and compare these with the results obtained for angiotensin II, ACTH and
potassium and serotonin within other systems.
The results clearly illustrate that serotonin stimulates cyclic AMP production, indicating
that in the adrenal, the serotonin receptor, which is most probably 5HTic / 5HT2 like, is
positively coupled to the adenylate cyclase second messenger system. This is in direct
contrast to 5HT2 and 5HTic receptors within the CNS and the cardiovascular system, which
act through the PI system ( De Chaffoy de Courcelles 1985), but is consistent with the results
obtained by a number of other groups (Albano et ai 1974, Fujita et al 1979, Matsuoka et al
1985). The stimulation ratio is however much less than that observed with ACTH. It may be
argued that the increase in cyclic AMP following serotoninergic stimulation results from the
stimulation of contaminating zona fasciculata cells. However, this is unlikely as the stimulatory
action of serotonin is unique to the zona glomerulosa (Muller et al 1970, Haning et al 1970).
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A further experiment using dideoxyadenosine, which supposedly inhibits adenyl cyclase, was
carried out to ascertain the role of cyclic AMP in the action of serotonin. However, at the
concentration used (10'6 M), the drug had no effect on steroidogenesis stimulated with
either serotonin or ACTH which acted as a oontrol.
It is of interest that the concentration of serotonin required to stimulate cyclic AMP is
much higher than that needed to increase steroidogenesis, indicating a clear dissociation
between second messenger and end response. A similar effect was observed for ACTH in
adrenocortical cells obtained from decapsulated adrenal gland by other groups who
demonstrated a discrepancy between adenylate cyclase activity and steroidogenesis. They
also showed that specific binding of ACTH to cells correlates well with cyclic AMP production,
but not steroidogenesis (Beall and Sayers 1972, Mackie et al 1972, Buckley and
Ramachandran 1981). These results strongly support the receptor reserve model by
Hornsby and Gill in 1978, which suggested that only a small fraction of cyclic AMP formed in
response to hormonal stimulation is required for steroidogenesis.
In addition to cyclic AMP, measurement of various components of the PI system were
also carried out. Serotonin had no effect on lipid content, or PI turnover within the cell,
indicating that serotonin acts, like ACTH, exclusively on the adenylate cyclase second
messenger system. In contrast, angiotensin II, which acted as an experimental control as it is
known to act through the PI system, had no effect on cyclic AMP production, but did
significantly decrease the % lipid content of the cell, in parallel to increasing the concentration
of IP3.
A secondary series of experiments using pertussis toxin and quinacrine (data not
shown) were also designed to completely eliminate the PI system in the action of serotonin.
Pertussis toxin ADP-ribosylates the a-subunit of the Gj-protein, therefore blocking its
inhibitory action on adenylate cyclase, whilst quinacrine supposedly inhibits phospholipase
activity. Therefore, if a stimulus utilises the Gj protein, the toxin should inhibit
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steroidogenesis. Pertussis toxin has proved a valuable experimental tool in evaluating the
role of the Gj protein in other systems, however, in the adrenal its effects are more difficult to
interpret. Pretreatment of zona glomerulosa cells with the toxin causes inhibition of both the
angiotensin II induced increase in cytoplasmic calcium and adenylate cyclase activity, without
having any effect on IP3 production or aldosterone secretion (Kojima et al 1986). This has led
to the suggestion that an unidentified G -protein mediates the action of angiotensin II and that
inhibition of adenylate cyclase is not a critical component of the steroid response (Ross and
Gilman 1980, Woodcock and Johnston 1984, Kojima et al 1986, Hausdorff et al 1987).
Similarly, the results obtained in this study were difficult to interpret and it was impossible to
derive any meaningful conclusions from the data as neither pertussis toxin nor quinacrine
showed any consistent significant effect on the aldosterone dose response to serotonin or
angiotensin II. It may be relevant that the design of the experiments was incorrect, as other
studies pre-incubate cells with the toxin for periods of up to 1 hour, whereas in these studies
the cells were not pre-incubated.
Having therefore established that serotonin acts through cyclic AMP, the role of calcium
as a second messenger was also studied. The experiment using the chelating agent EGTA,
which removes calcium from the extracellular medium, suggests that serotonin requires the
presence of extracellular calcium to stimulate aldosterone secretion. Gradual re-introduction
of calcium to the bathing medium is sufficient to return the steroidogenic response to almost
normal. A similar effect of EGTA on serotonin induced aldosterone secretion was shown by
Ganguly and Hampton in 1985. In experiments carried out by other groups EGTA abolished
the sustained phase of hormone secretion in response to angiotensin II, whereas the initial
rapid phase was unaffected (Spat 1988). However, it is as yet unclear whether the response
to serotonin is bi-phasic like angiotensin II or monophasic and sustained like ACTH (Kojima et
al 1985a). Unfortunately cyclic AMP was not measured in this particular study, as it would
have provided a clear indication of whether extracellular calcium influx was required at a site
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proximal or distal to cyclic AMP formation.
Ca2+ is therefore necessary in the incubation media for the action of serotonin.
However, it is unclear if it acts in a permissive and / or mediatory capacity. The permissive role
of calcium has been shown in the action of ACTH by radioligand binding studies in zona
fasciculata cells using an iodinated analogue in the presence of EGTA. These studies
demonstrated that both receptor binding and steroidogenesis exhibit an absolute
requirement for extracellular calcium, and addition of calcium restored both functions in
parallel (Cheitlin et al 1985). Until formal binding studies have been carried out using a
suitable serotonin radioligand the requirement of Ca2+ for the binding of serotonin to its
receptor cannot be assessed. The non-permissive role of Ca2+ in the action of serotonin
was investigated by indirect means using Ca2+ channel antagonists and directly by
measurement of 45ca2+ influx.
Verapamil and nifedipine are calcium antagonists which act on the L (long lasting, large
capacitance)-type calcium channels as opposed to the T (transient) and N (neuronal)
channels, although nifedipine is generally considered to be more selective. At the higher
concentration verapamil caused significant inhibition of the dose response to all the stimuli.
At the lower dose, verapamil was only an effective inhibitor at the lower dose of serotonin, and
had no effect on the response to angiotensin II and ACTH, although the response to
potassium was inhibited except at 13.2 mM. Nifedipine was used at higher concentrations,
and caused significant inhibition of the aldosterone response to serotonin and angiotensin II.
The response to ACTH was inhibited by the higher concentration of nifedipine, however the
smaller dose only inhibited at the lower dose of ACTH. The response to potassium was only
inhibited at 5.9 mM by both concentrations of nifedipine, and enhanced at 13.2 mM.
The results indicate that calcium influx across the cell membrane is a necessary
component of the signal transduction mechanism for serotonin. The effect of verapamil on
the aldosterone response to serotonin, angiotensin II, ACTH and potassium has also been
demonstrated by other groups (Balla et al 1982a, Ganguly and Hampton 1985). The inhibitory
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capacity of nifedipine was less than that of verapamil, consequently higher concentrations of
nifedipine had to be utilised. This difference in inhibitory properties of each antagonist may
reflect different modes of action, it is already known that verapamil acts on open channels,
whereas the dihydropyridine diitiazem, acts on closed channels (Janis and Scriabine 1983).
Therefore, it is possible that nifedipine may be more effective in the presence of inactivated
channels. It has also been reported that there are a number of sub-types of L-channel, which
can be divided on the basis of their opening and closing times, conductance and selectivity to
various toxins. In addition, it is possible that verapamil exhibits a number of other cellular
effects, such as the inhibition of calmodulin (Janis and Scriabine 1983). The limited inhibitory
effect of nifedipine on the steroid response to potassium may indicate that Ca2+ influx in this
system is primarily via another calcium channel. The enhancing effect of nifedipine observed
at 13.2 mM potassium, where the control steroid stimulatory response is in fact attenuated, is
not easy to explain and is only observed at the high potassium concentration when the zona
glomerulosa cell membrane is hyper-depolarised.
Once inside the cell, it is presumed that Ca2+ must interact with a binding protein in
order to mediate its action. One such binding protein is calmodulin, which has no intrinsic
enzyme activity, but on binding calcium it undergoes a conformational change that alters its
association with other components of the signalling system. In order to investigate the role of
calmodulin in the action of serotonin, trifluoperazine (TFP), an inhibitor of calmodulin, which
inhibits the binding of Ca2+, was incubated with the cells, and the results were compared with
those of angiotensin II, ACTH and potassium. High concentrations of TFP inhibited the dose
response to serotonin and the other stimuli. However, the lower dose of TFP only inhibited
steroidogenesis at low concentations of serotonin, and showed no effect on the response to
the other secretagogues. A number of other studies using TFP have confirmed that it
inhibited the stimulation of aldosterone production by angiotensin II, potassium,
prostaglandin E2 and ouabain, but the effects on ACTH and dibutyry! cyclic AMP stimulated
secretion were much less marked (Schifrin etal 1982, Balla et al 1982a, 1982b).
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The data suggest that in addition to Ca2+ influx across the plasma membrane, activation
of calmodulin is a necessary component in the mechanism of action of serotonin. It can be
assumed that the Ca2+ from the extracellular source may bind to and activate calmodulin.
However, it is also possible that there is release of Ca2+ from an intracellular storage site, such
as the ER, following hormone / receptor interaction, as is the case with angiotensin II. This
hypothesis was tested using TMB-8, which inhibits intracellular Ca2+ release. Both
concentrations of TMB-8 significantly inhibited the aldosterone response to serotonin,
angiotensin II and ACTH. Only the higher dose was an effective inhibitor of potassium
stimulated steroidogenesis. Although the data may suggest that the liberation of Ca2+ from
an intracellular source is required for the action of serotonin, the specificity of the compound
must be questioned, as the response to ACTH is also inhibited. ACTH is not generally
believed to cause release of Ca2+ from intracellular storage sites, therefore no inhibition
should be observed. Regarding the lack of specificity of the compound, it has recently been
reported that TMB-8 possesses both Ca2+ and Na+ channel blocking properties and also
reduces membrane conductance for potassium ions (Himmel and Ravens 1990) and it may be
these properties which contrbute to the results obtained in this study. However, the
alternative explanation is that cyclic AMP dependent stimuli such as serotonin and ACTH can
cause release of calcium from another intracellular pool which is not IP3 sensitive. Certainly,
studies in zona glomerulosa cells with ACTH and the calcium sensitive bioluminescent dye
aequorin have shown changes in intracellular free Ca2+ concentration (Kojima and Ogata
1986).
Although the pharmacological studies indicate that Ca2+ influx is an important part of
the action of serotonin, they are indirect studies which are open to the non-specific actions of
the drugs utilised. In order to confirm the transmembrane influx of Ca2+ in the action of
serotonin and compare the influx with that obtained with angiotensin II, radiolabeled Ca2+
uptake studies were carried out using 45caCl2, which can be detected inside the ceil by
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p-counting. The results show that the introduction of serotonin to zona glomerulosa cells
caused an immediate uptake of 45Ca2+, which continued for up to 105 seconds.
Angiotensin II also caused 45ca2+ uptake, however the effect was of a much smaller
magnitude, probably because the Ca2+ required for stimulation of steroidogenesis by
angiotensin II, is derived predominantly from an intracellular source, although it is clear there is
also some, albeit small, extracellular requirement. Angiotensin II has already been shown to
cause a sustained increase in Ca2+ influx via T-type channels, which can be blocked with
saralasin or nitrendipine (Kojima et al 1985a, 1987), although in contrast other workers have
reported no influx of Ca2+. As expected, the Ca2+ influx stimulated by serotonin can be
blocked by verapamil and also to some degree by the serotonin antagonists methysergide
and mesulergine. In sharp contrast, ketanserin the 5HT2 antagonist, promotes a large influx
of Ca2+ across the cell membrane, even though it inhibits steroidogenesis as chapter 4
illustrates. Ca2+ efflux experiments were not carried out as they have already been reported
in detail by other groups, who showed that serotonin, ACTH and potassium did not affect
Ca2+ efflux, unlke angiotensin II (Williams et a/1981).
In addition to the second messenger systems studied, it is possible that the action of
serotonin is mediated, at least in part, by a process other than those already discussed.
Indeed, serotonin has been shown to be rapidly taken up by rat capsular cells, therefore
implicating an additional intracellular action of the amine (Trost and Miiller 1976). Another
possibility is that intracellular potassium may regulate the aldosterone response to serotonin
as ouabain which inhibits the (Na.K)-ATPase, inhibits the aldosterone stimulating properties
of ACTH and cyclic AMP. However, it has been shown that in the adrenal, both intracellular
potassium concentration and the activity of the ATPase was unaffected by serotonin
(Mendelsohn and Mackie 1975, Mackie et a/1977, Mendelsohn and Warren 1975, Meuli and
Muller 1982)
In summary, the adrenal receptors for serotonin, identified on the basis of
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pharmacological agents as 5HTic / 5HT2 like, seem to be coupled to adenylate cyclase and
L-type Ca2+ channels which when activated by serotonin allow Ca2+ influx. The results
suggest that serotonin in the adrenal gland acts, like ACTH, by binding to a specific
membrane receptor and activating adenyl cyclase, resulting in an increase in cyclic AMP
secretion. Closely coupled to the enzymatic changes are ionic changes, whereby Ca2+
moves from the extracellular fluid across the plasma membrane via specific ion channels,
where it interacts with the Ca2+ binding protein calmodulin, thus initiating the poorly
understood cascade mechanism, resulting in steroidogenesis. There is no direct evidence
from these studies as such, to suggest that there is also release of Ca2+ from intracellular
storeage sites such as the ER or mitochondria. Further studies using Ca2+ specific
fluorescent dyes such as fura-2 may help to elucidate any possible bi-phasic increase in
intracellular Ca2+, as has already been carried out extensively for angiotensin II. These
studies could be carried out on both cell populations or single cells. It is noteworthy however,
that these studies be carried out in a species which is responsive to serotoninergic
stimulation, such as the rat, and not the cow, thus avoiding mis-interpretation of the lack of
response, as other groups have done (Capponi et al 1987).
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Chapter Six
Serotoninergic Control of Aldosterone Secretion
In Vivo.
fiJL Introduction
Although the stimulatory capacity of serotonin on aldosterone secretion in vitro is well
documented its physiological relevance in the control of mineralocorticoid secretion remains
unclear. Several studies have demonstrated that infusions of serotonin or its immediate
precursors tryptophan or 5HTP stimulate aldosterone secretion in vivo (Modlinger et al 1979,
Mantero et al 1982, Shenker et al 1985a, 1985b, Maestri et a/1988). However, it is unclear if
this is a direct effect of serotonin on the adrenal gland or whether it is mediated indirectly by
activation of the renin-angiotensin system, the hypothalamo-pituitary adrenal axis or indeed
some other factor such as potassium.
In order to study the effects of acute serotonin enhancement in vivo, the effect of 5HTP
administration was studied in conscious rats with indwelling arterial cannulae. Similar
experiments were then conducted on animals following pharmacological manipulation of the
renin-angiotensin system and hypothalamo-pituitary adrenal axis with the ACE inhibitor
captopril and the synthetic glucocorticoid dexamethasone respectively.
6.2. Alms of study
1. To study the acute effects of enhanced serotonin status by administration of 5HTP, the
immediate precursor of serotonin, on circulating 5HTP, 5HT, 5HIAA, PRA, corticosterone,
aldosterone, sodium and potassium concentrations.
2. To study the effect of 5HTP administration on blood pressure.
3. To study the relative contribution of the hypothalamo-pituitary axis in the action of 5HTP by
blocking the release of ACTH using the synthetic glucocorticoid dexamethasone.
4. To study the relative contribution of the renin-angiotensin system in the action of 5HTP by
pharmacological blockade of the system using the ACE inhibitor captopril.
5. To study the permissive, rather than mediatory, role of angiotensin II in the action of 5HTP,
by the co-infusion of angiotensin II together with ACE inhibition.
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fiJL Materials and methods
The materials and methods used in this chapter have already been described in detail in
chapter 3, sections 3.4 to 3.6. Briefly, serial blood samples were taken from conscious male
rats with indwelling arterial cannulae before and after i.p administration of 5HTP or saline. The
blood was analysed for 5HTP, serotonin and 5HIAA by HPLC, for PRA, corticosterone and
aldosterone by RIA and for sodium and potassium by flame photometry. The experiment was
then repeated following the various manipulations of the renin-angiotensin system and
hypothalamo-pituitary adrenal axis.
6A Statistical analysis
Results are illustrated as mean ± standard error mean (SEM). Statistical significance
between separate groups at the same time point was calculated using Student's t-test for
unpaired samples. Significance between different time points in the same group of animals
was estimated using Student's t-test for paired samples. A p value of <0.05 was considered
significant. NS indicates non-significance. The p values for this study are quoted in the text
and are not illustrated in the figures.
SJL Results
6.5.1. Study 1. The effect pf 5HTP or saline administration on untreated
animals
This preliminary study illustrates the changes in the various parameters in two groups of
animals (n=4/group), following i.p administration of either saline (1 ml 0.9% w/v) or 5HTP
(4 mg/ml), given immediately after collection of the basal blood sample.
i
Figure 6.1 shows the serum 5HTP concentration in both groups of animals throughout
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Figure 6.1. The effect of saline or 5HTP Injection on serum 5HTP
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Figure 6.2. The effect of saline or 5HTP injection on serum
serotonin concentration in the cannulated rat.
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each group. Following 5HTP administration, 5HTP levels increased maximally from 0.5 ± 0.1
to 10.0 ± 2.0 pM (p<0.05) at 45 minutes and returned to basal values within 24 hours.
Administration of saline showed no significant effect on 5HTP levels.
Figure 6.2 shows the serum serotonin concentration in both groups of animals
throughout the experimental time course. The basal levels of serotonin were not significantly
different in each group. Following 5HTP administration, serotonin levels increased maximally
from 1.8 ± 0.3 to 3.7 ± 0.2 pM (p<0.05) at 90 minutes and returned to basal values within 24
hours. Administration of saline showed no significant effect on serotonin levels.
Figure 6.3 shows the serum 5HIAA concentration in both groups of animals throughout
the experimental time course. The basal levels of 5HIAA were not significantly different in
each group. Following 5HTP administration, 5HIAA levels increased maximally from 0.23± 0.1
to 9.2 ± 2.2 pM (p<0.05) at 45 minutes and returned to basal values within 24 hours.
Administration of saline showed no significant effect on 5HIAA levels.
Figure 6.4 shows the PRA in both groups of animals throughout the experimental time
course. Basal PRA was not significantly different in each group. Following 5HTP
administration, PRA increased maximally from 1.4 ± 0.5 to 29.8 ± 9.5 ng/ml/hr (p<0.05) at 45
minutes and returned to basal values within 135 minutes. Administration of saline showed no
significant effect on PRA.
Figure 6.5 shows the plasma corticosterone concentration in both groups of animals
throughout the experimental time course. The basal levels of corticosterone were not
significantly different in each group. Following 5HTP administration, corticosterone
increased maximally from 60.0 ± 23.6 to 729.2 ± 217.0 nM (p<0.05) at 45 minutes and
























Figure 6.3. The effect of saline or 5HTP injection on serum 5HIAA
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Figure 6.5. The effect of saline or 5HTP injection on plasma
















Figure 6.6. The effect of saline or 5HTP injection on plasma
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effect on corticosterone levels.
Figure 6.6 shows the plasma aldosterone concentration in both groups of animals
throughout the experimental time course. The basal levels of aldosterone were not
significantly different in each group. Following 5HTP administration, aldosterone levels
increased maximally from 0.36 ± 0.06 to 1.18 ± 0.32 nM (p<0.05) at 45 minutes and returned
to basal values within 90 minutes. Administration of saline showed no significant effect on
aldosterone levels.
Figure 6.7 shows the plasma sodium concentration in both groups of animals
throughout the experimental time course. The basal levels of sodium were not significantly
different in each group and there was no significant change following administration of 5HTP
or saline.
Figure 6.8 shows the plasma potassium concentration in both groups of animals
throughout the experimental time course. The basal levels of potassium were not significantly
different in each group and there was no significant change within 45 minutes in either group,
although each group showed a general downward trend from the beginning to the end of the
study.
6.5.2. study 2. The effect of 5HTP or saline administration on blood
pressure.
It is possible that the hormonal changes observed following 5HTP administration may
be secondary to changes in blood pressure caused by serotonin. Serotonin is capable of
mediating both vasoconstriction and vaodilatation. A fall in blood pressure would be detected
by the juxtaglomerular apparatus of the kidney, resulting in renin release and subsequently










0-* 1 T 1 ■ 1 T 1 'I | 1—
0 45 min 90 min 135 min 24 hr
Time
Figure 6.7. The effect of saline or 5HTP injection on plasma
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vasoconstriction to normalise the falling blood pressure. For these reasons, blood pressure
was monitored in two groups of animals every 5 minutes for 45 minutes. One group (n=4)
received saline, whilst the other received 5HTP (n=4). Mean arterial blood pressure was
calculated from the systolic and diastolic values using the formula described in the materials
and methods section 3.4.7.
Figure 6.9 shows the effect of saline or 5FITP administration on mean arterial blood
pressure (MABP). Blood pressure was monitored at time=0, before administration of 5FITP or
saline, and every 5 minutes thereafter for 45 minutes. Comparison of basal values in the 2
groups revealed a significant (p<0.05) difference in blood pressure, which was 112 ± 2.1 mm
Hg in the 5HTP treated group and 125 ± 3.2 mm Fig in the saline treated group.
Administration of 5HTP caused a significant increase in blood pressure from 112 ± 2.1 to 122
±1.5 (p<0.01), 124 ±2.2 (p<0.01), 124 ±3.5 (p<0.05), 127 ±2.0 (p<0.01) and 127 ±2.9 mm
Fig (p<0.01) at 25, 30, 35, 40 and 45 minutes respectively. Saline administration caused no
significant change in blood pressure.
6.5.3. study 3. The effect of 5HTP or saline administration on
dexamethasone and non-dexamethasone pretreated animals.
Having established that administration of 5HTP increased aldosterone secretion, it was
necessary to investigate if this was a direct action on the zona glomerulosa, or an indirect
effect mediated by activation of the hypothalamo-pituitary adrenal axis, since serotonin is
already known to stimulate CRF and ACTH release and also in the preliminary study
corticosterone levels increased following 5HTP administration (Weiner and Ganong 1978,
Kreiger and Kreiger 1979, Fuller 1981). The possible involvement of the
hypothalamo-pituitary adrenal axis was studied by comparing the effect of 5HTP
administration on dexamethasone and non-dexamethasone pretreated animals (n=4/group).
A third group of animals (n=4), also pretreated with dexamethasone and given saline was also
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studied. The dexamethasone regime followed has already been described in chapter 3
section 3.4.3.
Figure 6.10 shows serum 5HTP concentration in each of the 3 groups throughout the
experimental time course. Basal 5HTP levels in the dexamethasone pretreated groups were
not significantly different from the untreated group. Following 5HTP administration, 5HTP
levels increased maximally at 45 minutes from 2.1 ± 0.9 to 16.9 ± 1.7 pM (p<0.001) in the
dexamethasone pretreated group and from 1.4 ± 0.1 to 21.9 ± 0.8 pM (p<0.001) in the
untreated group. Both returned to basal values within 135 minutes. Comparison of the
increases observed at 45 minutes revealed that dexamethasone pretreatment had no
significant effect on 5HTP uptake or clearance following its administration. Administration of
saline to dexamethasone pretreated animals showed no significant effect on 5HTP levels.
Figure 6.11 shows serum serotonin concentration in each of the 3 groups throughout
the experimental time course. Basal serotonin levels in the dexamethasone pretreated
groups were not significantly different from the untreated group. Following 5HTP
administration, serotonin levels increased maximally from 1.6 ± 0.4 to 3.1 ± 0.5 pM (p<0.05) at
90 minutes in the dexamethasone pretreated group and from 1.3 ± 0.3 to 4.8 ± 0.6 pM
(p<0.01) at 45 minutes in the untreated group. Both returned to basal values within 24 hours.
Although there was no significant difference in the maximum levels of serotonin following
5HTP administration, the time course of the increase was slightly altered. However,
comparison of the increase observed at 45 minutes in each group also showed no significant
difference. Administration of saline to dexamethasone pretreated animals showed no
significant effect on serotonin levels.
Figure 6.12 shows serum 5HIAA concentration in each of the 3 groups throughout the
experimental time course. Basal 5HIAA levels in the dexamethasone pretreated groups were
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Figure 6.10. The effect of saline or 5HTP on serum 5HTP
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Figure 6.12. The effect of saline or 5HTP on serum 5HIAA






Figure 6.13. The effect of saline or 5HTP on PRA In the cannulated
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not significantly different from the untreated group. Following 5HTP administration, 5HIAA
levels increased maximally at 45 minutes from 0.3 ± 0.05 to 15.8 ± 5.3 pM (p<0.01) in the
dexamethasone pretreated group and from 0.3 ± 0.04 to 16.8 ± 3.7 pM (p<0.05) in the
untreated group. Both returned to basal values within 24 hours. Comparison of the increases
observed at 45 minutes revealed that dexamethasone had no significant effect on the
formation of 5HIAA following administration of 5HTP. Administration of saline to captopril
pretreated animals showed no significant effect on 5HIAA levels.
Figure 6.13 shows PRA in each of the 3 groups throughout the experimental time
course. Basal PRA in the dexamethasone pretreated groups were not significantly different
from the untreated group. Following 5HTP administration, PRA increased maximally at 45
minutes from 1.2 ± 0.5 to 27.6 ± 15.4 ng/ml/hr (p<0.05) in the dexamethasone pretreated
group and from 0.9 ± 0.2 to 44.3 ± 12.8 ng/ml/hr (p<0.05) in the untreated group. Both
returned to basal values within 135 minutes. Comparison of the increases observed at 45
minutes revealed that dexamethasone had no significant effect on PRA following
administration of 5HTP. Administration of saline to dexamethasone pretreated animals
showed no significant effect on PRA
Figure 6.14 shows plasma corticosterone concentration in each of the 3 groups
throughout the experimental time course. Basal corticosterone levels in the dexamethasone
pretreated groups were 20.5 ± 12.9 nM and 41.9 ± 38.7 compared with 99.4 ± 28.7 in the
non-dexamethasone treated group. Following 5HTP administration, corticosterone levels
increased maximally from 99.4 ± 28.7 to 762.5 ± 147.4 nM (p<0.01) at 45 minutes in the
untreated group and returned to basal values within 90 minutes. There was no significant
increase in corticosterone in the dexamethasone pretreated group following 5HTP
administration. Comparison of the levels of corticosterone at 45 minutes in the 5HTP treated
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corticosterone following administration of 5HTP. Administration of saline to dexamethasone
pretreated animals showed no significant effect on corticosterone levels.
Figure 6.15 shows plasma aldosterone concentration in each of the 3 groups
throughout the experimental time course. Basal aldosterone levels in the dexamethasone
pretreated groups were not significantly different from the untreated group. Following 5HTP
administration, aldosterone levels increased maximally at 45 minutes from 0.25 ± 0.05 to 0.50
± 0.01 nM (p<0.01) in the dexamethasone pretreated group and from 0.24 ±_0.01 to 1.42 ±
0.21 nM (p<0.001) in the untreated group. Both returned to basal values within 135 minutes.
Comparison of the increases observed at 45 minutes revealed that dexamethasone
pretreatment significantly inhibited aldosterone secretion following administration of 5HTP
(p<0.01). Administration of saline to dexamethasone pretreated animals showed no
significant effect on aldosterone levels.
Figure 6.16 shows plasma sodium concentration in each of the 3 groups throughout
the experimental time course. Basal sodium levels in the dexamethasone pretreated groups
were not significantly different from the untreated group. There was no significant change in
sodium levels in any of the groups at any time point following administration of either 5HTP or
saline.
Figure 6.17 shows plasma potassium concentration in each of the 3 groups throughout
the experimental time course. There was a significant decrease in potassium levels in all 3
groups within 45 minutes. Following 5HTP administration, potassium decreased from 6.6 ±
0.2 to 6.0 ± 0.2 mM in the dexamethasone pretreated group and from 7.6 ± 1.3 to 5.8 ± 0.1
mM in the untreated group. Potassium levels in the dexamethasone pretreated group
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6.5.4. Study 4, The effect of 5HTP or saline administration on captonrll
and non-captopril oretreated animals
The results of the previous section suggest that the stimulatory effect of 5HTP on
aldosterone secretion is dependent upon an intact hypothalamo-pituitary adrenal axis.
However, it is also necessary to consider the role of the renin-angiotensin system, the major
physiological regulator of aldosterone secretion, as the increase in PRA following
administration of 5HTP in the preliminary study suggests that this is also activated.
Therefore, the effect of 5HTP administration was studied in a group of animals (n=4)
pretreated for 1 week with the ACE inhibitor captopril and compared with a non-pretreated
group also given 5HTP. A control group (n=4) pretreated with captopril and injected with
saline instead of 5HTP was also studied. Captopril effectively blocks formation of angiotensin
II, which increases aldosterone secretion. Hence any activation of the renin-angiotensin
system by 5HTP would be blocked and aldosterone secretion inhibited. The captopril regime
followed has already been described in chapter 3 section 3.4.2.
Figure 6.18 shows serum 5HTP concentration in each of the 3 groups throughout the
experimental time course. Basal 5HTP levels in the captopril pretreated groups were not
significantly different from the untreated group. Following 5HTP administration, 5HTP levels
increased maximally at 45 minutes from 1.5 ± 0.5 to 14.3 ± 0.9 pM (p<0.01) in the captopril
pretreated group and from 0.6 ± 0.2 to 18.6 ± 1.0 pM (p<0.00l) in the untreated group. Both
returned to basal values within 135 minutes. Comparison of the increases in each group at 45
minutes revealed that captopril pretreatment had a very small but significant inhibitory effect
on the uptake of 5HTP (p<0.05). Administration of saline to captopril pretreated animals
showed no significant effect on 5HTP levels.
Figure 6.19 shows serum serotonin concentration in each of the 3 groups throughout
the experimental time course. Basal serotonin levels in the captopril pretreated groups were
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not significantly different from the untreated group. Following 5HTP administration, serotonin
levels increased maximally from 3.1 ± 0.9 to 7.4 ± 0.6 pM (p<0.05) at 45 minutes in the
captopril pretreated group and from 2.5 ± 0.6 to 8.2 ± 0.5 pM (p<0.01) at 135 minutes in the
untreated group. The increase observed at 45 minutes in this group was also significant
(pcO.05), though not maximal. Both returned to basal values within 24 hours. Although there
was no significant difference in the maximal levels of serotonin following 5HTP administration
in each group, the time couse of the increase was slightly altered and comparison of the
increases at 45 minutes revealed that captopril pretreatment significantly enhanced formation
of serotonin (p<0.05).
Figure 6.20 shows serum 5HIAA concentration in each of the 3 groups throughout the
experimental time course. Basal 5HIAA levels in the captopril pretreated groups were not
significantly different from the untreated group. Following 5HTP administration, 5HIAA levels
increased maximally at 45 minutes from 0.8 ± 0.7 to 25.4 ± 4.8 pM (p<0.05) in the captopril
pretreated group and from 0.2 ± 0.1 to 28.9 ± 2.9 pM (p<0.001) in the untreated group. Both
returned to basal values within 24 hours. Comparison of the increases in each group at 45
minutes revealed that captopril pretreatment had no significant effect on the formation of
5HIAA following 5HTP administration. Administration of saline to captopril pretreated animals
showed no significant effect on 5HIAA levels.
Figure 6.21 shows PRA in each of the 3 groups throughout the experimental time
course. Basal PRAs were 10.7 ± 2.0 (p<0.01) and 10.9 ± 7.7 ng/ml/hr (NS) in each of the
captopril pretreated groups compared with 2.4 ±1.0 ng/ml/hr in the non-captopril pretreated
group. Following 5HTP administration, PRA increased maximally at 45 minutes from 10.9 ±
7.7 to 137.3 ± 19.2 ng/ml/hr (p<0.05) in the captopril pretreated group and from 2.4 ± 1.0 to
67.4 ± 21.3 ng/ml/hr (p<0.05) in the untreated group. Both returned to basal values within 24
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group at 45 minutes revealed that captopril pretreatment had no significant effect on the
increase in PRA following 5HTP administration. However, the time course of the return to
basal levels was considerably prolonged in the captopril pretreated group. Administration of
saline to captopril pretreated animals showed no significant effect on PRA.
Figure 6.22 shows plasma corticosterone concentration in each of the 3 groups
throughout the experimental time course. Basal corticosterone levels in the captopril
pretreated groups were not significantly different from the untreated group. Following 5HTP
administration, corticosterone levels increased maximally at 45 minutes from 92.6 ± 28.4 to
842.4 ± 62.8 nM (p<0.001) in the captopril pretreated group and from 48.7 ± 15.5 to 791 ±
90.8 nM (p<0.01) in the untreated group. Both returned to basal values within 135 minutes.
Comparison of the increases in each group at 45 minutes revealed that captopril pretreatment
had no significant effect on the formation of corticosterone following 5HTP administration.
Administration of saline to captopril pretreated animals showed no significant effect on
corticosterone levels.
Figure 6.23 shows plasma aldosterone concentration in each of the 3 groups
throughout the experimental time course. Basal aldosterone levels in the captopril pretreated
groups were not significantly different from the untreated group. Following 5HTP
administration, aldosterone levels increased maximally at 90 minutes from 0.34 ± 0.04 to 0.65
± 0.02 nM (p<0.05) in the captopril pretreated group and from 0.38 ± 0.02 to 2.0 ± 0.56 nM
(p<0.05) in the untreated group. Both returned to basal values within 24 hours. Comparison
of the increases in each group at 90 minutes revealed that captopril pretreatment significantly
inhibited aldosterone secretion following 5HTP administration (p<0.05). Administration of
saline to captopril pretreated animals showed no significant effect on aldosterone levels.
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Figure 6.22. The effect of saline or 5HTP on plasma corticosterone
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the experimental time course. Basal sodium levels in the captopril pretreated groups were
160 ± 7.4 (NS) and 150 ± 1.6 mM (p<0.01) compared to 166.8 ± 3 mM in the untreated
control group. There was no significant change in sodium levels in any of the groups at any
time point following administration of either 5HTP or saline.
Figure 6.25 shows plasma potassium concentration in each of the 3 groups throughout
the experimental time course. Basal potassium levels in the captopril pretreated groups were
5.9 ± 0.2 (NS) and 5.6 + 0.1 mM (p<0.05) compared to 6.2 ± 0.2 mM in the untreated control
group. Potassium levels showed no significant change within 45 minutes in any of the
groups. However, the levels in all 3 groups showed a general downward trend from the
beginning to the end of the experiment.
6.5.5. Study 5. The permissive requirement of angiotensin II In the action
Of SMTP
The previous study using captopril illustrates quite clearly that the renin-angiotensin
system is involved to some degree in the action of 5HTP. However, it fails to clarify if the
effects of 5HTP are mediated by increases in circulating angiotensin II itself, or whether it acts
purely in a permissive capacity, and is required to maintain normal adrenal function. In order to
investigate this hypothesis the effect of 5HTP administration has been compared in untreated
animals (n=4), those pretreated with captopril (n=5) as before, and also in a third group (n=4),
pretreated with captopril but supplemented with normal circulating levels of angiotensin II
administered by osmotic mini-pump. In effect, the treatment with captopril plus angiotensin II
continues to block activation of the renin-angiotensin system by serotonin. However, normal
adrenal function is maintained by the presence of the angiotensin II.
Figure 6.26 shows serum 5HTP concentration in each of the 3 groups throughout the
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Figure 6.26. The effect of 5HTP injection on serum 5HTP
concentration In the cannulated rat, untreated or
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Figure 6.27. The effect of 5HTP Injection on serum serotonin
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between the 3 groups. Following 5HTP administration, 5HTP increased maximally at 45
minutes trom 1.0 ± 0.3 to 11.4 ± 3.6 pM (p<0.05) in the captopril pretreated group, from 0.4 ±
0.1 to 12.3 ± 1.7 pM (p<0.01) in the captopril plus angiotensin II pretreated group and from
0.2 ± 0.02 to 12.3 ± 4.0 pM (p<0.05) in the group receiving no pretreatment. Comparison of
the increases observed at 45 minutes revealed no significant difference between the 3
groups.
Figure 6.27 shows serum serotonin concentration in each of the 3 groups throughout
the experimental time course. There was no significant difference in basal levels of serotonin
between the 3 groups. Following 5HTP administration, serotonin increased maximally at 45
minutes from 2.0 ± 0.6 to 8.3 ± 1.3 pM (p<0.05) in the captopril pretreated group, from 1.4 ±
0.4 to 5.7 ±1.1 pM (p<0.05) in the captopril plus angiotensin II pretreated group and from 1.0
± 0.1 to 6.0 ± 1.4 pM (p<0.05) in the group receiving no pretreatment. Comparison of the
increases observed at 45 minutes revealed no significant difference between the 3 groups.
Figure 6.28 shows serum 5HIAA concentration in each of the 3 groups throughout the
experimental time course. There was no significant difference in basal levels of 5HIAA
between the 3 groups. Following 5HTP administration, 5HIAA increased maximally at 45
minutes from 0.9 ± 0.2 to 23.3 ± 8.0 pM (p<0.05) in the captopril pretreated group, from 0.6 ±
0.2 to 18.7 ± 3.3 pM (p<0.05) in the captopril plus angiotensin II pretreated group and from
0.4 ± 0.1 to 19.0 ± 8.8 pM (p<0.05) in the group receiving no pretreatment. Comparison of
the increases observed at 45 minutes revealed no significant difference between the 3
groups.
Figure 6.29 shows PRA in each of the 3 groups throughout the experimental time
course. Captopril pretreatment alone caused a significant increase in basal PRA, which was
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Figure 6.28. The effect of 5HTP injection on serum 5HIAA
concentration in the cannulated rat, untreated or
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Figure 6.29. The effect of 5HTP Injection on PRA in the cannulated
rat, untreated or pretreated with captopril or captopril
plus angiotensin II.
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angiotensin II pretreatment did not significantly affect basal PRA which was 3.1 ± 0.7 ng/ml/hr.
Following 5HTP administration, PRA increased maximally at 45 minutes from 16.1 ± 2.8 to
100.4 ± 22.2 ng/ml/hr (p<0.05) in the captopril pretreated group, from 3.1 ± 0.7 to 76.4 ±
21.8 ng/ml/hr (p<0.05) in the captopril plus angiotensin II pretreated group and from 3.7 ± 0.7
to 51.3 ± 19.7 ng/ml/hr (p<0.05) in the group receiving no pretreatment. Comparison of the
increases observed at 45 minutes revealed no significant difference between the 3 groups.
However, the time course of the return to basal levels was considerably prolonged in the
captopril only pretreated group.
Figure 6.30 shows plasma corticosterone concentration in each of the 3 groups
throughout the experimental time course. There was no significant difference in basal levels
of corticosterone between the 3 groups. Following 5HTP administration, corticosterone
increased maximally at 45 minutes from 84.4 ± 20.3 to 638.6 ± 80.0 nM (p<0.001) in the
captopril pretreated group, from 86.8 ± 71.6 to 921 ±158.6 nM (p<0.05) in the captopril plus
angiotensin II pretreated group and from 91.4 ± 54.2 to 692 ± 130 nM (p<0.01) in the group
receiving no pretreatment. Comparison of the increases observed at 45 minutes revealed no
significant difference between the 3 groups.
Figure 6.31 shows plasma aldosterone concentration in each of the 3 groups
throughout the experimental time course. There was no significant difference in basal levels
of aldosterone between the 3 groups. Following 5HTP administration, aldosterone increased
maximally at 45 minutes from 0.16 ± 0.04 to 2.26 ±0.58 nM (p<0.05) in the captopril plus
angiotensin II pretreated group, from 0.13 ± 0.01 to 2.38 ± 0.61 nM (p<0.01) in the group
receiving no pretreatment, and to a lesser degree from 0.17 ± 0.02 to 0.69 ± 0.18 nM
(p<0.05) in the captopril pretreated group. Comparison of the increase in aldosterone
observed at 45 minutes in each of the pretreated groups with the untreated group revealed




















Figure 6.30. The effect of 5HTP Injection on plasma corticosterone
concentration In the cannulated rat, untreated or





Figure 6.31. The effect of 5HTP Injection on plasma aldosterone
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However, co-administration of angiotensin II with the captopril returned the response to
normal.
Plasma sodium and potassium concentration were not measured in this particular study.
Discussion
The effect of acute serotonin enhancement in vivo on adrenal function, particularly
aldosterone secretion, was studied in conscious rats with indwelling arterial cannulae, a
technique designed to enable the easy withdrawal of blood without the use of an anaesthetic
which would itself lower blood pressure and activate the renin-angiotensin system. Serial
blood samples were taken under minimal stress conditions via the cannulae, before and after
administration of either saline or 5HTP, the immediate precursor of serotonin. In order to
assess the relative involvement of both the renin-angiotensin system and the
hypothalamic-pituitary-adrenal axis the study was repeated in animals following
pharmacological blockade of one of the systems using captopril and dexamethasone
respectively.
5HTP was administered in preference to serotonin itself as it has been reported to
show no effect on blood pressure, in contrast to serotonin which decreases blood pressure
when peripherally administered to man (Barney et al 1981). However, other groups have
reported no change in blood pressure when serotonin was administered to man (Mantero et
al 1982), or a decrease in blood pressure when 5HTP was administered i.p to rats, although
the concentrations of 5HTP used were much higher than those utilised in these studies
(Henning and Rubenson 1971). A fall in blood pressure would result in stimulation of renin
release from the kidney with a consequent activation of the renin-angiotensin system.
Administration of 5HTP also allows a slower more controlled increase in the circulating levels
of serotonin, which may be rapidly metabolised or taken up into storage sites such as the gut if
given directly. However 5HTP, unlike serotonin, crosses the blood brain barrier and may
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therefore elicit centrally mediated actions.
In the preliminary study 2 groups of animals were utilised. One group received saline
after the collection of the basal blood sample, whilst the other group received 5HTP. The
results show that 5HTP administration greatly increased circulating levels of 5HTP itself,
5HIAA and to a lesser degree serotonin, each of which returned to basal levels by the end of
the study. Some groups have failed to measure any increase in circulating serotonin
following 5HTP administration (Shenker et al 1985a, 1985b). Although this study has shown
an increase in serotonin levels, the apparent inconsistency between the magnitude of the
increase in serotonin compared to that of its precursor and metabolite may be due to a
number of reasons. Firstly, serotonin is rapidly metabolised to 5HIAA. Secondly, it may be
taken up into extra-circulatory storage sites such as the gut or the adrenal gland, and this
would remain undetected in serum estimations. Thirdly, the conversion of 5HTP to serotonin
is known to occur both in CNS and in the kidney and this would also remain undetected in
serum measurements. Finally, serum levels of 5HTP and 5HIAA are low, whereas plasma
serotonin levels are high due to the fact that platelets store serotonin. Therefore, the
increase in serotonin is being measured against high endogenous serotonin, whilst the
increase in 5HTP and 5HIAA are measured against low plasma levels. However, despite the
inconsistency between the serotonin and the 5HTP and 5HIAA responses it must be
assumed that at some point the circulating and/or central levels of serotonin are increased to a
similar extent as 5HTP and 5HIAA, as this is the only pathway available for conversion of 5HTP
to 5HIAA.
In addition to the changes observed in 5HTP, serotonin and 5HIAA concentration ,
significant increases in PRA , corticosterone and aldosterone were also observed following
5HTP administration. Other groups have reported similar increases in aldosterone following
administration of 5HTP, 5HT or tryptophan, although conflicting results surround the increase
in PRA and ACTH (Modlinger et a/1979, Zimmerman and Ganong 1980, Maestri et a/1988,
Mantero et al 1982, Shenker et al 1985a, 1985b). It is unclear at this stage if the increase in
181
corticosterone results from direct activation of 11-p-hydroxylase enzyme activity or indirectly
by a central effect of serotonin on ACTH release from the pituitary. No change in potassium or
sodium levels, which may account for the increase in aldosterone secretion, were observed in
this or the aforementioned studies by other groups. It is interesting to note that the basal
plasma potassium concentration is higher than the accepted physiological concentration of
3.9 mM. There is no increase in plasma sodium concentration, even although aldosterone
secretion is enhanced. This is to be expected as it is unlikely that the time course followed
would show any changes in plasma sodium as the renal effects of aldosterone commence 1
to 2 hours after steroid secretion, reflecting the time required for protein synthesis. In
addition it is more likely that any changes in sodium would be observed in the urine rather than
in the plasma.
The control group of animals which received saline showed no significant change in any
parameter, indicating that any stress induced by the injection or animal handling was not
responsible for the results in the 5HTP treated group.
The preliminary data indicate that acute 5HTP administration stimulates aldosterone
secretion in vivo. However, it is unclear what the mechanism of this effect is, although the
results suggest a number of feasible possibilities. Firstly, serotonin formed from 5HTP may
cause changes in blood pressure, as it has been previously been reported. A fall in blood
pressure would activate the renin-angiotensin system and manifest itself in the changes in
PRA and aldosterone observed in the preliminary study.
Secondly, 5HTP may be converted to serotonin either centrally, peripherally or indeed
locally, and act directly on the zona glomeruosa to increase aldosterone and corticosterone
secretion, as has previously been reported in vitro in isolated cells and in the whole isolated
perfused adrenal gland (Mu'ller and Zeigler 1968, Haning et al 1970, Bing and Schulster
1977, Hinson and Vinson 1989). The presence of specific receptors for serotonin in the
zona glomerulosa has already been discussed in some detail in chapter 4 and has also been
reported by a number of other groups. It is known that capsular tissue can metabolise
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serotonin to 5HIAA and another unidentified metabolite (Trost and Muller 1976), and that
L-aromatic amino acid decarboxylase, the enzyme which converts 5HTP to serotonin, may
also be present in the adrenal gland, although localisation within the zona glomerulosa has yet
to be investigated (Waugh, Dockrell and Gow, unpublished observation). 5HTP has been
shown to have a small stimulatory effect on aldosterone secretion in vitro, although the
concentration required to evoke a similar response is approximately 100 times greater than
serotonin. Presumably this effect is mediated by the action of serotonin which is synthesised
from 5HTP by the zona glomerulosa. Further experimentation is required in order to confirm
this possibility.
Thirdly, the increase in PRA suggests serotonin may activate the renin-angiotensin
system. Renin release from the juxta-glomerular cells of the kidney is controlled by
P-adrenergic receptors, renal perfusion pressure and volume, sodium absorption across the
macula densa, circulating levels of vasopressin and angiotensin II and the CNS, perhaps by
serotoninergic neurones (Reid et a/1978, Brosnihan et a/1981, Van de Kar et al 1981,1982,
Zimmerman and Ganong 1980). Serotonin may also increase renin release by lowering blood
pressure. Previous studies have given conflicting reports of the effects of serotonin or 5HTP
on blood pressure (Henning and Rubenson 1971, Barney et a/1981, Mantero etal 1982). In
order to resolve the question of an indirect effect of 5HTP on blood pressure, the blood
pressure of the animals was measured at time = 0, prior to, and for 45 minutes following
administration of saline or 5HTP. No significant decrease in blood pressure was observed
with either saline or 5HTP which would account for the activation of the renin-angiotensin
system. Therefore changes in hormone status secondary to a decrease in blood pressure
can be excluded and so renin release mediated by a fall in blood pressure after 5HTP
administration seems unlikely. There is however a significant increase in blood pressure
within 25 minutes, in the group of animals receiving 5HTP, which is probably secondary to
activation of the renin-angiotensin system.
The fourth hypothesis is that serotonin formed within the CNS may act on the
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hypothalamus to release CRF, which subsequently acts on the pituitary, increasing ACTH
secretion. ACTH would increase both aldosterone and corticosterone secretion from the
adrenal cortex. This theory is supported by the large increase in corticosterone secretion
observed in the preliminary study following 5HTP administration and also several in vitro
studies by other groups which have shown that serotonin stimulates CRF release from the
hypothalamus and ACTH release from the pituitary (Weiner and Ganong 1978, Kreiger and
Kreiger 1979, Fuller 1981).
Finally, the last explanation is that serotonin acts to increase plasma potassium or
decrease plasma sodium concentration, both of which would increase aldosterone secretion,
resulting in sodium retention and potassium excretion. However, these parameters were
measured throughout the study and they showed no consistent significant change which
would account for the observed changes in aldosterone secretion.
The involvement of the hypothalamo-pituitary adrenal axis was investigated by
conducting an experiment, similar to the preliminary study, with the exception that some of
the animals were pretreated with dexamethasone, a synthetic glucocorticoid which inhibits
ACTH release from the pituitary gland. Successful dexamethasone suppression was
monitored by the decrease in basal corticosterone concentration in the two groups which
received it, compared to the control group which received saline. The results show that
dexamethasone pretreatment did not impair the uptake of 5HTP or its subsequent
conversion to serotonin and 5HIAA. Similarly the PRA response to 5HTP was unaffected.
However, the increases in both corticosterone and aldosterone were significantly inhibited,
although the aldosterone response was not completely suppressed. This inhibition of the
aldosterone response with dexamethasone suggests that the action of serotonin on adrenal
function in this model may be mediated, at least in part, by activation of the
hypothamo-pituitary adrenal axis, causing release of ACTH which stimulates aldosterone and
corticosterone secretion, or that ACTH is required permissively for the central action of
serotonin. Centrally mediated actions of serotonin have been suggested by a number of
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groups, although the data reported contrasts somewhat with the results obtained in this study
and may indicate that other central pathways in addition to the hypothalamo-pituitary adrenal
axis may mediated the action of serotonin. Dexamethasone blocked the increase in ACTH
and Cortisol observed with 5HTP administration in man, but had no effect on aldosterone
(Maestri et al 1988, Shenker et al 1985a, 1985b). Blockade of the peripheral conversion of
5HTP to serotonin with carbidopa, which allows complete central elevation of serotonin,
enhanced the aldosterone response to 5HTP. However, it must be taken into consideration
that carbidopa also blocks the formation of dopamine which inhibits aldosterone secretion.
Therefore, the enhancement of aldosterone may be due to decreased production of
dopamine rather than a centrally mediated action of serotonin. For this reason carbidopa was
not utilised in any of these studies.
The effect of serotonin on the renin-angiotensin system was studied in animals
pretreated with the ACE inhibitor captopril, which prevents the formation of angiotensin II from
angiotensin I. Successsful blockade of the renin-angiotensin system was judged by the
increase in PRA in the captopril treated groups. This is due to the loss of the negative
feedback system, whereby increases in angiotensin II act to suppress renin secretion and the
subsequent formation of angiotensin II. The results show that captopril pretreatment did not
impair the uptake of 5HTP or its conversion to serotonin and 5HIAA. Similarly there was no
effect on the corticosterone respose. The PRA response was also unaffected, although at
first sight it seems the reponse in the captopril pretreated group was enhanced, however
basal PRA was much higher in this group. The time required to return to basal PRA following
5HTP administration was prolonged in the group receiving captopril. This could be due to the
blockade of angiotensin II formation which cannot act to suppress further renin release from
the kidney, as it does in the untreated group. The aldosterone response to 5HTP was
inhibited in the presence of captopril, though not completely.
The curtailment of the aldosterone response with ACE inhibition suggests that
serotonin increases PRA and subsequently angiotensin II levels, which act directly at the zona
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glomerulosa to increase aldosterone secretion. Activation of the renin-angiotensin system by
serotonin and its precusors has been shown by many other groups. Peripheral administration
of 5HTP in rats results in a potent dipsogenic effect accompanied by an increase in PRA .
The dipsogenic effect can be blocked with carbidopa, propanolol, captopril and
methysergide, suggesting that 5HTP is converted to serotonin peripherally, as carbidopa
blocks peripheral formation of serotonin, and then acts on specific serotonin and
^-adrenergic receptors, increasing renin release from the kidney. Similar results were
observed with serotonin itself, with the exception that carbidopa had no inhibitory effect (Kikta
et al 1981, 1983, Threatte et al 1981). The drinking response to serotonin but not 5HTP
could be abolished by bi-lateral nephrectomy, suggesting that thirst induced by serotonin is
mediated exclusively by the renal renin-angiotensin system, whereas 5HTP induced drinking
may also involve a renin-independent possibly centrally mediated mechanism (Rowland etal
1987). Serotoninergic control of renin release was also postulated by Van de Kar et al 1981,
who showed, conversely, that depletion of serotonin levels using PCPA or
5,7-dihydroxytryptamine decreases PRA, although other groups have shown no effect
(Shisheva et a/1987, Mikulic etal 1988). The mechanism by which activation of serotonin
receptors results in renin release from the kidney is not well understood and it was not
attributed to a decrease in blood pressure by these groups. However, it may involve the
release of catecholamines from the adrenal medulla, or a centrally activated pathway. A central
activation of the renin-angiotensin system was postulated by Zimmerman and Ganong 1980,
who showed that the stimulatory effect of 5HTP and tryptophan on renin secretion in
anaesthetised dogs could be inhibited by renal denervation, blockade of serotonin receptors
and inhibition of serotonin formation within the brain.
Although other groups have shown no activation of the renin-angiotensin system with
administration of 5HTP or serotonin (Maestri et al 1988, Mantero et al 1982, Shenker et al
1985a, 1985b), the results of this study show a clear increase in PRA. However, it is unclear
from the study if aldosterone secretion is increased by the action of angiotensin II on the zona
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gtomenilosa or that normal circulating levels of angiotensin II are required permissively for the
action of serotonin on the adrenal or its action on another system such as the CNS.
Depletion of circulating angiotensin II levels during a sodium replete diet results in the
down regulation of adrenal angiotensin II receptors, which decrease in receptor number and
binding affinity, and so reduce the aldosterone response to angiotensin II (Glossman et al
1974, Aguilera et al 1978, Aguilera et al 1980). This regulatory effect may cause similar
changes in adrenal and / or other serotonin receptors which, from the work of chapter 4 and
that of other groups, seems to interact synergistically in some way with the angiotensin II
receptor. Indeed it has been shown that sodium depletion enhances the in vitro aldosterone
response to angiotensin II and serotonin, whilst sodium loading diminishes the response
(Aguilera et al 1978, Al-Dujaili et al 1982). Similar changes in the adrenal are observed with
captopril treatment as this effectively decreases circulating levels of angiotensin II. However,
with regard to the role of angiotensin II within the CNS, it is unclear if captopril would cross the
blood-brain barrier and block the central renin-angiotensin system, and if the effects of ACE
inhibition on the angiotensin II receptor observed in the adrenal, extend to peripheral
angiotensin and serotonin receptors, as alterations in sodium balance have the opposite
effects in the vascular system as they have in the adrenal (Gunther et al 1980, Aguilera et al
1981b).
The permissive, rather than mediatory, role of angiotensin II in the action of 5HTP was
investigated by comparing the effect of 5HTP on captopril pretreated animals inserted with
osmotic mini-pumps delivering normal circulatory levels of angiotensin II, but concomitantly
blocking activation of the renin-angiotensin system itself. The response to 5HTP in this group
was compared with a group receiving captopril alone and another receiving no pretreatment.
The aldosterone levels in this particular study were somewhat lower than in the other
experiments. This may be due to a small overdose of heparin, which is known to decrease
aldosterone secretion (Abbott etal 1966).
Successful normalisation of circulating levels of angiotensin II was monitored by basal
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PRA which, compared to the untreated group, is elevated in the group receiving captopril,
due to the loss of the negative feedback as previously explained, and normal in the group
receiving captopril plus angiotensin II, due to the presence of the negative feedback, and
inhibition of further renin release by the angiotensin II. Angiotensin II measurements would
have provided a clearer picture, however the assay requires a large volume of blood (>5ml)
which was not possible to take in these studies.
The results from this experiment clearly demonstrate that blockade of the renin
angiotensin system using captopril does not affect the aldosterone response to 5HTP if
circulating angiotensin II levels remain normal, suggesting that the increase in PRA and
subsequent increase in angiotensin II caused by 5HTP administration does not mediate the
increase in aldosterone secretion. They do however suggest that angiotensin II is required
permissively for the action of 5HTP on aldosterone secretion. The exact site of this
requirement is unclear. As previously discussed it may be at the site of the adrenal gland
where it is required to maintain adrenal responsiveness to serotonin or indeed ACTH, as the
dexamethasone experiments suggest the aldosterone response is mediated by release of
ACTH and it has been shown by other groups that the adrenal responsiveness to ACTH is
dependent on angiotensin II (Venning et al 1962, Kinson and Singer 1968, Muller and Huber
1969). Another possibility is that normal circulating levels of angiotensin II are required within
the CNS for the action of serotonin, indeed some studies have shown that angiotensin II
promotes ACTH release from the pituitary gland (Sobel et al 1983). However, although a
central renin-angiotensin system does clearly exist (Ganten and Speck 1978), it is unclear if
peripheral adminisatration of captopril would cross the blood brain barrier and decrease central
levels of angiotensin II, although some studies by other groups suggest that systemic
administration of captopril does inhibit the brain renin-angiotensin system in rats (Scholkens
et a/1983, Gepetti etal 1987).
Although acute enhancement of serotonin seems to act to increase aldosterone
secretion by a largely indirect mechanism, it must be assumed that the activation of these
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systems is mediated by serotonin receptors. Studies with serotonin antagonists were not
carried out, mainly because of the uncertainty of the class of receptor involved, and also
because of the possible effects on other parameters such as blood pressure, which has been
shown to decrease following ketanserin administration (Fozard 1982). This would itself
activate the renin-angiotensin system and make clear interpretation of the results very difficult.
In addition, the use of these antagonists would not distinguish between peripheral and
centrally mediated events, as presumably serotonin elicits its action in either system by
activating specific receptors.
In summary, the results of this chapter clearly show that administration of 5HTP, which
increases circulating levels of serotonin, activates the renin-angiotensin system, the
hypothalamo-pituitary axis and aldosterone secretion by the adrenal gland. However, the
actual increase in aldosterone secretion does not appear to be mediated by activation of the
renin-angiotensin system, although angiotensin II is required in a permissive capacity for
steroidogenesis. This exact site of this remains unclear and requires further investigation. A
permissive role of ACTH is also equally possible. However, experiments with osmotic pumps
delivering ACTH were not conducted because of the inability of the pumps to mimic the
diurnal rhythm of ACTH secretion, which in the nocturnal rat reaches a peak in the late
afternoon and a nadir in the early morning (Matsuyama eta/1971).
The apparent failure of both captopril and dexamethasone to inhibit the aldosterone
response to 5HTP completely, suggests that another mechanism is also operative and this
may be a direct action of serotonin on the adrenal cortex. Therefore, the full steroidogenic
response to 5HTP involves a complex interplay between the CNS, the renin-angiotensin
system and perhaps a direct effect of serotonin at the level of the zona glomerulosa. Any
alterations in this fine equilibrium may result in altered adrenal responsiveness leading to
changes in mineralocorticoid secretion. Further studies using nephrectomised or
hypophysectomised animals may be useful in establishing the relative contribution of the
renin-angiotensin system or the hypothalamo-pituitary adrenal axis in the stimulation of
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aldosterone secretion by serotonin in vivo.
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Chapter Seven
Serotoninergic Control of Adrenal Growth.
IA, Introduction
It is well documented that altered sodium status results in changes in both the width and
the responsiveness of the zona glomerulosa, in that a sodium deplete diet increases the
width and the responsiveness to angiotensin II, whilst a sodium replete diet has the opposite
effect. These effects are thought to be mediated respectively by an up-regulation and
down-regulation of the angiotensin II receptor.
Although serotonin increases aldosterone secretion both in vivo and in vitro, its
importance as a trophic factor for the zona glomerulosa has until now received little attention.
The possibility that serotonin may act as a trophic factor was studied in rats in which serotonin
status was enhanced pharmacologically by administration of 5HTP.
7.2. Alms of study
1. To assess the role of serotonin as a trophic factor by measuring zona glomerulosa and
zona fasciculata / reticularis width following chronic administration of 5HTP, the immediate
precursor of serotonin.
2. To compare any changes in zona glomerulosa width observed with 5HTP with those
observed during altered sodium status.
3. To assess the contribution of the renin-angiotensin system in the effects caused by 5HTP
administration by measuring PRA, angiotensin II and also zona glomerulosa width following
administration of 5HTP and 5HTP plus the ACE inhibitor captopril.
4. To assess the contribution of the hypothamo-pituitary adrenal axis in the effects caused by
5HTP by measuring corticosterone and zona glomerulosa width following administration of
5HTP and 5HTP plus the synthetic glucocorticoid dexamethasone.
7.3. Materials and methods
The materials and methods for this chapter have been fully described in chapter 3.
Briefly, animals were maintained on various dietary regimes for periods of up to 2 weeks. The
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animals were then sacrificed and a biood sample taken for estimation of angiotensin II, PRA,
aldosterone, corticosterone and serotonin by RIA. The adrenal glands were removed, snap
frozen, sectioned, stained and the zona glomerulosa (ZG) and zona fasciculata / reticularis
(ZFR) width measured. The staining method utilised haematoxylin and oil red-O, which are
nuclear and lipid stains respectively. Using this method the capsule and zona glomerulosa
stained dark blue, the zona fasciculata / reticularis stained red and the medulla stained light
blue. The zona fasciculata and zona reticularis were measured only in the preliminary studies
and together as it was technically difficult to distinguish accurately between the two zones.
IAm Statistical analysis
All the results are illustrated as mean ± SEM. Statistical significance was calculated
using Student's t-test for unpaired samples. A p value of < 0.05 was considered significant.
NS indicates non-significance. The p values obtained are quoted in the text and are
illustrated on the figures. *, " and *** on the figures indicates that p<0.05, p<0.01 and
p<0.001 respectively.
ZJL Results
7.5.1. The effect of 5HTP administration on serum serotonin concentration
A preliminary study was carried out to assess whether chronic administration of 5HTP in
the animals drinking water increased the circulating levels of serotonin. The 5HTP dietary
regime is given in chapter three section 3.8.1.
Figure 7.1 shows the circulating levels of serotonin in normal animals (controls) and in
those receiving 5HTP in their drinking water for 1 and 2 weeks. Serum serotonin increased
from 4.7 ± 0.8 pM in the control group to 14.5 ± 1.9 pM (p<0.001) and 10.4 ±1.1 pM
(p<0.001) after 1 and 2 weeks of 5HTP treatment respectively.
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Figure 7.2. The effect of 5HTP administration on zona
glomerulosa width.
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7.5.2. The effect of 5HTP administration on zona alomerulosa and zona
fasclculata / reticularis width
Having established that 5HTP administation, via the animals drinking water, does
increase the circulating concentration of serotonin, the effect of this diet on the width of the
zona glomerulosa and zona fasciculata / reticularis was studied.
Figure 7.2 shows the width of the zona glomerulosa after 1 and 2 weeks of 5HTP
treatment. The width of the zone in the control animals showed no significant change
between weeks 1 and 2, therefore the values from each week were pooled. The zona
glomerulosa width increased from 72 ± 1.4 p in the control group to 86.8 ± 1.4 p (p<0.001)
and 97.6 i 1.4 p (p<0.001) after 1 and 2 weeks of 5HTP treatment respectively.
Representative photographs of adrenal sections (zona glomerulosa) under normal conditions
and after 1 and 2 weeks of 5HTP treatment are illustrated in figures 7.3, 7.4 and 7.5.
Figure 7.6 shows the width of the zona fasciculata / reticularis after 1 and 2 weeks of
5HTP treatment. The width of the zone in the control animals showed no significant change
between weeks 1 and 2, therefore the values from each week were pooled. The zona
fasciculata / reticularis width decreased from 1216 ±16 p in the control group to 1085 ± 23 p
(p<0.001) and 980 ± 30 p (p<0.001) after 1 and 2 weeks of 5HTP treatment respectively.
7.5.3. The effect of sodium depletion and sodium loading on zona
qlomerulosa and zona fasclculata I reticularis width
It seems clear from the previous section that chronic administration of 5HTP has a
trophic effect on the zona glomerulosa and a parallel atrophic effect on the zona fasciculata /
reticularis. In order to assess the magnitude of this response and provide a control for the
methodology, the effect of altering sodium status on the width of the zones was also studied.




A representative photograph of the adrenal zona
glomerulosa under normal conditions.
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Figure 7.4.
A representative photograph of the changes in zona





A representative photograph of the changes in zona
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Figure 7.6. The effect of 5HTP administration on zona




Fiqure 7.7. The effect of sodium depletion on zona
glomerulosa width.
44 sections from 22 animals
46 sections from 23 animals









Figure 7.7 shows the width of the zona glomerulosa after 1 and 2 weeks of sodium
depletion. The width of the zone in the control animals showed no significant change
between weeks 1 and 2, therefore the values from each week were pooled. The zona
glomerulosa width increased from 60.8 ± 1.2 p in the control group to 104 ± 3.4 p. (p<0.001)
and 113.4 ±1.4 (p<0.001) after 1 and 2 weeks of sodium depletion respectively.
Representative photographs of adrenal sections (zona glomerulosa) after 1 and 2 weeks of
sodium depletion are illustrated in figures 7.8 and 7.9.
Figure 7.10 shows the width of the zona fasciculata / reticularis after 1 and 2 weeks of
sodium depletion. The width of the zone in the control animals showed no significant change
between weeks 1 and 2, therefore the values from each week were pooled. The zona
fasciculata / reticularis width in the control group was 1182 ± 20 p compared to 1209 ± 19 p
(NS) and 1027 ±16 p (p<0.001) after 1 and 2 weeks of sodium depletion respectively.
Figure 7.11 shows the width of the zona glomerulosa after 1 and 2 weeks of sodium
loading. As this was carried out at the same time as the previous sodium depletion
experiment, the same normal values are used. Sodium loading caused the zona glomerulosa
width to decrease from 60.8 ± 1.2 p in the normal group to 55.6 ± 1.3 p (p<0.01) and 57.2 ±
0.6 p (p<0.05) after 1 and 2 weeks of treatment respectively. Representative photographs of
adrenal sections (zona glomerulosa) after 1 and 2 weeks of sodium loading are illustrated in
figures 7.12 and 7.13.
Figure 7.14 shows the width of the zona fasciculata / reticularis after 1 and 2 weeks of
sodium loading. The width of the zone in the control animals showed no significant change
between weeks 1 and 2, therefore the values from each week were pooled. The zona
fasciculata / reticularis width in the control group was 1182 ± 20 p, compared to 1099 ± 30 p
(p<0.05) and 1165 ± 15 p (NS) after 1 and 2 weeks of sodium loading respectively.
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Figure 7.8.
A representative photograph of the changes in zona
glomerulosa width observed after 1 week of sodium
depletion.
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Figure 7.9.
A representative photograph of the changes in zona
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Figure 7.10. The effect of sodium depletion on zona
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A representative photograph of the changes in zona





A representative photograph of the changes In zona
glomerulosa width observed after 2 weeks of sodium
loading.
204
46 sections from 22 animals
35 sections from 18 animals














Figure 7.14. The effect of sodium loading on zona fasciculata /
reticularis width.
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Figure 7.15 shows the zona fasciculata / reticularis : zona glomerulosa ratios during the
various dietary regimes. The ratios were derived from the means of the width of the zones
from each group. The normal ratio ranged from 16.8 to 19.4. Both a low sodium and a 5HTP
diet decreased the ratio, whilst a sodium replete diet increased the ratio.
7.5.4. The mechanism of 5HTP stimulated adrenal growth
It is clear that chronic administration of 5HTP, which enhances circulating levels of
serotonin, results in an increase in adrenal zona glomerulosa width. However, it is unclear if
this is mediated by specific serotonin receptors which increase in number and binding affinity
following 5HTP administration in a similar way to the angiotensin II receptor during sodium
restriction, or whether it is mediated indirectly by activation of either the renin-angiotensin
system or the hypothalamo-pituitary adrenal axis.
In order to investigate this, the zona glomerulosa was measured after administration of
5HTP alone or in the presence of either captopril or dexamethasone. In addition,
measurements of PRA, plasma angiotensin II, corticosterone and aldosterone were made,
firstly to study any activation of the renin angiotensin system or the hypothalamo-pituitary
adrenal axis following 5HTP administration and secondly as a marker to test the efficacy of
captopril and dexamethasone in suppressing each of the systems respectively. As controls,
plasma angiotensin II and serotonin concentration were measured during altered sodium
status, which is already known to cause changes in morphology via the renin-angiotensin
system.
Figure 7.16 shows plasma levels of angiotensin II in normal animals and those on
sodium deplete and sodium replete diets for 1 week. Angiotensin II concentration increased
from 38.6 ± 5 pM in the normal group to 104 ± 16.7 pM (p<0.001) in the sodium deplete
group. Sodium loading caused angiotensin I! to decrease to 24.5 ± 3.5 pM (p<0.05).
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Figure 7.15.
The effect of the various dietary regimes on the
zona fasciculata / reticularis : zona glomerulosa ratio.
DIET/DURATION ZF/ZR : ZG RATIO
Normal (chow) 16.8
Normal sodium (wholemeal) 19.4
Low sodium (1 week) 11.6
Low sodium (2 weeks) 9.2
High sodium (1week) 19.7
High sodium (2 weeks) 20.3
5HTP (1 week) 12.5













Figure 7.16. The effect of sodium status on plasma
angiotensin II concentration.
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Figure 7.17 shows serum serotonin concentration in animals after 1 week of sodium
loading and sodium depletion. Serum serotonin levels showed no significant change with
sodium loading. The concentration in the control group was 7.7± 0.6 pM compared with 7.2 ±
0.7 pM in the sodium loaded group. Sodium depletion caused a small but significant
decrease in serotonin levels to 6.0 ± 0.6 pM (p<0.05).
Figure 7.18 shows PRA following 1 week of captopril or 5HTP plus captopril treatment.
PRA increased from 2.6 ± 0.5 ng/ml/hr in the control group to 22.8 ± 3.3 (p<0.001) and 20.6
±5.1 ng/ml/hr (p<0.001) following captopril and captopril plus 5HTP treatment respectively.
PRA levels following 5HTP treatment alone are shown in a subsequent illustration.
Figure 7.19 compares the effect of either 5HTP or captopril treatment alone, with 5HTP
plus captopril treatment for 1 week on the width of the zona glomerulosa. The width of the
zona glomerulosa increased, as before, from 69.6 ± 0.6 p in the normal (control) group to 86.6
± 0.9 p (p<0.001) afterl week of 5HTP administration. Captopril treatment alone caused a
small but non-significant decrease in width to 66.9 ± 1.9 p. Captopril plus 5HTP treatment
caused a significant increase in width to 75.8 ± 0.8 p (p<0.001), compared to the control
group, however the increase was significantly less than that observed with 5HTP alone
(px0.001). Representative photographs of adrenal sections (zona glomerulosa) after 1 week
of captopril or captopril plus 5FITP treatment are illustrated in figures 7.20 and 7.21.
Figure 7.22 shows plasma corticosterone levels following 1 week of dexamethasone
and 5HTP plus dexamethasone treatment. Corticosterone concentration decreased from
483 ±84 nM in the control group to 4.9 ±0.8 (p<0.001) and 7.9 ± 1.6 nM (p<0.001) following
dexamethasone and dexamethasone plus 5HTP treatment respectively. Corticosterone
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Figure 7.18. The effect of captopril and 5HTP plus captopril on
plasma renin activity.
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101 sections from 34 animals
106 sections from 36 animals
97 sections from 32 animals

















Figure 7.19. The effect of 5HTP, captopril and 5HTP plus
captopril on zona glomerulosa width.
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Figure 7.20.
A representative photograph of the changes in zona






A representative photograph of the changes in
zona glomerulosa width observed after 1 week





















Figure 7.22. The effect of dexamethasone and 5HTP plus
dexamethasone on plasma corticosterone
concentration.
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Figure 7.23 compares the effect of either 5HTP or dexamethasone treatment alone,
with 5HTP plus dexamethasone treatment for 1 week on the width of the zona glomerulosa.
The width of the zona glomerulosa increased, as before, from 69.6 ± 0.6 p in the normal
(control) group to 86.6 ± 0.9 p (p<0.001). Dexamethasone treatment alone caused a
significant increase in width to 77.1 ± 1.4 p (p<0.001). Dexamethasone plus 5HTP treatment
caused a small but significant increase in width to 93.7 ± 1.4 p (p<0.001) compared to the
control group. The increase observed with 5HTP plus dexamethasone was significantly
higher than that observed with 5HTP alone (p<0.001). Representative photographs of
adrenal sections (zona glomerulosa) after 1 week of dexamethasone or dexamethasone plus
5HTP treatment are illustrated in figures 7.24 and 7.25.
Figure 7.26 shows PRA in the control group and after 1 week of 5HTP treatment. 5HTP
treatment showed no significant effect on PRA which was 2.6 ±0.6 ng/ml/hr in the control
group compared to 2.7 ± 0.8 ng/ml/hr in the 5HTP treated group.
Figure 7.27 shows plasma angiotensin II levels in the control group and those receiving
5HTP for 1 week. 5HTP treatment caused no significant change in plasma angiotensin II
concentration, which was 34.5 ± 7.7 pM in the normal group and 40.5 ± 7 pM in the 5HTP
treated group.
Figure 7.28 shows plasma corticosterone levels in the control group and after 1 week of
5HTP treatment. 5HTP treatment showed no significant effect on corticosterone
concentration which was 484 ± 84 nM in the control group compared with 274 ± 53 nM in the
5HTP treated group.
Figure 7.29 shows plasma aldosterone levels in the control group and after 1 week of
5HTP treatment. 5HTP treatment showed no significant effect on aldosterone concentration
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101 sections from 34 animals
106 sections from 36 animals
50 sections from 25 animals




























Figure 7.23. The effect of 5HTP, dexamethasone and 5HTP
plus dexamethasone on zona glomerulosa width.
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Figure 7.24.
A representative photograph of the changes in
zona glomerulosa width observed after 1 week
of dexamethasone treatment.
H 100 microns
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A representative photograph of the changes In
zona glomerulosa width observed after 1 week
of 5HTP plus dexamethasone treatment.
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Figure 7.29. The effect of 5HTP administration on plasma
aldosterone concentration.
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which was 0.40 ± 0.05 nM in the control group compared with 0.42 ± 0.05 nM in the 5HTP
treated group.
ZJL Discussion
A number of factors which are thought to play either a major or a minor role in the
regulation of aldosterone secretion, have been found to have a marked effect on the growth
of the adrenal zona glomerulosa. These include sodium depletion, potassium loading,
prolactin and a-MSH, which increase the width of the zone, whilst sodium loading, potassium
depletion and somatostatin cause a decrease (Deane et al 1948, Marx and Deane 1963,
Muller and Huber 1969, Rebuffat et a/1984, Mazzochi et al 1980, 1985, 1986, Robba et al
1986). These studies attempted to investigate the effect of chronic elevation of circulating
serotonin levels on adrenal growth in animals treated with 5HTP, the precursor to serotonin,
for up to 2 weeks. 5HTP was dissolved in the animals drinking water and was made up fresh
twice daily to avoid any degradation. The experiments in this chapter were confined to
studying the effects of enhanced serotonin status on adrenal growth and hormone secretion.
Depletion of circulating levels of serotonin using PCPA, which inhibits central and peripheral
formation of serotonin and therefore acts as a serotonin depleting agent, were terminated as
the drug caused the animals to become extremely ill after only 2 days of treatment. Depletion
of serotonin levels using carbidopa was not considered as it causes a concomitant decrease
in the circulating levels of dopamine, which may play a role in the maintenance of adrenal zonal
width and make interpretation of the results difficult.
The results show clearly that circulating serotonin levels showed approximately a 3 and
2 fold increase after 1 and 2 weeks of 5HTP treatment respectively. This was accompanied by
a marked increase in zona glomerulosa width and a concomitant decrease in zona fasciculata /
reticularis width. The zona glomerulosa increased by 20 and 30% and the zona fasciculata /
reticularis decreased by 10 and 20% after 1 and 2 weeks of treatment respectively. These
changes were compared with those observed during alterations in sodium status. The
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sodium diets acted both as a control for the methodology as the results have been
documented by a number of groups, and as a marker for the relative potency of each dietary
manipulation. Sodium depletion, as expected, caused a 65 and 83% increase in zona
glomerulosa width after 1 and 2 weeks respectively. Zona fasciculata / reticularis width
showed very little change after 1 week and decreased by 13% after 2 weeks of treatment.
Conversely, sodium loading, as expected, caused an 11 and 8% decrease in zona
glomerulosa width after 1 and 2 weeks of treatment respectively. The zona fasciculata /
reticularis, however, also decreased by 7 and 2% after 1 and 2 weeks of treatment
respectively.
The results show clearly that chronic elevation of circulating serotonin results in an
increase in zona glomerulosa width and a parallel decrease in zona fasciculata / reticularis
width. It cannot be concluded yet whether this is a true hypertrophic effect i.e. an increase in
cell division, as observed in the zona glomerulosa following sodium restriction (Race and
Green 1955), or indeed a hyperplastic effect leading to an increase in the mass of the
glomerulosa cells and changes in their ultra-structure, as observed in zona fasciculata cells
following chronic administration of ACTH (Bransome 1968, Nickerson 1975). However, for
simplicity the increase in width will be referred to as a "trophic" effect. Comparison of the
increase in width with 5HTP and low sodium status indicate that serotonin is not as potent a
stimulus for glomerulosa growth as a sodium deplete diet. A number of other studies have
demonstrated the mitogenic properties of serotonin, particularly in vascular smooth muscle
cells and fibroblasts (Nemecek et a/1986, Seuwen et at 1988). More recently, melatonin,
which is formed from serotonin by two enzymatic reactions, has been shown to stimulate
zona glomerulosa hypertrophy and aldosterone secretion, primarily by increasing the volume
of mitochondria and smooth ER, which contain the enzymes involved in aldosterone
biosynthesis (Tamaoki ef a/1973, Rebuffat et a/1988,)
Although the "trophic" action of serotonin is clear, the mechanism by which it exerts its
effects is difficult to establish, and a number of possibilities exist. Firstly, it may act by direct
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modulation of specific serotonin receptors located on the zona glomerulosa, which may
up-regulate in response to increased serotonin status, therefore increasing in number, affinity
and responsiveness to serotonin. This has at least been demonstrated in vitro, whereby the
responsiveness of aldosterone secretion to serotonin is enhanced in zona glomerulosa cells
isolated from animals maintained on a 5HTP diet (Shaikh et a! 1986), in a similar way to the
changes observed in angiotensin II receptors and responsiveness during a sodium deplete
diet (Glossman et al 1974, Aguilera et al 1978, Aguilera et al 1980). Alternatively, serotonin
may act indirectly to modulate other systems such as the renin-angiotensin system or the
hypothalamo-pituitary adrenal axis. In this respect, the "trophic" effect of ACTH on the zona
fasciculata is considered to be indirect, and may be mediated by its other actions such as
increased blood flow or cyclic AMP secretion (O'Hare and Neville 1973, Marton et al 1976,
Lewinski and Szkudlinski 1981).
Considering the renin-angiotensin system first, the results of chapter 6 and data from
other groups have shown that serotonin can activate the renin-angiotensin system
(Zimmerman and Ganong 1980). This would increase circulating levels of angiotensin II, in a
similar way as a sodium deplete diet. This chapter and a number of other groups have shown
that sodium restriction results in increased angiotensin II levels and zona glomerulosa
hypertrophy , resulting directly from an increase in the mitotic index of the glomerulosa cells
(Deane et al 1948, Peschel and Race 1954). The effects on the inner zones are conflicting,
some groups showing no change (Deane et al 1948, Muller and Huber 1969), whilst others
have shown a parallel decrease (Hartroft and Eisenstein 1957, Blair-West et al 1968). The
increase in the zona glomerulosa width is associated with an increase in rough and smooth
ER, golgi apparatus and mitochondrial surface area, and an increase in the activity of many
enzymes (Shelton and Jones 1971, Giacomelli et al 1965, Fisher and Horvat 1971, Marx and
Deane 1963, Cohen 1965, Kuhn and Kissane 1964, Elema et al 1968). In addition to the
cellular changes, the aldosterone response to angiotensin II, ACTH, potassium and serotonin
is enhanced during sodium restriction, although conflicting reports surround the
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enhancement of the response to ACTH (Thorn et al 1957, Venning et al 1962, Kinson and
Singer 1968, Muller 1968,1970, Muller and Huber 1969, Blair-West et al 1970, Vinson et al
1983). Therefore, it is possible that serotonin may elicit its effect on the zona glomerulosa by
activating the renin-angiotensin system. This hypothesis was tested by comparing the effect
of 5HTP treatment alone on zonal width with that of 5HTP plus captopril or captopril alone. In
addition, PRA and angiotensin II measurements were made following chronic 5HTP
treatment. Successful blockade of the renin-angiotensin system by captopril was monitored
by the increase in PRA in the 2 groups receiving the ACE inhibitor. There was no change in
PRA in the group receiving 5HTP alone and consequently, there was also no change in
angiotensin II levels, in contrast to the results obtained with altered sodium status, which quite
clearly causes alterations in the renin-angiotensin system. The zona glomerulosa
measurements in this study show that captopril treatment alone caused a small (NS) decrease
in width, probably due to the decrease in circulating levels of angiotensin II which maintain the
zona glomerulosa width. The "trophic" action of 5HTP was attenuated by the
co-administration of captopril with 5HTP. However, the width was not returned to control
values, as would be expected if the action of serotonin is mediated solely by activation of the
renin-angiotensin system. The attenuating effect of captopril on 5HTP induced growth is
most probably attributable to the action of captopril itself on the renin-angiotensin system,
rather than the blockade of the stimulatory effect of serotonin on the system, thus causing a
similar effect to sodium loading. This has already been documented by Mazzocchi et al 1985,
who showed that prolonged captopril treatment caused a significant decrease in the volume
of zona glomerulosa cells, in addition to the content of nucleii, mitochondria and SER. The
effect is almost certainly more pronounced when the zona glomerulosa width is increased
beyond the normal range, as with 5HTP treatment. The alternative explanation is similar to
that of chapter 6, wherby angiotensin II is required permissively for the trophic action of
serotonin on zona glomerulosa growth, probably to maintain both the angiotensin and
serotonin receptors. Indeed it has been shown that down-regulation of the angiotensin II
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receptor by sodium loading, decreases the adrenal responsiveness to both angiotensin II and
serotonin, therefore it is possible that down-regulation of the angiotensin II receptor with
captopril may similarly effect the responsiveness of the serotonin receptor in vivo and
attenuate the trophic effect. Considering the measurements of glomerulosa width following
captopril plus 5HTP treatment, together with the PRA and angiotensin II measurements it
seems unlikely that activation of the renin-angiotensin system mediates the trophic changes
in the zona glomerulosa observed after chronic 5HTP administration.
The activation of the hypothalamo-pituitary adrenal axis by serotonin has been reported
by many groups, and the in vivo results of chapter 6 also show that stimulation of aldosterone
secretion by 5HTP can be blocked with dexamethasone, suggesting involvement of this
branch of the CNS. However, these have been primarily acute studies, whereas this study
has concentrated on the chronic action of serotonin. It is expected that chronic activation of
the hypothalamo-pituitary adrenal axis would result in overproduction of ACTH which is
primarily concerned with glucocorticoid secretion and maintainance of zona fasciculata width.
Therefore, chronic elevation of ACTH levels by serotonin would presumably increase zona
fasciculata width and decrease zona glomerulosa width. The trophic effects of ACTH have
been reported by other groups who have shown chronic elevation of ACTH decreased zona
glomerulosa width and caused structural disruption leading to the conversion of glomerulosa
cells to fasciculata-like cells and the loss of responsiveness of aldosterone secretion to
serotonin which is unique to the glomerulosa (Shire and Stewart 1972, McDougall et al 1980,
Muller 1978). Nevertheless, the role of the hypothalamo-pituitary adrenal axis was studied by
comparing the effect of 5HTP administration alone with 5HTP plus dexamethasone or
dexamethasone alone. Dexamethasone itself caused a significant increase in zona
glomerulosa width. This may be due to removal of ACTH which maintains zona fasciculata /
reticularis width, resulting in zona fasciculata / reticularis atrophy and subsequent glomerulosa
hypertrophy. A similar effect was shown in pre-pubertal rats, whereby administration of a
glucocorticoid resulted in the cessation of adrenocortical growth, and later adrenal atrophy
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(Wright et al 1974). Similarly the trophic action of 5HTP was enhanced to a small degree in
the presence of dexamethasone, again this may be due to zona fasciculata atrophy and
concomitant zona glomerulosa hypertrophy caused by the glucocorticoid. These results,
together with the corticosterone measurements after 5HTP treatment which show no
significant change, suggest that activation of the hypothalamo-pituitary adrenal axis does not
mediate the chronic effects of serotonin. It is noteworthy that the corticosterone levels in this
particular study were relatively high compared with measurements made in other studies. This
is probably indicative of stress levels in the animals preceding cervical dislocation. It is also of
interest to note that the corticosterone levels in the 5HTP treated animals are somewhat
lower than in the control group, although it is non-significant. This is perhaps due to the
decrease in zona fasciculata / reticularis width following 5HTP treatment, as this zone is the
major site of corticosterone biosynthesis.
In summary, the results suggest that chronic elevation of plasma serotonin results in
zona glomerulosa "hypertrophy", similar to, but not as effective as a sodium deplete diet. The
studies carried out were not able to determine if this was a result of increased mitotic activity or
an increase in cell volume and ultra-structure, nor did they determine whether serotonin is a
direct growth factor like angiotensin II or an indirect factor like ACTH. The effect does not
seem to be mediated by activation of either the renin-angiotensin system or the
hypothalamo-pituitary adrenal axis. Therefore, it seems possible that the effect may be
mediated by discreet alterations in specific receptors for serotonin within the zona
glomerulosa, although the possibility that serotonin could stimulate the production of another
growth factor (s) cannot be excluded at this stage. It is of particular interest that despite
stimulating the growth of the zona gtomerulosa, chronic administration of 5HTP, fails to show
any significant effect on aldosterone secretion. This is in contrast to other trophic factors such
as sodium depletion, suggesting an "escape" mechanism from increased aldosterone
secretion. This may be by increasing secretion of another factor which inhibits aldosterone
secretion such as ANP, which has been previously reported to increase tritiated thymidine
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uptake in cultured zona glomerulosa cells (Horiba et al 1985). The stimulatory effect of ANP
on mitogenesis indicates that increasing steroid secretion is not a pre-requisite for the trophic
action of a hormone. Further studies are required to determine the exact nature of the
"trophic" effect of serotonin on the adrenal cortex, and investigate changes in the number
and affinity of serotonin receptors within the zona glomerulosa and establish the role of the
amine in uncontrolled cell growth as seen in carcinoma of the adrenal gland.
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Chapter Eight
General Discussion and Future Studies.
8.1. Discussion
The data obtained from the four chapters suggest, at least in part, that serotonin may
play a physiological role in the regulation of mineralocorticoid secretion.
The serotonin antagonist studies provide some, though not conclusive, evidence for
the existence of specific serotonin receptors within the zona glomerulosa. These appear to
be predominantly 5HT-|C / 5HT2 like receptors. However, the limitations of such studies,
measuring end steroid in the presence of drugs and extrapolating these back to the initial
receptor event, must be taken into full consideration in the interpretation of the results.
Definitive proof of specific serotonin receptors would require a more detailed pharmacological
profile, using a more extensive range of antagonists, in addition to molecular studies probing
the adrenal cortex for the expresssion of the genes encoding the serotonin receptors, some
of which have already been cloned and sequenced in other tissue (Julius et al 1988, Fargin et
al 1988, Pritchett et al 1988). Radioligand binding studies in isolated zona glomerulosa cells,
using either radiolabeled serotonin or a serotonin antagonist would also be a useful
experimental tool for investigating both the type, number and affinity of the serotonin
receptors. These studies would also be useful in the investigation of changes in receptor
number and affinity during altered serotonin or sodium status or indeed in the hypertensive
animal model. Autoradiography with radiolabelled serotonin, using sections of whole adrenal
glands could also be used to demonstrate the presence of binding sites and confirm their
confinement to the zona glomerulosa. However, attempts at radioligand binding studies in
this laboratory, using 125|_ serotonin were largely unsuccessful, probably because of the
unstable nature of the compound.
The serotonin receptors within the zona glomerulosa, like those of ACTH, appear to be
coupled to the adenylate cyclase second messenger system. There is no evidence of PI
turnover as observed with angiotensin II. In addition, the presence of extracellular calcium and
inward transmembrane flux of calcium seem to be prerequisite for the induction of the
cascade mechanism leading to enhanced aldosterone secretion. The role of calcium as a
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mediator of the end steroid response in these studies has been monitored by largely indirect
methods, using calcium antagonists and chelating agents etc, yielding qualitative results. A
more detailed and quantified analysis could have been obtained from fluorescent dye
studies, whereby dyes such as Fura-2 permeate the cell membrane and fluoresce intensely
on binding of calcium, following stimulation. These can be carried out in both cell suspensions
and single cells. In addition, it would be possible to define the source of the calcium, be it
extracellular or from intracellular organelles such as the endoplasmic reticulum. Although
these type of experiments were not carried out in this laboratory, they have been carried out
by a number of other groups who have shown that in vascular tissue there is a large increase
in intracellular calcium ion concentration, following serotoninergic stimulation, which is
liberated from an intracellular store in response to formation of IP3. However, the adrenal
serotonin receptor does not appear to utilise the PI second messenger system and
fluorescent dye studies carried out in bovine cells have shown no change in calcium levels
(Capponi et al 1987). However, as bovine adrenal cells have no steroidogenic response to
serotonin, this is not an unexpected result. Therefore, similar studies using rat zona
glomerulosa cells are necessary, and it would also be useful to compare and contrast the
adrenal response with that of the vascular system.
Although it seems almost certain that serotonin receptors exist within the zona
glomerulosa and these appear to be coupled to a signal transduction mechanism, it is unclear
how serotonin within the body acts to stimulate steroidogenesis or play a role in diseases
such as hypertension. Unlike ACTH, which acts as a circulating hormone, free serotonin is
found in very small, if any, amounts within the circulatory system. This guards against its
potentially lethal capacity to mediate vascular permeabilisation and anaphylactic shock.
Therefore, it is stored almost exclusively within platelets, bound to serotonectin or in
extra-circulatory compartments such as the gut. Within the CNS, serotonin acts as a
neurotransmitter and within the vascular system it is released as part of the blood clotting
cascade mechanism. As it cannot circulate freely, serotonin cannot act like a classical
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endocrine agent, and must therefore act on the adrenal in an alternative way. It is possible
that the platelets act as a circulating storage site of serotonin, which can be released locally at
the site of the adrenal by a mechanism not involving the blood clotting process. This may be
the result of a shape change or momentary adhesion of the platelet to the surface of the zona
glomerulosa cells, which are richly supplied with blood vessels (Osim and Wylie 1983).
Alternatively, serotonin stored within the chromaffin cells of the adrenal medulla, may exert a
paracrinal influence on the zona glomerulosa, although this hypothesis contradicts the
preformed idea that adrenal blood flow is unidirectional from the exterior towards the interior of
the gland (Vinson etal 1985). In this respect it would be interesting to study the effect of total
medullectomy on the steroidogenic response to serotonin. A loss of response would
indicate that serotonin receptors within the zona glomerulosa are almost exclusively
maintained and stimulated by serotonin stored within the medulla. Mast cells are another
possible local source of serotonin. These have been localised in the rat adrenal gland in
arterioles just as they penetrate the connective tissue of the capsule (Hinson et al 1989).
Stimulation of serotonin and histamine release by these cells results in increased perfusion
and steroid secretion in the isolated perfused rat adrenal gland preparation, suggesting that
mast cells may modulate both vascular and secretory responses in the adrenal. As in the
CNS, serotonin may also stimulate the adrenal by acting as a neurotransmitter, although it is
unclear how innervated the outer zones of adrenal are compared to the highly innervated
medulla. Another theory is that the adrenal gland may be capable of synthesising serotonin
locally from the circulating precursors 5HTP or tryptophan or indeed by cleaving the amine
from its binding protein serotonectin. In addition, a number of other mechanisms may
implicate serotonin as a possible causative or exacerbating factor in hypertension. These
include decreased uptake capacity and serotonin content of platelets, accelerated platelet
turnover and enhanced sensitivity to various agonists, causing release of serotonin.
In addition to the presence of serotonin receptors within the adrenal, the seeming
synarchic relationship between the serotonin and angiotensin II receptor is of particular
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interest, although the exact nature of the interaction and the receptors involved requires
further investigation. A fine equilibrium between free serotonin derived either from platelets
or other storage sites and angiotensin II may play a role in the maintenance of normal
mineralocorticoid secretion, and any disturbance in this balance may manifest itself in altered
adrenal function leading to conditions such as essential hypertension and idiopathic
hyperaldosteronism. This inter-relationship may also be important in other diseases such as
adrenal carcinoma. This originates from studies which have shown the mas-oncooene
contains the genetic sequence for the angiotensin II receptor, whilst the genetic message
encoding the 5HTic receptor acts as a proto-oncogene under certain circumstances
(Jackson et a/1988, Julius et a/1989). Carcinoma of the adrenal could therefore be caused or
associated with discreet changes in the expression of these two genetic messages, although
this theory is purely speculative. Once again, molecular studies investigating the level of
expression of the genes encoding the angiotensin II and serotonin receptor in normal and
tumourous adrenal tissue would be interesting, as both compounds seem to act as growth
factors within the adrenal, as shown by the increase in zona glomerulosa width with sodium
depletion and serotonin loading.
The putative interplay between the angiotensin II and serotonin receptor may also be a
valuable point of exploitation in the treatment of a number of conditions resulting in
mineralocorticoid hypersecretion. Selective serotonin antagonists are relatively new drugs
and their therapeutic benefits remain largely unknown. However, the advantages of 5HT3
antagonists as anti-emetics in chemotherapy have shown particular promise and the treatment
of vascular disorders such as migraine and hypertension with other serotonin receptor based
drugs have shown moderate success.
The morphological data clearly show that administration of 5HTP increases zona
glomerulosa width. However, it is unclear from the studies if the increase is due to a direct
mitogenic action of serotonin or a hyperplastic action, resulting in changes in the cell
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ultrastructure and hence cell volume and mass. In addition, the possibility that serotonin
could stimulate the secretion of another growth factor(s) cannot be ruled out. Tritiated
thymidine uptake studies in cultured glomerulosa cells would confirm a direct mitogenic action
of serotonin, which has already been shown in vascular smooth muscle cells and fibroblasts
by other groups (Nemecek et al 1986, Seuwen et al 1988). In addition radioligand binding
studies with serotonin or angiotensin II would confirm a direct up-regulatory effect of serotonin
on its own receptor, and also if there was a parallel change in the angiotensin II receptor. It is
of interest that in contrast to other trophic factors such as sodium depletion or potassium
loading, there appears to be an uncoupling of glomerulosa growth and steroidogenic
capacity, as shown by the lack of increase in aldosterone secretion with chronic 5HTP
treatment. Therefore, if the increase in width is mediated by the direct action of serotonin on
the adrenal, it seems there is an "escape" mechanism which prevents a parallel increase in
aldosterone secretion. This may be due to a concomitant increase in one of the humoral
agents which decrease aldosterone secretion, such as dopamine or AN P. ANP has been
shown to enhance tritiated thymidine uptake in cultured glomerulosa cells, indicating that
stimulation of steroid output is not always pre-requisite for a hormone to act as a trophic factor
(Horiba et al 1985). In addition to the thymidine uptake studies, a clearer picture would also
emerge by measuring plasma levels of ANP or a number of other possible growth factors such
as prolactin or vasopressin, besides PRA and angiotensin II. In addition, the effects of
serotonin depletion on adrenal growth would be interesting, although the lack of availibility of
a suitable depleting agent which produces no side-effects on the animals or interferes with
circulating catecholamine levels make this technically difficult.
The trophic effects of serotonin are also of potential interest in that changes in the
concentration of serotonin at the site of the adrenal may result in uncontrolled cell division, as
observed in the cancerous state. As already discussed, the genetic material encoding the
5HT-jc receptor acts as a proto-oncogene, therefore there may be some relationship
between uncontrolled adrenal growth as observed in cancer and over-expression of the
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genes encoding the serotonin receptor, or an increase in local serotonin concentration at the
site of the adrenal. Indeed mast cells have been described in one human adrenocortical
tumour (Aiba et al 1985).
In addition to the direct actions of serotonin on the adrenal, it seems that serotonin, at
least acutely, can activate both the renin-angiotensin system, the hypothalamo-pituitary
adrenal axis and steroidogenesis. The central pathway appears to be at least partially
responsible for the increase in aldosterone observed following administration of 5HTP in the
cannulated rat model and normal circulating levels of angiotensin II are required permissively
for the full steroidogenic response. Acutely, it appears that there is a close inter-relationship
between the renin-angiotensin system and the hypothalamo-pituitary axis following
serotoninergic stimulation and also most probably a direct adrenal effect, due to the failure of
captopril or dexamethasone to completely inhibit the aldosterone response. A clearer picture
of the relative involvement of each system may have been provided using
hypophysectomised and / or nephrectomised animals. Studies giving serotonin, which unlike
5HTP cannot cross the blood brain barrier, would also establish the relative involvement of the
centrally mediated effects, assuming that there were no changes in blood pressure or that it
would not be immediately metabolised.
In conclusion, serotonin acts in a multi-functional capacity to maintain normal
mineralocorticoid secretion, having the ability to act directly at the adrenal cortex or modulate
the renin-angiotensin system and the hypothalamo-pituitary adrenal axis. Although further
investigations are required to cleary establish the physiological role of the amine, these
studies provide a small insight into the potentially large and now unfolding area of research
into serotonin and its role in adrenal and cardiovascular homeostasis.
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